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SUMMARY
Herpes simplex virus type 1 (HSV-1), contains a 
large (153Kb) double-stranded DNA genome, the complete 
sequence of which has now been fully determined. Of the 
predicted open-reading frames (ORFs), a number have still 
to have a protein product assigned to them and their 
ability to encode a polypeptide confirmed. The 
availability of this sequence has allowed the use of short 
oligopeptides to generate antisera reactive with HSV-1 
proteins of which the peptide was predicted to form a 
part. This technique has been used successfully to 
identify a number of HSV-1 encoded polypeptides or to 
assign previously identified viral encoded proteins to 
their ORF. Unfortunately the antipeptide sera produced 
using the standard method whereby peptides are coupled to 
carrier proteins are often of low titre making 
experimentation difficult.
Work presented here has shown that peptides presented 
in a branched form attached to a polylysine core were more 
immunogenic than monomeric peptides coupled to carrier 
proteins or peptides attached to a resin matrix. Branched 
peptides elicited both higher titre antipeptide and 
antiprotein immune reponses in rabbits. In addition, these 
responses were achieved after a single immunisation of 
peptide, whereas both other forms of antigen required two 
or more immunisations to produce a response. Branched 
peptides were also shown to be successful at producing 
high titre antipeptide responses in inbred mice when 
presented in combination with a "foretcjn" Th—cell epitope.
Antisera generated in this study were used to 
identify the protein products of four HSV—1 genes namely; 
UL31, UL45, UL46 and UL47. The product of gene UL31 has an 
apparent Mr of 30,000. This polypeptide was first detected 
in infected cells in minor amounts at 5 hours after 
infection at 37°C but was later (from 10-18 hours) present 
in large amounts. UL31 regulation was investigated using 
phosphonoacetic acid (PAA), an inhibitor of viral DNA 
synthesis: the regulation of the 30K protein was compared
with 65Kd b p , an early gene product, and 21/22K, a true- 
late gene product. This data demonstrated that UL31 is 
regulated as a true-late gene.
The product of gene UL45 has an apparent Mr of
38.000. This polypeptide is a component of HSV-1 virions; 
it was first detected in infected cells in minor amounts 
at 1 hour after infection at 37°C but was later (12-24 
hours) present in large amounts. This polypeptide 
therefore displayed the kinetics of an early protein.
The product of gene UL46 has an apparent Mr of
100.000. This protein was first detected in infected cells 
at 2 hours after infection at 37°C but was later (8—24 
hours) present in large amounts. This polypeptide also 
displayed the kinetics of an early protein.
An antiserum raised against a peptide from the 
predicted product of gene UL47 has identified two encoded 
proteins. They have apparent Mr of 82,000 and 81,000 and 
have both been demonstrated to be major components of the 
virion located in the tegument. The 82/81K proteins were 
first detected in infected cells in minor amounts 6 hours 
after infection at 37°C but were later (from 10 to 24 
hours) present in large amounts. Regulation was 
investigated using PAA as described for the UL31 gene 
product and the data showed that UL47 is regulated as a 
true-late gene.
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1INTRODUCTION.
The work presented in this thesis concerns a 
qualitative and quantitative evaluation of three 
different approaches to antigen delivery for the 
generation of antipeptide antisera. It further describes 
the use of these antisera to identify and characterise 
the products of four HSV-1 genes, namely UL31, UL45,
UL46 and UL47. The protein products of genes UL31, UL45 
and UL46 had not previously been detected while that of 
UL47 had not been assigned to a gene nor had it been 
characterised.
1. THE FAMILY HERPESVIRIDAE
Members of the Herpesviridae form a large virus 
family with over eighty identified members and have a 
range of hosts spanning many species (reviewed by 
Roizman, 1982). The family is characterised by 
possessing a linear, double-stranded DNA genome which 
undergoes an intranuclear replicative cycle. The virion 
particles are 150-200nm in diameter and conserve a 
distinct morphological structure comprised of four 
distinct elements.
The core, which is an electron dense fibrillar 
spindal surrounded by the genomic DNA (Epstein, 1962; 
Furlong et al.9 1972; Nazerian, 1974). A capsid which is 
icosahedral in shape and formed from 162 capsomeres of 
which 150 are hexameric and 12 are pentameric prisms 
surrounding the core (Wildy et al., 1960; Schrag et al., 
1989). Surrounding the capsid is an undefined layer of 
proteinaceous material known as the tegument (Schwartz 
and Roizman, 1969; Morgan et al., 1968; Roizman and 
Furlong, 1974) which comprises about 65% of the virion 
by volume (Schrag et al., 1989). The capsid and tegument 
are surrounded by a lipid membrane, containing numerous 
viral encoded glycoprotein spikes (Morgan et al., 1959;
2Wildy et al. , 1960; Asher et al. , 1969; Spear and 
Roizman, 1972).
In addition to being morphologically identical and 
having an intranuclear replicative cycle the 
herpesviruses share the ability to persist in a latent 
state in their infected hosts. Despite these 
similarities, they have hou/ever been divided on the 
basis of their biological properties, into three groups; 
alpha, beta and gamma, divided on criteria of host 
range, reproductive cycle, cytopathology and the 
characteristics of their latent infection (Roizman,
1981, 1982; Matheu/s, 1982).
The alphaherpesviruses frequently establish latency 
in the ganglia. They have a relatively short replication 
cycle of less than 24 hours in cell culture. Members of 
this family include HSV-1, HSV-2, VZV and pseudorabies 
virus.
The betaherpesviruses, have a restricted host range 
and a longer reproductive cycle, u/ith infection 
spreading slowly in culture. Infection results in 
enlarged infected cells and generally establishment of 
latency in lymphoreticular cells, secretory glands and 
kidneys. HCMV is an example of a member of this sub­
family.
The final sub-family are the gamnaherpesviruses, 
these too have a narrow host range which is generally 
restricted to B or T lymphocytes. They have a variable 
reproductive cycle, often leading to a persistent rather 
than lytic infection with establishment of latency in 
lymphoid tissue. This family includes Epstein-Barr 
virus.
2.THE HUMAN HERPESVIRUSES.
To date seven different herpesviruses have been 
identified that are capable of infecting humans: HSV-1, 
HSV-2, VZV, HCMV, EBV ; HHV-6 (Salahuddin et al., 1986) 
and HHV-7 (Frenkel et al., 1990). The majority of the
3infections caused by these viruses are either mild or 
asymptomatic, however more serious problems can occur 
especially in immunocompromised individuals.
2.1 THE PATHOGENICITY OF THE HUMAN HERPESVIRUSES
HSV-1 AND HSV-2: Herpes simplex virus is unusual 
among viruses in causing a wide variety of clinical 
syndromes. Diseases that are due to the virus can be 
divided into two forms; either the primary infection or 
those resulting from the reactivation of latent virus. A 
large majority of the population become infected with 
HSV, and although most primary infections are 
asymtomatic, there are several exceptions.
The most common primary infection is 
gingivostomatitis, which results in ulceration of the 
buccal mucosa. The eye can also be a target for primary 
infection with the virus able to infect both the 
conjunctiva and the cornea, producing a vesicular 
eruption and swelling of the eyelid. More serious 
manifestations can also occur, acute necrotising 
encephalitis is a very rare but extremely serious 
disease, resulting in severe necrosis of the temporal 
lobe of the brain. This disease can also take a milder 
form which has a better prognosis and is usually found 
in children. It is unclear whether encephalitis due to 
HSV is as a result of a primary infection or a 
reactivation.
The genital region is also a common site of primary 
infection, which takes the form of a vesicular eruption. 
In the majority of cases this infection is caused by 
HSV—2, however a growing number of cases of genital 
herpes have been shown to be as a result of HSV-1 
infection. Also more commonly associated with HSV—2 is a 
severe generalised infection in neonates due to a 
genital infection in the mother. This can prove 
extremely serious with a high case mortality rate.
Reactivation of latent HSV can be triggered by
4nerve damage or trauma and also by stimulation of the 
neuron and can occur Sporadically throughout life 
(Stevens, 1975; Wildy et al. , 1982; Hill, 1985). The 
most common clinical forms of reactivation are "cold 
sores", which occur around the mucocutaneous junctions 
of the nose and mouth. Reactivation causing genital 
lesions can also occur and is generally associated with 
HSV-2. Less common, is reactivation affecting the eye, 
recurring dendritic ulcers can be produced u/hich in a 
feu; cases can lead to scarring and blindness. 
Reactivation can also pose problems in patients whose 
immune system is depleted, either through 
immunosuppressive therapy (e.g. organ transplant 
patients) or through disease that depletes the host 
immune system like infection with HIV.
VZV: Varicella-zoster virus causes two different 
diseases: Varicella- the primary infection and zoster, a 
recurrent manifestation of the primary infection. 
Varicella more commonly known as chicken-pox is a common 
childhood fever with a characteristic rash. Zoster or 
shingles is a reactivation of the latent virus from the 
dorsal root or cranial nerve ganglia, mainly affecting 
adults and resulting in the eruption of painful 
vesicles.
HCMV: Diseases caused by cytomegalovirus are mainly 
opportunistic infections in patients with lower than 
normal resistance to infection. Asymptomatic infections 
are also common, however more serious problems are 
occasionally encountered. An asymptomatic infection in 
the mother can lead to infection in the newborn, with 
about one fifth of these infants going on to develop 
severe generalised infection (cytomegalic inclusion 
disease), surviving infants usually suffer from deafness 
and mental retardation. HCMV has also been associated 
with the European form of Kaposi's sarcoma (Giraldo et 
al., 1975). In addition, HCMV can also cause problems in 
immunocompromised patients and is at present a 
particular problem with HIV patients.
5EBV Epstein-Barr Virus infects B-lymphocytes and is 
the causative agent of infectious mononucleosis or 
glandular fever. It has also been linked to 
nasopharyngeal carcinoma and Burkitt.s lymphoma (Epstein 
et al., 1964; de-The et al. , 1978; de-The, 1982).
HHV—6 Initially termed human lymphotrophic virus, 
human herpesvirus—6 can infect T—cells in vitro and was 
first isolated from patients with lymphproliferovtive 
disorders (Salahuddin et al., 1986), it has been 
associated with the condition exanthem subitum, a common 
disease of infancy, characterised by high fever and the 
appearance of a rash (Yamanishi et al., 1988).
HHV-7 Recently isolated from CD4+ T-cells; human 
herpesvirus 7 has yet to be connected with any specific 
disease (Frenkel et al., 1990).
2.2 TRANSFORMATION AND ONCOGENESIS
Herpesviruses have for some time been implicated 
with tumourogenic activity. In particular HSV-2 has been 
found to have an association with squamous cell 
carcinoma of the cervix; although a direct link between 
HSV infection and subsequent carcinoma development is 
unclear (reviewed by Rawls, 1985; Macnab, 1987), with 
evidence somewhat conflicting. There does seem to be 
some association between previous infection with HSV-2 
and a later development of carcinoma, although the 
presence of HSV gene products and DNA in tissues from 
cervical carcinoma is detected to a much lesser extent 
than those from human papilloma virus (Macnot), 1987).
Three regions of the HSV genome which induce 
cellular transformation have been identified in vitro by 
transfection assays:
Camacho and Spear (1978), identified a transforming 
region present in HSV-1 which is termed MTR-I 
(morphological transforming region). This region has 
been mapped in the Xba I f (0.29—0.45 map units [m.u.]) 
and Bgl II i (0.311-0.415 m.u.)(Reyes et al., 1979;
6Gallou/ay and McDougall, 1983).
MTRs II and III are present in the HSV-2 genome; 
these are found in restriction fragments Bglll n and c 
respectively (Reyes et al., 1979; Macnab and McDougall, 
1980; Galloway and McDougall, 1981; Cameron et al.,
1985; Peden et al., 1982). Both of which are required 
for oncogenesis (Jariwalla et al., 1983, 1986). The 
minimal transforming region of MTR-II has been localized 
to a small, putative stem-loop structure of 737bp which 
is bounded by direct repeats and located in the left- 
hand portion of the Bglll n fragment (Galloway et al., 
1984). These authors proposed that a similar structure, 
present in HCMV, may induce morphological 
transformation. It was proposed that such structures may 
be important as they can also be formed by insertion 
sequences (IS) that are capable of integrating into the 
cellular genome.
However the evidence in support of this proposal is 
not strong: Since the 737bp sequence does not conform to 
the standard description of an IS; it does not appear to 
be capable of moving around the genome and does not seem 
to encode a transposase (Lewin, 1990). Although this 
enzyme could be supplied by other regions of the genome 
no evidence for this exists. In addition, the 
significance of these potential secondary structures is 
unclear as it is possible to derive similar structures 
from many random DNA sequences (Macnab, 1987), indeed 
computer scanning has demonstrated many such structures 
elsewhere in the HSV genome (ShiHitoe, 1988).
It is however still unclear what role is played by 
this region as the evidence is somewhat confusing; other 
experiments have observed that the left-hand portion of 
the Bglll n fragment caused neither transformation nor 
mutagenesis in NIH3T3 cells whereas the right-hand end 
was transforming but not mutagenic (Pilon et al., 1989)
The minimal transforming region of MTR-III that is 
capable of causing transformation has been mapped to a 
486bp fragment located on the PstI c restriction
7fragment (Jones et al., 1986). Recent experiments have 
shown that the 486bp region has been shown to function 
as a transcriptional promoter when fused to the 
bacterial CAT gene (Jones, 1989), it was therefore
suggested that this fragment might act to alter the 
expression of a cellular gene. It has been further 
suggested that the 486bp fragment in combination with 
cellular factors may initiate unscheduled rounds of 
cellular chromosonal replication which may ultimately 
result in cellular transformation (Zhu and Jones, 1990, 
Abstracts: 15th International Herpesvirus Workshop). In 
addition Bglll c also contains most of the coding 
sequences for Ri , including a region with protein kinase 
activity (Chung et al., 1989) and although 
transformation can be achieved with the 486bp fragment 
alone a role for Ri has not been dismissed.
As HSV does not seem to carry a viral oncogene 
analogous to those found in retroviruses or DNA tumour 
viruses such as papova or adenoviruses, it is thought 
that HSV oncogenesis may develop from a disruption of 
normal cellular events to which HSV may have been 
involved (Galloway and McDougall, 1983; Macnab et al.,
1987). It has been proposed that HSV may act via a "hit 
and run" type mechanism where activation of a viral or 
cellular oncogene might occur before the HSV DNA is 
rapidly exised from the host cell (Skinner, 1976; 
Galloway and McDougall, 1983).
The failure of HSV—transformed cells in vitro to 
retain viral sequences is in contrast to the small but 
significant number fcervical cancer biopsies where it has 
been detected. This difference may however be due to the 
fact that cervical cancers are generally of epithelial 
origin whereas the rat cells examined in vitro are 
predominantly fibroblastic (Macnab, 1987). In fact, it 
is of doubt whether transformation experiments carried 
out under in vitro conditions have any direct 
correlation to the role played by HSV in causing tumours 
in vivo. However if HSV does play any role in cervical
8carcinoma, it is probable that it acts in conjunction 
u/ith a number of other factors like human papillomavirus 
(Zur Hausen, 1982; Durst et al., 1983; Boshart et al., 
1984).
2.3 LATENCY
A characteristic feature of infection with HSV is 
the persistance of viral genetic information in a non- 
infectious state in neurons of the peripheral nervous 
system (Stevens and Cook, 1971; Baringer and Swoveland, 
1973; Galloway et al., 1974; McLennan and Darby, 1980; 
Hill, 1985). It is this ability to remain associated 
with their hosts following primary infection that plays 
an important role in the pathogenic potential of 
herpesviruses.
Puga et al., (1978) using hybridisation techniques 
detected HSV DNA in the sensory ganglia of latently 
infected mice. The precise nature of the viral DNA in 
latently infected cells is unclear, however it is 
probably not present as a linear molecule as it has not 
been possible to detect any terminal genomic fragments 
(Rock et al., 1983, 1985; c*\ et al. , 1986).
Studies with mouse models of HSV latency have shown that 
latent DNA does not seem to be integrated into the 
cellular DNA, rather it appears it is maintained in an 
episomal state (Rock and Fraser, 1983; Mellerick and 
Fraser, 1987).
Recently transcription of HSV-1 DNA during latency 
has been shown to occur, with latency associated 
transcripts (LATs) detected in latently infected ganglia 
(Deatly et al., 1987; Stevens et al., 1987; Rock et al., 
1987; Spivak and Fraser, 1987; Steiner et al., 1988). 
Three transcripts of 2.0, 1.5 and 1.45 Kb are present in 
latently infected neurons and originate from one area of 
the viral genome located in the repeat regions IRl and 
TRl (Spivak and Fraser, 1987; Wagner et al., 1988a). The
1.5 and 1.45 Kb LATs being spliced (Wagner et al.,
91988b; Wechler et al., 1988). These LATs map to a region 
of the the genome that partially overlaps with immediate 
early gene 1 (Vmw 110), although they are transcribed 
from the opposite strand of the viral DNA (Spivak and 
Fraser, 1987; Stevens et al., 1987). Open-reading frames 
have been identified in this region, however no evidence 
exists for any convincing coding sequences or associated 
proteins (McGeogh et al., 1988; Weschler et al., 1988, 
1989) .
It seems likely however, that the LATs are not 
essential for the establishment of HSV-1 latency, as an 
HSV-1 x HSV—2 recombinant has been isolated which is 
unable to express LATs while retaining the ability to 
establish a latent infection in mice (Javier et al.,
1988). Although this recombinant has recently been shown 
to be impaired in its ability to reactivate in vivo 
using a rabbit eye model (Hill et al., 1990). Additional 
studies with an HSV-1 deletion mutant 1704 (MacLean and 
Brown, 1987) which fails to express LATs in tissue 
culture or in latently infected mice (Steiner et al.,
1989) have shown that although 1704 establishes latent 
infection in mice, reactivation of virus from explanted 
ganglia was slower than that of wild-type (Steiner et 
al., 1989). In addition a LAT- deletion mutant has been 
isolated that reactivates less efficiently than the 
parent LAT+ virus (Leib et al., 1989). The data from 
these experiments suggests that LATs, although not 
essential for establishment, play some role in mediating 
reactivation of latent virus. Recently experiments with 
a mutant that fails to express LATs during latency, but 
expresses truncated LATs in vitro have indicated that 
the first 838bp of the transcript seem to be important 
for biological function (Block et al., 1990).
Both in vivo and in vitro models have been used to 
study HSV latency. These studies have been used in 
attempts to identify the viral functions necessary or 
dispensible for latent infection, although no gene 
products have as yet been shown to be individually
FIGURE 1
Organization of the HSV-1 genome. A conventional 
representation of the HSV-1 genome is shown with unique 
sequences (Ul and Us ) as solid lines and the major 
repeat elements (TRl and IRl , IRs and TRs) as open 
boxes. Terminal a sequences and the internal, tiWerM 
orientation a ‘ sequence are indicated. The arrows 
indicating the orientation of the four isomeric forms 
are also indicated, these isomers occur in equimolar 
amounts. This figure is modified from McGeoCh et al.$ 
(1988).
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required (Polvino-Bodnar et al., 1987; Meigneir et al., 
1988; Russell et al. , 1987). However, in vitro studies 
have implicated immediate early gene 1 in the 
reactivation of latent HSV as a mutant in IE gene 1 
(c/11403), fails to reactivate HSV-2 in vitro by 
superinfection (Russell et al. , 1987). In addition 
recent experiments have also indicated a role for the 
viral thymidine kinase: it is not essential for the 
establishment of a latent infection but may play a role 
in reactivation of the virus (Coen et al., 1989; 
Efstathiou et al., 1989; Tenser et al., 1989). There has 
also been a report of a mutant in HSV ribonucleotide 
reductase which fails to establish a reactivatable 
latent infection (Jacobsen et al., 1989).
3. THE HSV-1 GENOME.
3.1 THE STRUCTURE OF THE HSV-1 GENOME
The genome of HSV-1 is a large (153Kb), linear, 
molecule consisting of two components, termed L(long) 
and S(short). These components are made up of unique 
sequences termed Ul and Us respectively, which are 
flanked by inverted repeat sequences TRl TRs , IRl IRs 
(Fig 1) (Sheldrick and Berthelot, 1975; Hayward et al., 
1975). Each end of the genome shares a small terminal 
repeat sequence (termed the a sequence)(Davison and 
Wilkie, 1981). A single copy of this a sequence is found 
at the S terminus, with multiple copies detected at the 
L terminus, and a variable number of copies (in the 
trufef&d orientation to the terminal repeats) located 
internally between the L and the S segments (Wadsworth 
et al., 1975; Wagner and Summers, 1978).
During viral DNA replication, the two unique 
regions invert relative to each other (Hayward et al., 
1975). The resulting viral DNA consists of an equimolar 
mixture of four isomeric forms (Fig. 1) differing only 
in the relative orientation of Ul and Us (Delius and
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Clements, 1976; Wilkie, 1976). The isolation of HSV 
mutants with genomes "frozen" in all four isomeric 
arrangements, which are still capable of replicating 
independently, suggests that inversion is not essential 
for viral DNA replication (Jenkins and Roizman, 1986).
3.2 THE NUCLEOTIDE SEQUENCE OF HSV-1
The nucleotide sequence of the entire genome of 
HSV-1 (strain 17) has now been determined (Davison and 
Wilkie, 1981; Murchie and McGeoch, 1982; McGecC;h et al 
1985; McGec&h et al.> 1986; Perry and McGeoch, 1988; 
McGeoCh et al.t 1988). The genome contains 152260 
residues, although this is slightly variable due to 
differences in the copy number of the a sequence and 
slight sequence reiterations.
A high percentage of the HSV-1 genome codes for 
proteins, with the genes densely packed on the genome. 
89% of Ul and 79% of Us is occupied by coding sequences, 
thought to specify proteins (Fig. 2) (Rixon and McGeoch, 
1985; McGeoch et al., 1988). The genome includes 56 
genes in U l (UL1-UL56) and a further 12 in Us (US1-US12) 
with one in each copy of Rl and Rs . The analysis of 
McGeogh et al.t 1988, suggested a total of 72 genes 
encoding 70 distinct proteins. A further gene whose 
product is designated ICP 34.5, present in Rl upstream of 
immediate early gene 1 has been identified (Ackerman et 
al., 1986; Chou and Roizman, 1986). In addition in 
latently infected cells a major virus—specific 
transcript, the latency associated transcript (LAT) has 
been show to initiate'downstream of IE gene 1 (Stevens 
et al., 1987; Wagner et al., 1988; see earlier, section 
2.3). It is possible that still further genes will be 
identified in the future.
Several of the genes encoded by HSV-1 in Ul have 
been shown to be non-essential for growth in vitro, 
including those genes encoding the viral thymidine 
kinase and the large sub-unit of ribonucleotide
FIGURE 2
Layout of genes in the genome of of HSV-1. The HSV-1 
genome is shown on four successive lines with unique 
regions represented by solid lines and major repeat 
elements as open boxes. The lower scale represents 
kilobases numbered from the left terminus, and the upper 
scale represents fractional map units. The sizes and 
orientations of proposed functional ORF's are shown by 
arrows. Overlaps of adjacent, similarly orientated ORF^s 
are not shown explicitly. Location of origins of DNA 
replication are shown as X. Locations of proposed 
transcription polyadenylation sites are indicated as 
short vertical bars. Genes are numbered UL1-UL56 and 
US1-US12 plus IE175 and IE110. This figure is taken 
directly from McGeoch et al.% 1988.
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reductase (Revleu/ed by McGeoeh, 1988, see later), with 
almost all of Us encoding genes which are dispensible 
for growth (Longnecker and Roizman, 1986, 1987; Weber et 
al., 1987; Brown and Harland, 1987).
4. INFECTION OF CELLS WITH HSV-1
The pathway by which HSV-1 gains entry into host 
cells still remains to be defined. However HSV 
infections are thought to involve three distinct steps: 
Initial virion attachment, followed by fusion of the 
viral envelope with the cell's plasma membrane, and 
finally removal of the envelope with the nucleocapsid 
being released into the cytoplasm of the cell where it 
migrates to nuclear pores, disassembles, with the viral 
DNA being released into the nucleus.
4.1 ABSORPTION
Absorption of HSV-1 to the cell surface is a rapid 
process which may initially be of a non-specific nature, 
leading to an irreversible binding to the cell surface 
(Hochberg and Becker, 1968; Rosenthal et al., 1984). It 
is as yet unclear which viral proteins are involved in 
binding to the cell surface. Of the identified 
glycoproteins only gB (Sarmiento et al., 1979; Little et 
al., 1981), gD (Ligas and Johnson, 1988), and gH (Weller 
et al., 1983; McGeoch and Davison, 1986; Gompels and 
Minson, 1986; Desia et al., 1988) are essential for 
infectivity. Of these three, only gH remains a candidate 
for a viral glycoprotein essential for absorption; as 
mutants are available in both gB and gD that retain the 
ability to absorb to the cell surface, but fail to 
synthesize viral polypeptides (Cai et al., 1988; Ligas 
and Johnson, 1988).
It is however possible that any one, or a 
combination of the glycoproteins, could play a 
facilitating role in absorbtion. As absorption can occur
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in the absence of normal glycosylation it is also 
possible that a non-glycoprotein virion component may 
play a role (Campadelli-Fiume et al., 1982; Spivak et 
al.t 1982; Svennerholm et al., 1982; Kuhn et al., 1988).
It seems likely that HSV types 1 and 2 have different 
receptors on the cell surface (Vahlne et al., 1979; 
Addison et al., 1984) although WuDunn and Spear (1989) 
have shown that an initial stage of virion attachment of 
both HSV-1 and HSV-2 to the cell surface is through an 
interaction between the virus and heparin-like cell- 
associated glycoaminoglycans (GAGs).
It has been demonstrated that the antibiotic 
neomycin inhibits the infection in vitro of HSV-1 while 
it fails to interfere with HSV-2 infection (Langeland et 
al., 1986). As neomycin has to be present at the time of 
infection to exert maximum effect it is believed that 
the drug acts at the receptor attachment level. This 
effect is observed for other aminoglycosides and also to 
be dependent on the charge of the particular compound 
(Langeland et al., 1987). This implies that 
phosphoinositides have a role in the type 1 receptor 
interaction, as the ability of aminoglycosides to bind 
phosphinositides is also related to their cationic 
charge (Marche et al., 1983) and it has previously been 
shown that phosphinositides may be involved in the 
"anchoring" of plasma membrane glycoproteins at the cell 
surface (Low et al., 1985, 1986). Similar inhibition 
effects to those exhibited by neomycin have also been 
demonstrated with polyamino acids such as polylysine and 
polyarginine which are also thought to be due to 
interference with the receptor (Langeland et al., 1988; 
WuDunn and Spear, 1989).
Langeland et al., (1990) took advantage of their 
observation that neomycin inhibits the binding of HSV-1 
but not HSV-2 to map, using intertypic recombinants, the 
region encoding a protein or proteins involved in the 
absorption process blocked by neomycin. The region 
mapped from coordinates 0.580-0.687 which is predicted
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to contain 2 partial (UL39 and UL48) and 8 complete 
(UL40-UL47) genes (McGeoch et al., 1988) including gC 
and tu/o others with potential transmembrane sequences: 
UL43 and UL45 (McGeoch et al., 1988).
More recently Campadelli-Fiume et al., (1990) also 
made use of intertypic recombinants to map neomycin 
resistance to within the same region. Both they and 
Langeland et al., (1990) observed that HSV-1 gC~ mutants 
absorbed more slowly to cells and were fully as 
sensitive to neomycin and polylysine as the parent virus 
and both groups concluded that gC-1 was not the virion 
component which was responsible for sensitivity to these 
drugs. Implicit in the analysis by Langeland et al., 
(1990) was the assumption that both gC-1 and gC-2 
attached to the same cellular receptor (though the 
possibility of low affinity type specific receptors was 
not excluded) and they concluded that whilst gC-1 seemed 
to facilitate absorption it was not the virion 
attachment component that was being mapped. However 
Campadelli-Fiume et al., (1990) have more precisely 
defined the HSV—2 sequence that confers resistance of 
HSV-2 to neomycin to either gC-2 or the N-terminal 28 
aminO acids of gene UL45 and concluded that in BHK cells 
there exists in addition to the pathway blocked by 
neomycin and polylysine a pathway which is parallel and 
gC-2 dependent. That is, gC-1 and gC-2 attach to 
different receptors in BHK cells. This conclusion seems 
quite reasonable although insertion of a stop codon in 
gC-2 in the drug resistant construct of Campadelli-Fidme 
et al., (1990) produced virus with an unexpectedly wioe 
range of sensitivities to neomycin (4%-70% pfu compared 
with parent virus).
It is also possible that the N-terminal amino acids 
of UL45, which constitute the major portion of the 
region predicted to be external to a transmembrane 
region (see later) play a role in the putative 
alternative pathway. Pre^iSs DNA sequencing of the 
relevant regions of the various neomycin/polylysine
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resistant constructs u/ill be required to determine 
exactly what proteins are encoded.
4.2 PENETRATION AND UNCOATING
As previously mentioned gB and gD are non-essential 
for absorption of the HSV-1, although both have been 
shown to be required for penetration (Deluca et al., 
1982; Bond et al., 1982; Bzik et al., 1984; Johnson and 
Ligas, 1988), with neutralising monoclonal antibodies 
against gD not affecting attachment but blocking 
penetration (Highlander et al., 1987). In addition 
experiments have shown that soluble forms of gD can 
inhibit virus entry into cells by binding to a limited 
number of cell surface receptors (Johnson et al., 1990).
Recent experiments have indicated that following 
initial interaction with heparin-sulphate, HSV-1 may be 
able to use the high affinity receptor for fibroblast 
growth factor (FGF) to penetrate cells after absorption 
(Kaner et al., 1990). Inhibitors of basic FGF binding to 
its receptor and competitive polypeptide antagonists of 
basic FGF have been shown to prevent HSV-1 uptake. In 
addition a cell line which fails to express basic FGF 
receptor, Chinese hamster ovary (CHO) cells were shown to 
be resistant to penetration by HSV-1, whereas following 
transfection of the gene encoding the basic FGF 
receptor, CHO cells become susceptible to HSV-1 uptake 
(Kaner et al., 1990). Interestingly some homology exists 
between the basic FGF receptor and gD, although somewhat 
tenuous it does occur in the region of the receptor 
responsible for substrate binding (Kaner et al., 1990).
Following penetration the viral capsids are then 
translocated to the nucleus, where, after uncoating the 
viral DNA then enters the nucleus at a nuclear pore. It 
is likely a viral-encoded protein(s) play a role in this 
process, as a ts mutant exists which is blocked in 
release of the DNA; this mutation has located between 
map units 0.501-0.503 (Knipe et al., 1981; Batterson et
v
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al., 1983); a position corresponding to the HSV-1 gene 
UL36 (McGeoCh et al., 1988).
4.3 THE EFFECT OF HSV INFECTION ON THE HOST CELL 
METABOLISM
Upon infection of cells, HSV causes a disruption of 
the metabolic processes of the host, in order to provide 
a suitable environment for the efficient replication of 
its DNA. There is a rapid decline in the synthesis of 
host macromolecules: cellular DNA and RNA synthesis is 
inhibited (Roizman and Roane, 1964), there is a 
termination of mitosis (Wildy et al., 1961) and protein 
synthesis decreases rapidly, within 2-4 hours post 
infection (reviewed by Fenwick, 1984).
As a consequence of infection there is a decline in 
host mRNA accumulation (Pizer and Beard, 1976; Fenwick,
1984), although some cellular genes are activated, which 
in some cases is connected with expression of the 
product of IE gene 3-Vmw 175 (Latchman et al., 1987;
Kemp and Latchman, 1988). HSV infection induces 
efficient shut-off of the majority of host specified 
polypeptide synthesis (Sydiskis and Roizman, 1966,
1967), with HSV-2 generally more efficient at shut-off 
than HSV-1 (Powell and Courtney, 1975; Pereira et al., 
1977; Fenwick et al., 1979; Schek and Bachenheimer,
1985), although HSV-2 strain HG52 is less efficient than 
HSV-1 strain 17 (Marsden et al., 1978).
Cells infected in the presence of actinomycin D or 
with u.v. irradiated virus are still subjected to a 
rapid shut-off of host protein synthesis, a result which 
indicates that the shut-off process is controlled by a 
virion component(s) (Sydiskis and Roizman, 1967; Fenwick 
and Walker, 1979; Fenwick et al., 1979; Schek and 
Bachenheimer, 1985). Using mutant viruses incapable of 
inducing host shut-off, it has been possible to identify 
the gene involved as UL41 (Read and Frenkel, 1983; Kwong 
et al., 1988). When this gene was cloned and transferred
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from HSV-2 strain G (which exhibits a particularily 
strong shut-off function) into the early shut-off 
deficient HSV-1 strain 17, efficient early shut-off u/as 
restored (Fenwick and Everett, 1990). Recently HG52 has 
now been found to encode a truncated UL41 product which 
most likely accounts for its poor shut-off (Everett and 
Fenwick, 1990).
In addition, recent experiments which have inserted 
the rabbit beta-globin gene under the control of its own 
promoter, into the HSV genome. Have demonstrated that 
this gene was activated upon infection by HSV immediate- 
early polypeptides whereas the expression of the 
endogenous cellular beta-globin gene was strongly 
suppressed, with beta-globin mRNA degraded (Simbert and 
Smiley, 1990). This Effect was abolished by a LacZ 
insertion into the reading frame of the UL41 gene. The 
results of these experiments suggest that the 
preferential expression of HSV genes that occurs during 
infection is not ach ved sollUj through a sequence 
specific differentation between viral and cellular 
promoters or mRNAs.
5. HSV-1 DNA REPLICATION
The mechanism of HSV DNA replication is at present 
poorly understood due primarily to the size and 
structural complexity of the genome. Most viral DNA 
molecules have been shown to lo se their free ends 
shortly after infection, which is thought to be due to 
circularisation of the genome (Jacob and Roizman, 1977; 
Davison and Wilkie, 1983; Poffenberger and Roizman,
1985), possibly as a result of direct ligation of the 
ends (Marks and Spector, 1988). It is likely that 
ligation is carried out by either a host cell enzyme or 
a component of the virion particle as fusion of the 
termini shows no requirement for de novo protein 
synthesis (Poffenberger and Roizman, 1985).
Newly replicated viral DNA probably exists as
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circular molecules or more likely large head-to-tail 
concatamers as examination with restriction enzyme 
digest shows that it fails to possess any detectable 
termini, (Jacob et al. , 1979; Jongeneel and 
Bachenheimer, 1981). Late in viral infection the ease 
with which the DNA can be sedimented is thought to be 
due to the presence of extensive concatamers (Jacob et 
al. 9 1979). It is proposed that these molecules are 
generated via a rolling-circle type replication 
mechanism, with the HSV DNA intermediates generated, 
then being processed and packaged into capsids in the 
nucleus (Becker et al. , 1978; Frenkel et al., 1981; 
Vl&zny et al., 1982). This theory has been supported by 
recent experiments utilising an in vitro HSV DNA 
replication system at a preformed replication fork 
(Rabkin and Hanlon, 1990). These workers have used 
electron microscopy and alkaline agarose gel 
electrophoresis to show that DNA replication in this 
system is via a rolling circle type mechanism.
5.1 ORIGINS OF DNA REPLICATION
Analysis of defective HSV genomes generated during 
serial passage of the virus at high multiplicity 
infections, provided evidence for the existence of cis- 
acting origins of replication (Frenkel et al., 1975, 
1976; Schroder et al., 1975; Frenkel et al.9 1980; 
Kaerner et al., 1981). It was demonstrated that 
monomeric units from defective genomes could be 
amplified, regenerating tandemly repeated defective 
DNAs, when co-transfected with wild-type HSV DNA which 
provides essential helper functions in trans (Vlazny and 
Frenkel, 1981; Spaete and Frenkel, 1982) so providing 
evidence for the presence of replication origins.
These origins of replication were fine mapped by 
identifying DNA fragments capable of inducing 
replication of plasmid sequences, when vectors 
containing the sequence of interest were introduced into
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HSV-infected cells (Stow, 1982). Tu/o copies of oris are 
located in the Rs segments of the genome (Stow and 
McMonagle, 1983) containing a 90bp fragment with a 45bp 
palindromic sequence featuring a central AT rich region, 
which by comparison with other known origin sequences is 
potentially a site of protein induced unwinding 
(Challberg and Kelly, 1989). It has been demonstrated 
that disruption of sequences making up the palindrome 
abolishes origin function (Stow, 1985). The single copy 
of oriL is located in Ul between the genes encoding the 
DNA polymerase and the major DNA binding protein (Weller 
et al., 1985) and contains a 72bp palindrome which shows 
85% homology to oris (Gray and Kaerner, 1984; Quinn and 
McGeoch, 1985).
6. POLYPEPTIDES ENCODED BY HSV-1
6.1 GENES INVOLVED IN HSV-1 DNA REPLICATION
Proteins involved in the replication of HSV DNA 
fall into two catagories. Firstly those which are 
required directly for DNA synthesis and also those 
factors involved in nucleotide metabolism.
6.1.1 Genes required directly for DNA synthesis
The complete set of viral genes which are essential 
for DNA replication were identified by the use of a 
transient complementation assay (Challberg, 1986; Wu et 
al.t 1988). This was used to identify loci on the HSV 
genome which were required to replicate a bacterial 
plasmid containing the HSV-1 origin of replication oris . 
Comparison with the DNA sequence of McGeoch et al., 
(1988) identified two sets of genes: Those which are 
essential for the replication of the origin containing 
plasmid and those genes which, although not absolutely 
required were able to increase the amplfication of the 
plasmid, this latter group containing IE genes 1, 2 and 
3 and the genes specifying ribonucleotide reductase.
20
There are seven HSV genes that have been shown to 
be essential for replication of viral DNA, all of which 
are located in the long segment of the genome: UL5, UL8, 
UL9, UL29, UL30, UL42 and UL52. Of these the genes 
encoding the major DNA binding protein (MDBP) and the 
viral DNA polymerase, encoded by genes UL29 and UL30 
respectively had already been identified and shown to be 
essential by genetic studies of mutant viruses (Hay and 
Subak—Sharpe, 1976; Chartfand et al. , 1979; Conely et 
al. , 1981; Weller et al., 1983; Coen et al. , 1984; Gibbs 
et al. , 1985). Although genetic studies suggest that no 
other HSV gene products are essential for DNA 
replication, it is howevever a possibility that one or 
more as yet unidentified host cell proteins might also 
play an essential role.
6.1.1.1 MDBP
This protein is encoded by gene UL29. The protein 
binds preferentially to single stranded DNA (ssDNA) with 
no detectable sequence specificity (Bayliss efc’al.,
1975; Powell and Purifoy, 1976; Conely et al. , 1981; 
Knipe et al. , 1982). MDBP also seems to have a role in 
gene regulation since viral ts mutants in MDBP 
overexpress gC, with the MDBP also playing a role in the 
repression of the IE 3 and major capsid protein (Vmw 
155) genes (Godowski and Knipe, 1983, 1985, 1986). It is 
believed that the MDBP may bind to ssDNA formed at a 
replication fork, by the unwinding of the parental DNA, 
so facilitating the use of these strands as templates 
for DNA polymerase (Challberg and Kelly, 1989).
6.1.1.2 Viral DNA polymerase(UL30)
Extracts of HSV-infected cells contain a DNA 
polymerase (pol) which is biochemically distinct from 
host DNA polymerases (Keir and Gold, 1963; Purifoy et 
al., 1977). Experiments with ts and drug-resistant 
mutants has shown that the polymerase is vjrally encoded 
and essential for DNA synthesis (Aron et al., 1975; Hay
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et al., 1976; Purifoy and Pou/ell, 1981). pol shows 
several regions of homology with both prokaryotic and 
eukaryotic DNA polymerases, including the mammalian 
replicative DNA polymerase (Gibbs et al. , 1985; Quinn 
and McGeoCh, 1985; Wong et al., 1988; Knopf, 1986;
Larder et al. , 1987), although it differs from most 
eukaryotic polymerases by possesion of a 3' to 5' 
exonuclease (proof reading) activity (Knopf, 1979; 
O'Donnell et al. , 1987b; Marcy et al., 1990). The pol 
has also recently been shown to posses a 5'-3' 
exonuclease activity capable of functioning as a RNaseH 
(Crute and Lehman, 1989; Marcy et al., 1990).
Experiments showed that the 140kd polymerase 
product of HSV-2 co-purified with a 55Kd polypeptide 
(Vaughan et al., 1984) and this has since been 
demonstrated to be the HSV-2 serotype equivalent of the 
product of the UL42 gene of HSV-1 (Gallo et al.,
1988)(see below). In addition the 226 carboxy-terminal 
amino acids of pol have been found to be necessary and 
sufficient for the interaction with UL42, which maps the 
UL42 binding site to a region distinct from that thought 
to be involved in substrate recognition (Digard and 
Coen, Abstracts: 15th International herpesvirus 
workshop). Other regions of pol could be involved in 
binding UL42 but isolation of the 226 amino acid 
fragment and comparison of its affinity for UL42 with 
that of intact pol will be needed to test this 
possibility.
6.1.1.3 UL42
The product of gene UL42 is a 65Kd DNA binding 
protein (65Kdbp )(Marsden et al., 1987; Parris et al., 
1988; Gallo et al., 1988). Immunoaffinity purification 
of the UL42 protein has demonstrated an interaction 
between 65Kdbp and pol (Gallo et al., 1988) although 
this protein is not required for the catalytic activity 
of the HSV DNA polymerase. The 65Kdbp binds strongly in 
a sequence—independent manner to double—stranded DNA
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(Bayliss et al. , 1975; Gallo et al., 1988). Experiments 
have further shown that 65Kdbp excerts a 4-10 fold 
specific stimulatory activity on the HSV-1 polymerase, 
an effect that was blocked by addition of a 65Kdbp 
specific monoclonal antibody (Gallo et al., 1989).
Recent experiments with sedimentation and gel 
filtration analysis have indicated that the complex 
formed between UL42 and pol is a heterodimer (Gottlieb 
et al. , 1990). The data indicates that UL42 acts as an 
accessory sub-unit of the DNA polymerase: the results 
demonstrate that the UL42 acts to increase the 
processivity of polymerisation, with the UL42 increasing 
the affinity of the polymerase for primer termini 
(Gottlieb et al., 1990). An earlier report (O'Donnell et 
al. , 1988a) had suggested that the MDBP (ICP8) may be 
required for processivity, however the work of Gottlieb 
et al., (1990), using more purified proteins 
demonstrates no such requirement.
6.1.1.4 UL9
The polypeptide encoded by gene UL9 binds 
specifically to ori DNA sequences (Olivo et al., 1988; 
Weir et al., 1989). Purified UL9 protein binds to oris 
at two sites located on each arm of the palindrome 
(Elias and Lehman, 1988; Olivo et al., 1988). The role, 
played by the product of UL9 in DNA replication is 
unknown, although by analogy with other replication 
origin recognition sequences the binding to oris and 
oriL may initiate the assembly of a multiprotein 
replication complex (Challberg and Kelly, 1989).
6.1.1.5 UL5, UL8 and UL52
The three proteins encoded by genes UL5, UL8 and 
UL52 have been shown to form a complex in HSV-1 infected 
cells which exibits DNA dependent ATPase activity, DNA 
dependent GTPase activity, DNA helicase and DNA primase 
activities (Dodson et al., 1989; Crute et al., 1988,
1989). Although it is not yet known which of these
23
activities are associated with which of the subunits of 
the complex it has been demonstrated that the product of 
the UL8 gene is not required for DNA-dependent ATPase or 
DNA-helicase activity; as co-expression of the UL5 and 
UL52 products in a baculovirus expression system, is 
sufficient for production of these activities (Calder 
and Stow, 1990), in addition recent experiments using 
immunofluoresence have indicated that the UL8 protein 
may be involved in transporting the helicase-primase 
complex into the cell nucleus (Calder and Stow, 1990; 
Abstracts: 15th International herpesvirus workshop).
6.1.2 Viral enzymes involved in nucleotide metabolism
6.1.2.1 Ribonucleotide reductase (HR)
Ribonucleotide reductase (RR) catalyses the 
reduction of all four ribonucleotides to 
deoxyribonucleotides and as such plays an essential role 
in DNA synthesis. Cohen, (1972) provided the first 
evidence that HSV induced a novel RR activity; with 
Averett et al. , (1983) providing the first good 
biochemical evidence for an enzyme in infected cells 
with properties distinct from that of the cell enzyme.
HSV-1 and 2 have been shown to specify two sub­
units of RR, Rl and R2, with Mrs 136K and 38K for HSV-1 
and 138K and 36K for the HSV-2 enzyme (Dutia, 1983; 
McLauchlan and Clements, 1983; Preston et al., 1984; 
Cohen et al., 1985; Frame et al. , 1985; Bacchetti et 
al.% 1986; Ingermarson and Lankinen, 1987; Darling et 
al.t 1988). The HSV-1 Rl and R2 polypeptides are 
translated from two mRNAs of 5Kb and 1.2Kb which share a 
common 3' terminus (McLauchlan and Clements, 1982, 1983) 
and are encoded by genes UL39 and UL40 respectively 
(McGeoch et al., 1988). Direct evidence that these sub­
units formed a complex was provided by experiments with 
specific antisera and ts mutants (Frame et al., 1985; 
Bacchetti et al., 1986; Preston et al., 1984, 1988). 
Later, Ingermarson and Lankinen, (1987), demonstrated
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that the complex contained two molecules of Rl and two 
of R2.
Experiments with mutants in RR have shown that HSV- 
1 RR activity is largely dispensible for virus growth 
and DNA replication in exponentially growing cells in 
vitro at 34°C; although it is required for optimal 
growth in resting cells or in cells at high temperature 
(39.5°C) (Goldstein and Weller, 1988a, 1988b; Preston et 
al. , 1988) . This suggests that a cellular factor 
capable of complementing HSV RR is present in growing 
cells at lower temperatures, but is somehow inactive at 
39.5°C. Indicating that the viral requirement for its 
own RR is largely dependent on the conditions at which 
infection occurs.
Observations that a short synthetic oligopeptide 
corresponding to the carboxyl 9 amino acids of the small 
sub-unit, specifically inhibited the viral but not the 
cellular enzyme activity led to the belief that this 
enzyme may be a possible target for antiviral 
chemotherapy (Dutia et al. , 1986, Coen et al. , 1986). It 
was proposed that the inhibition of activity resulted 
from the ability of the nonopeptide to competitively 
inhibit binding of the small sub-unit with the binding 
site on Rl. This proposal has now been confirmed 
(McClements et al., 1988; Paradis et al., 1988; Darling 
et al., 1990). These findings lead to the interesting 
possibility that small peptides could be selected on the 
basis of sequence and structural information for their 
potential to inhibit sub-unit interaction. This view 
is supported by a similar finding with peptides 
from the thymidylate synthetase enzyme of VZV (Marsden 
et al., 1990; Abstracts, 15th International Herpesvirus 
Workshop).
Support for the view that HSV RR might be a valid 
antiviral target comes from the observation that the 
virulence of RR mutants in mice is highly attenuated 
(Cameron et al., 1988). Another mutant (in Rl) was shown 
to be severely impaired in its ability to replicate in
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the mouse eye model and failed to establish 
reactivatable latent infection (Jacobson et al., 1989). 
In contrast RR mutants have been demonstrated to 
replicate in a guinea-pig model (Turk et al., 1989). It
is not clear however, hou; appropriate either of these 
models are in relation to the situation encountered in 
human infection.
6.1.2.2 Thymidine kinase
The HSV-encoded Thymidine kinase (TK)(Kit and 
Dubbs, 1963), phosphorylates thymidine (Dubbs and Kit, 
1964) as well as deoxycytidine (Jamieson and Subak- 
Sharpe, 1974) and a variety of nucleoside analog&e^Elion 
et al., 1977). The TK gene has been mapped to around 0.3 
on the HSV-1 genome (Wigler et al., 1977; Halliburton et 
al., 1980; Reyes et al., 1982) a position corresponding 
to gene UL23 (McGeo&h et al., 1988). Studies with tk~ 
mutants have indicated that HSV TK is dispensible for 
growth in growing tissue culture cells (Dubbs and Kit, 
1964) but not in resting cells (Jamieson et .
Recent results have suggested that virus- 
encoded TK, although not essential for the establishment 
of latent infection, may be necessary for reactivation 
of the virus (Coen et al., 1989; Efstathiou et al.,
1989; Tenser et al., 1989). Several anti-HSV drugs, 
principally acyclovir become activated following 
phosphorylation by HSV TK (Elion et al., 1977; Fyfe et 
al., 1978; Field et al., 1980).
6.1.2.3 dUTPase
The HSV-1 induced enzyme dUTPase catalyses the 
hydrolysis of dUTP to dUMP and pyrophosphate (Wohlrab 
and Franke, 1980; Caradonna and Cheng, 1981; Williams,
1984). The gene encoding the dUTPase has been mapped on 
the HSV-1 genome to a region corresponding to the UL50 
gene (Preston and Fisher, 1984, McGeoch et al., 1988). 
The viral dUTPase is not essential for growth in
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dividing cells in tissue culture (Fisher and Preston,
1986).
6.2 OTHER ENZYMES ENCODED BY HSV-1
6.2.1 Uracil-DNA glycosylase
The uracil-DNA glycosylase is an enzyme involved in 
DNA repair which removes uracil residues from DNA. The 
presence of a HSV-induced uracil-DNA glycosylase has 
been detected in HSV-infected cells (Caradonna and 
Cheng, 1981) and has been mapped to a position 
corresponding to the UL2 gene on the HSV-1 genome 
(Worrad and Caradonna, 1988; Mullaney et al. , 1989). A 
mutant in this gene has also been shown to behave 
identically to wild type HSV, indicating this gene is 
dispensible for growth in tissue culture (Mullaney et 
al., 1989).
6.2.2 Alkaline exonuclease
HSV induced alkaline exonuclease activity has been 
described in both HSV-1 and HSV-2 infected cells (Keir 
and Gold, 1963; Morrison and Keir, 1968; Hay et al.,
1971). It seemed likely that alkaline exonuclease 
activity was virally encoded as a ts mutant has been 
isolated that affected the activity of the enzyme 
(Franke et al., 1978) and microinjection of HSV DNA 
fragments into Xenopus laevis ooctyes resulted in the 
production of the nuclease activity (Preston and 
Cordingly, 1982). The gene responsible for the nuclease 
activity has been mapped on the HSV-1 genome between 
0.168-0.175 map units (Preston and Cordingly, 1982;
Costa et al., 1983; Wathen and Hay, 1984; Banks et al.,
1985). A position which corresponds to the UL12 gene 
(McGeogh et al., 1988).
Early experiments with a HSV-2 ts mutant suggested 
that the alkaline exonuclease was essential for viral 
DNA replication (Moss, 1986). However, recent 
experiments with a lacZ insertion mutant in this gene
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(Weller et al. , 1990) have shown that although the 
mutant is severely compromised for growth in Vero cells, 
it was able to produce wild-type levels of DNA and late 
proteins, indicating that it is not essential for viral 
DNA synthesis. Electron microscopy of this mutant has 
revealed that it accumulated large numbers of partially 
cored capsids. It therefore seems likely that the 
alkaline exonuclease is involved at a later stage 
possibly in the processing of the viral DNA into capsids 
(Weller et al. , 1990).
6.2.3 Protein kinase
Following infection of cells with HSV-1 a novel 
protein kinase activity is induced (Blue and Stobbs, 
1981; Purves et al., 1986). Comparisons of eukaryotic 
protein kinase sequences with the published sequences of 
HSV-1, HSV-2 (McGeoch et al. , 1985, 1987) and VZV 
(Davison and Scott, 1986) has revealed homology with the 
US3 gene of HSV-1 (McGeoch and Davison, 1986).
Experiments with antisera raised against a 
synthetic peptide from the predicted DNA sequence and 
purification of the kinase activity from HSV infected 
cells has confirmed that the protein kinase is indeed 
encoded by gene US3 (Frame et al., 1987) although this 
activity is dispensible for viral growth in tissue 
culture (Frame et al., 1987; Purves et al. , 1987). The 
product of gene UL13 has also been proposed as being a 
protein kinase (Smith and Smith, 1989), however the 
protein remains to be identified.
6.3 HSV-1 IMMEDIATE EARLY PROTEINS
HSV-1 encodes five IE polypeptides: VmwllO, Vmw63, 
Vmwl75, Vmw68 and Vmwl2 encoded by IE genes 1-5 
respectively (Reviewed by Everett, 1987). Although 
recent work of Wymer et al., (1989) with HSV-2 has 
demonstrated a TAATGARAT—1 ike element in the promoter of 
the HSV-2 Rl gene, it therefore seems likely that Rl
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should also be classified as an IE gene; as in addition 
it is express^ very early in infection and in the 
presence of cyclohexamide and the absence of immediate 
early transactivation (Preston, 1979a; DeLuca et al. , 
1985; Roizman and Batterson, 1985).
During infection in the presence of inhibitors of 
protein synthesis, there is an accumulation of IE mRNAs 
(Preston, 1979a). These transcripts expressed in the 
absence of de novo protein synthesis (Kozak and Roizman, 
1974; Clements et al. , 1977; Jones and Roizman, 1979) 
have been mapped on the HSV-1 genome (Clements et al. ,
1979). All the immediate genes u/ith the exception of IE 
gene 2 are located in the vicinity of the repeat regions 
of the genome, with IE genes 1 and 3 situated 
within the long and short inverted repeats respectively, 
resulting in the presence of two copies of each (Watson 
et al., 1979; Anderson et al., 1980; Mackem and Roizman, 
1980; Marsden et al., 1982; Rixon et al., 1982).
6.3.1 Vmwl75
This is an essential protein and a major 
transactivator of both early and late genes. A number of 
viral ts mutants in IE gene 3 have been isolated: These 
fail to synthesize DNA or to produce early or late 
proteins at the NPT (Bef\yesh-Melnick et al., 1974; 
Marsden et al., 1976; Preston et al., 1979a; Dixon and 
Schaffer, 1980; Watson and Clements 1978, 1980). These 
ts mutants overproduce IE transcripts at the NPT 
(Preston et al., 1979a; Dixon and Schaffer, 1980) 
implicating Vmwl75 in the autoregulation of IE genes: 
Infact plasmids that express Vmwl75 can repress 
transcription from the IE-3 promoter, (O'Hare and 
Hayward, 1985b). The other IE promoters can also be 
repressed by Vmwl75 under certain conditions in 
transfection assays (Deluca and Schaffer, 1985; Gelman 
and Silverstein, 1987a, b).
Vmwl75 binds specifically to the target consensus 
sequence 51-ATGCTG-3', which is present at the
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transcription start site of its own gene (Beard et al. , 
1986; Faber and Wilcox, 1986; Kristie and Roizman, 1986; 
Muller, 1987) and it was thought that this binding 
mediated autoregulation (Gelman and Silverstein, 1987b; 
Muller, 1987; Roberts et al., 1988). However recent work 
has suggested that the Vmwl75 binding site in the IE-1 
promoter has no apparent role in the expression of 
VmwllO. Although a mutation in the Vmwl75 binding site 
reduced the ability of Vmw 175 to repress the IE-1 
promoter in transfection assays, it had no effect on the 
levels of VmwllO expression during normal HSV-1 
infection (Everett and Orr, 1990).
6.3.2 Vmw63
This protein is also essential for viral growth in 
vitro, with ts mutants over-producing Vmwl75 and VmwllO 
at the NPT (Sacks et al. , 1985). It is thought that this 
protein is implicated in the regulation of late gene 
expression, as although Vmw63 mutants exhibit normal 
levels of early protein and DNA synthesis they have a 
severe reduction in production of late proteins. (Rice 
and Knipe, 1988).
6.3.3 VmwllO
This protein is involved in activation of both 
viral and cellular promoters in vitro (Everett 1984;
O'Hare and Hayward, 1985a,b; Quinlin and Knipe, 1985; 
Gelman and Silverstein, 1985; Mavromara-Nazos et al. ,
1986). However, experiments with a VmwllO deletion 
mutant c/11403 (Stow and Stow, 1986, 1989), have shown 
that the polypeptide is not absolutely essential for 
growth in tissue culture, with a high moi able to 
surmount the absence of the polypeptide. However the 
virus did show reduced growth with low moi.
The transactivation effect of VmwllO on viral and 
cellular promoters has been shown to occur with VmwllO 
by itself or in association with Vmwl75 (Everett 1984b, 
1986; O'Hare and Hayward, 1985; Quinlan and Knipe, 1985;
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Gelman and Silverstein, 1986). It also seems likely that 
VmwllO is unable by itself to activate the expression of 
early genes without the presence of Vmwl75, as a 
deletion mutant in IE gene 3 lacked the ability to grow 
in normal cells (DeLuca et al., 1985).
6.3.4 Vmw68
The role of the product of the IE gene 4 is at 
present unclear and no ts mutants in this gene have been 
isolated at present. However experiments have linked 
Vmw68 with a possible role in the expression of late 
genes, as a mutant virus has been constructed which 
lacks part of the polypeptide (Post and Roizman, 1981).
scprtfc- ouis
The mutant grows poorly in /tissue culture^and is 
deficient in the expression of L genes (Sears et al.,
1985).
6.3.5 Vmwl2
This is the least characterised IE protein. Its 
function is unclear and is unique among the IE genes in 
that it lacks phosphorylation and localises 
predominantly to the cytoplasm instead of the nucleus 
(Preston 1979b; Marsden et al., 1982; Palfreyman et al.,
1984). Vmwl2 is non-essential for growth in tissue 
culture as recombinant viruses have been constructed 
which exhibit normal growth characteristics, while 
lacking the entire IE gene 5 (Longnecker and Roizman, 
1986; Umene, 1986; Brown and Harland, 1987).
6.4 HSV-1 STRUCTURAL PROTEINS
Greater than 30 proteins have been detected in 
virions of HSV-1 (Spear and Roizman, 1972; Heine et al., 
1974; Marsden et al., 1976; reviewed by Dargan, 1986). 
These can be grouped into either capsid proteins, 
tegument proteins or glycoproteins.
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6.4.1 Capsid proteins
Capsids isolated from infected cells are either 
"empty" or those u/hich contain viral DNA. Empty capsids 
are made-up of at least 5 proteins,VP5 (Vmwl55), VP19 
(Vmw53), VP23 (Vmw36), VP24 (Vmw24)(Gibson and Roizman, 
1972) and 12K (Vmwl2) (Heilman et al., 1979; Cohen et 
al. , 1980).
VP5 is commonly referred to as the major capsid 
protein (MCP). By use of polyvalent antisera to assay 
in vitro translation products, (Costa et al., 1984) VP5 
has been shown to be encoded by gene UL19 (Davison and 
Scott, 1986b; McGeoch et al., 1988). VP19C is a DNA 
binding protein (Braun et al., 1984) and was initially 
mapped using intertypic recombinants to a region of the 
HSV-1 genome between UL39 and UL42 (Braun et al., 1984). 
However recent work involving direct amino acid 
sequencing of purified capsid proteins has demonstrated 
that VP19C is infact encoded by gene UL38 (Rixon et al., 
1990). This work of Rixon et al., (1990) additionally 
assigned VP23 to gene UL18.
In addition to those five polypeptides, capsids 
containing HSV DNA also posess two further proteins, one 
of which is polypeptide VP21, a major component of the 
cylindrical protein plug which in combination with the 
viral DNA forms the virion core (Gibson and Roizman,
1972). The second is VP22a (p40): This was thought to be 
a component of full not empty capsids (Gibson and 
Roizman, 1972, 1974; Heilman et al., 1979; Preston et 
al., 1983) and was intially thought to be a capsid 
protein which may have undergone processing to form the 
abundant virion protein VP22 that forms a loose 
association with the nucleocapsid (Gibson and Roizman, 
1974).
Preston et al., (1983) showed that a mutant 
containing a temperature sensitive lesion in gene UL26 
is defective in the processing of VP22a and proposed 
that UL26 encodes VP22a. Experiments with this ts 
mutant, tsl201, have shown that during infections at the
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NPT viral DNA is not packaged into capsids, suggesting a 
possible role for this protein in DNA packaging (Preston 
et al. , 1983. Further experiments with ts mutants (Rixon 
et al., 1988) have indicated that VP22a is indeed 
present in empty capsids, but does not form a major 
component of full capsids. These experiments indicate 
that VP22a probably forms a transient association with 
capsids during their assembly, however its removal from 
capsids seems to be connected with the DNA packaging 
process (Rixon et al., 1988).
Map locations have as yet not been assigned to 
proteins VP24, VP21 and 12K.
6.4.2 Tegument proteins
The virion tegument is a poorly defined structure 
which lies between the envelope and the capsid and 
comprises approximately 65% of the virion by volume 
(Schrag et al., 1989). Tegument proteins (in addition to 
glycoproteins) can be identified when released from 
virions in the presence of non-ionic detergents. However 
some proteins seem to associate more strongly with 
capsids than others (Lemaster and Roizman, 1980; Roizman 
and Furlong, 1974; Spear, 1980). It is unclear how many 
proteins are located within this region or how they are 
orientated, however a major component of the tegument is 
the protein involved in transinduction of IE genes Vmw65 
(VP16), the product of gene UL48 (Post et al., 1981; 
Batterson and Roizman, 1983; Campbell et al., 1984).
6.4.3 Glycoproteins
HSV-1 encodes at least seven distinct 
glycoproteins: gB, gC, gD, gE, gG, gH and gl (Spear, 
1976; Marsden et al., 1978, 1984; Bauke and Spear, 1979; 
Buckmaster et al., 1984; Roizman et al., 1984; Gomp els 
and Minson, 1986; Frame et al., 1986; Longnecker et al., 
1987; Johnson and Feenstra, 1987; McGeoch, 1987). These 
genes are encoded by the genes UL27, UL44, US6, US8,
US4, UL22 and US7 respectively (McGeoch et al., 1985,
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1988). Sequence analysis has also suggested an 
additional glycoprotein potentially encoded by gene US5 
(McGeoph et al., 1985). Recent experiments with an 
antisera raised against a US5-fusion protein have 
identified a 40K virion associated protein, which is 
somewhat larger than that predicted by the DNA sequence 
(Gao and Spear, 15th International herpesvirus 
workshop). This new glycoprotein will be designated gJ.
Of these glycoproteins mutations in gC have shown 
that it is non-essential for infectivity (Heine et al. , 
1974; Holland et al. , 1984; Draper et al., 1984., Homa 
et al., 1986), in addition glycoproteins, gE, gG, gl and 
the product of the US5 gene have all also been shown to 
be dipensible for growth in tissue culture (Longnecker 
and Roizman, 1986, 1987; Longnecker et al., 1987; Weber 
et al., 1987; Harland and Brown, 1988).
Only three of the glycoproteins therefore have been 
shown to be essential for infectivity in vitro, namely 
gB, gD and gH (Sarmiento et al., 1979; Little et al., 
1981; Ligas and Johnson, 1988; Weller et al., 1983; 
Gompels and Minson, 1986; McGeoch and Davison, 1986b; 
Desia et al., 1988). Of these only gH is possibly 
essential for absorption (Buckmaster et al., 1984; 
Gompels and Minson, 1986; Desia et al., 1988) as virus 
mutants in both gB and gD have been shown to bind 
efficiently to the cell surface (Cai et al., 1988; Ligas 
and Johnson, 1988; see earlier), while failing to 
synthesis viral polypeptides.
7. CONTROL OF HSV-1 GENE EXPRESSION
Lytic infection of cells in vitro by HSV-1 leads to 
expression of its genes in a defined pattern which can 
be divided into three main phases: Immediate early (IE), 
early (E) and late (L), alternatively termed alpha, beta 
and gamma (Honess and Roizman, 1974; Clements et al., 
1977). Experiments with inhibitors of viral DNA and 
protein synthesis have shown that this expression occurs
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in a temporal cascade (Honess and Roizman, 1974, 1975; 
Clements et al., 1977; Jones and Roizman, 1979), with 
expression of IE polypeptides being essential for the 
induction of early genes and functional E proteins 
subsequently being required for expression of late 
proteins.
7.1 IMMEDIATE-EARLY GENES
IE proteins are first detected about lh after 
absorption with gene expression initially thought to 
peak at about 2-3 hours, however these observations were 
usually made on measurements of transcription in the 
absence of viral protein synthesis or functional Vmwl75 
(Honess and Roizman, 1975, Preston et al., 1978), rather 
than on observations of time course in a normal 
infection.
Infact, where studies have been carried out in the 
course of a normal infection, high levels of IE 
polypeptide accumulation have been detected in the 
middle and late stages of infection (Reviewed by Everett 
and Orr, 1990). Indeed recent experiments have shown 
that VmwllO steadily accumulates throughout infection 
with no obvious evidence of repression (Everett and Orr,
1990).
The promoter regions of the IE genes, consists of 
two components, a "TATA" box sequence necessary for 
basal and induced levels of transcription, and upstream 
regulatory sequences containing multiple cis-acting 
elements conferring enhancer function and responsivity to 
IE regulation (Mackem and Roizman, 1982a,b; Cordingley 
et al. , 1983; Preston et al., 1984; Kristie and Roizman, 
1984; Bzik and Preston, 1986).
All the IE promoters contain GC-rich regions (Spl 
binding sites) and one to three copies in either 
orientation of the element TAATGARAT (where R is a 
purine), which is a cis-acting motif (Mackem and 
Roizman, 1982c; Whitton et al., 1983; Whitton and 
Clements, 1984; Preston et al., 1984; Galloway et al.,
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1985), which has been shown to mediate the stimulation 
of IE transcription by the major virion tegument protein 
Vmw65 (VP16), the product of gene UL48, upstream of the 
mRNA initiation sites (Post et al. , 1981; Mackem and 
Roizman, 1982; Campbell et al., 1984; Preston et al.,
1984).
Vmw65 does not form a direct interaction with DNA 
(Marsden et al., 1987) but instead interacts with one or 
more cellular factors to form a ternary complex (IEC) 
that binds to TAATGARAT (McKnight et al., 1987; Preston 
et al., 1988; O'Hare et al., 1988). A cellular component 
of this complex appears to be a ubiquitous protein with 
a variety of names NFIII (Pruijn et al., 1986), OBPIOO 
(Baumruker et al., 1988; Strum et al., 1987), OTF-1 
(Gerster and Roeder, 1988), TRF (O'Hare and Goding,
1988) and alpha-Hl (Kristie and Roizman, 1987).
This component recognizes the TAATGARAT element and 
also an octomer consensus sequence ATGCAAAT. Although 
NFIII is capable of binding to a range of sequences, 
there is only efficient formation of the IEC complex 
when the TAATGARAT element is present (O'Hare et al., 
1988; Gerster and Roeder, 1988; ApRhys et al., 1989).
IEC complex formation facilitates an acidic activating 
domain, which is located within the c-terminus of Vmw65 
to interact with a transcription complex and so amplify 
gene expression (Dalrymple et al., 1985; Triezenberg et 
al., 1988; Sadowski et al., 1988; Cousens et al., 1989).
7.2 EARLY GENES
Synthesis of early genes is initiated after the 
appearance of immediate-early polypeptides (Honess and 
Roizman, 1974; Wagner, 1985; Weinheimer and McKnight, 
1987; Zhang and Wagner, 1987), as early genes require 
prior synthesis of IE gene products for their expression 
(Honess and Roizman, 1974; Clements et al., 1977).
However there seems to be a greater deal of 
variation in the kinetics of expression of early genes 
in comparison to IE genes. gD although expressed as an
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early gene, is not maximally produced until the onset of 
viral DNA replication (Gibson and Spear, 1983: Johnson 
et al., 1986) and as such has been described as a beta- 
gamma or early-late (EL) gene (Roizman and Batterson, 
1985; Wagner, 1985; Harris-Hamilton and Bachenheimer,
1985). This increase in transcription of EL genes does 
not neccesarily show a direct requirment for viral DNA 
synthesis, as increased expression may be due soley to 
an increased template copy number (Everett and Johnson, 
1986a).
The promoter regions of HSV early genes have been 
well studied and no viral specific sequences involved in 
transactivation have been detected. A typical HSV early 
promoter has been found to contain a "TATA" box element 
upstream of the transcriptional start site in 
combination with other elements, including "CCAAT" 
boxes, GC-rich regions (for Spl binding) and G-rich 
elements (McKnight et al., 1985; Everett, 1983;
Eisenberg et al., 1985; El Kareh et al., 1985). Binding 
of various cellular transcription factors such as the 
"CCAATT" box binding factor and Spl has been 
demonstrated for the promoter of the HSV tk gene (Jones 
et al., 1985; Graves et al., 1986). Although many HSV 
promoters contain homologies to TATA, CCAAT and GC-rich 
elements, there has been found to be a great deal of 
diversity between promoters of the same class (Mackem 
and Roizman, 1982c; Wagner, 1985). This may explain the 
differential rates of expression described previously 
for genes of the same class (Honess and Roizman, 1974; 
O'Hare and Hayward, 1985a, Harris-Hamilton and 
Bachenheimer, 1985).
7.3 LATE GENES
Late gene product accumulation can initially be 
detected at about 3 hours post absorption, reaching a 
peak at around 10-16 hours, this is approximately 2 
hours after the peak of viral DNA synthesis at 8 hours 
post absorption (Munk and Sauer, 1964; Roizman, 1969;
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Wilkie, 1973). The expression of late genes is dependent 
on the presence of a functional Vmu/175 protein (Watson 
and Clements, 1980) and is also dependent upon the 
replication of the viral DNA. As demonstrated by 
experiments with ts DNA- mutants and inhibitors of DNA 
synthesis (Swanstrom and Wagner, 1974; Honess and 
Roizman, 1974; Powell et al. , 1975; Marsden et al. ,
1978; Jones and Roizman, 1979; Holland et al. , 1980; 
Conely et al., 1981; Pederson et al., 1981).
Late genes can be split into two classes; either 
gammai or gamma2 , otherwise termed "leaky-late" and 
"true—late" respectively. "Leaky-lates" are those genes 
whose expression is detectable in the absence of viral 
DNA replication, although they require DNA synthesis for 
maximal expression. Whereas "true-late" genes have an 
absolute requirement for DNA synthesis for expression 
(Wagner, 1985; Roizman and Batterson, 1985; Johnson et 
al., 1986). An example of a "leaky-late" gene is the 
product of gene UL19, Vmwl55-the major capsid protein. 
Whereas a protein which exhibits "true-late" 
characteristics is the product of gene US11 (Johnson et 
al., 1986).
Experiments which linked an HSV origin of 
replication with the US11 promoter found that only the 
"TATA" boxyland replication of the host plasmid in cis 
were all that was required for full expression (Johnson 
and Everett, 1986a, b). It is unclear what connection 
exists between the replication of viral DNA and late 
gene expression, although an increase in template copy 
number is unlikely to be responsible, as some effect 
would be detectable on early genes also.
A possible role has been indicated for IE proteins 
Vmw63 and Vmw68 in late gene induction, as mutants in 
these genes exist which are deficient in expression of 
certain late polypeptides (Sacks et al., 1985; Sears et 
al., 1985).
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8. CLEAVAGE AND PACKAGING OF VIRAL DNA
Two steps are involved in the maturation of HSV 
DNA: The processing of the concatameric DNA into unit 
lengths and the assembly of capsids containing a genome 
equivalent of the viral DNA.
It is thought likely that the maturation of the 
viral genome and its subsequent packaging involves site 
specific cleavage of viral DNA concatamers. The cis- 
acting sequence required for this cleavage is located 
within the a sequence (Vlazny and Frenkel, 1981;
Mocarski and Roizman, 1982; Spaete and Mocarski, 1985; 
Stow et al. , 1983); with two seperate cis-acting 
sequences within the a sequence appearing to be 
essential for the cleavage and package process (Varmuza 
and Smiley, 1985; Deiss et al. , 1986). The cleavage 
signal has now been further defined to a 179-bp fragment 
across a a-a junction (Nasseri and Mocarski, 1988). Some 
common mechanism seems to be involved in the maturation 
of herpesvirus genomes, as structural conservation 
exists in the signals involved in processing and 
packaging among many of the herpesviruses (Davison,
1984; Albrecht et al., 1985; Spae te and Mocarski, 1985; 
Hammerschmidt et al., 1988; Marks and Spector, 1988).
Studies have been aided by isolation of viral 
mutants that are capable of replicating viral DNA but 
are deficient in processing and packaging. The viral 
alkaline exonuclease, has been implicated in this 
process, as an insertion mutant in this gene produces 
wild-type levels of DNA synthesis and late proteins 
while failing to process and package its DNA (Weller et 
al., 1990, see previous section 4.7). At least five 
other genes have been implicated; UL6, UL26, UL28, UL32 
and UL54: with viral mutants existing in these genes 
which are defective in DNA processing and encapsidation. 
suggesting that capsid formation and DNA packaging are 
dependent on several viral gene products (Weller et al., 
1983, 1987; Preston et al., 1983; Rixon et al., 1988;
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Matz et al., 1983; Sacks and Schaffer, 1987; Sherman and 
Bacchenheimer, 1987, 1988; Addison et al., 1990). It is 
unclear at present u/hat particular role in 
processing/packaging is played by each of these genes.
9. GENERATION OF ANTISERA TO SYNTHETIC OLIGOPEPTIDES
During the last decade the rapid development of DNA 
sequencing methods has produced a convenient way of 
determining the amino-acid sequence of proteins which 
are predicted to be encoded by identified open-reading 
frames. Although it proved relatively easy to generate 
primary sequence data for genes it was then necessary to 
link gene sequences with specific proteins. One obvious 
solution was to produce an antibody probe against the 
putative protein.
Due to size and cost limitations, chemical 
synthesis of complete predicted proteins is generally 
not practical. As an alternative short peptide sequences 
were one suggestion as possible mimics for antigenic 
sites on proteins which would allow the useful 
development of antibodies of pre-determined specificity. 
Early results from studies with the bacteriophage MS2 
provided evidence that indicated peptides may be able to 
function as immunising antigens (Langebeheim et al., 
1976). These experiments showed that a fragment of the 
coat protein of MS2 and the corresponding synthetic 
peptide with the same sequence elicited antibody which 
reacted with the intact virus particle.
However work on the immunogenicity of proteins 
(reviewed by Lerner, 1982; Benjamin et al., 1984) 
predicted that most immunogenic sites were composed of 
conformational determinants, formed by complex tertiary 
interactions between amino acid residues that although 
proximal in the protein tertiary structure, were distal 
in relation to the primary linear amino acid sequence. 
Therefore it was thought that small portions of a 
protein would, in general, be unlikely to elicit
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antiserum reactive against an intact protein. It was 
believed that for a peptide to elicit antibodies that 
could react with an intact protein containing the 
peptide sequence, it would be neccessary to construct 
the peptide in such a way as to attempt to reproduce the 
tertiary confirmation of an antigenic site on the intact 
protein (Arnon, 1980).
This theory was challenged by experiments with 
chemically synthesised protein fragments from the amino 
or carboxy terminals of viral proteins whose amino acid 
sequences had been predicted from analysis of nucleic 
acid sequences. Two groups were first to describe 
protein reactive antibodies generated by synthetic 
peptides: antibodies to the amino and carboxy terminal 
regions of the simian virus 40 (SV40) transforming 
protein were found to react with the native protein 
(Walter et al. , 1980), providing indirect confirmation 
that the DNA sequence and the presumed open reading 
frame were correct. In addition antisera to an 
oligopeptide corresponding to a region of an unknown 
suspected gene, predicted by analysis of Moloney 
Leukemia virus (MOLv) DNA, allowed identification of a 
previously unidentified gene product (Sutcliffe et al.,
1980).
These initial observations were followed by 
numerous other reports of oligopeptide induced antisera 
acting as probes for polypeptides (e.g. Lerner et al., 
1981; Baron and Baltimore, 1982; Bittle et al., 1982; 
Green et al., 1982; Sutcliffe et al.t 1983).
9.1 UTILISATION OF ANTIPEPTIDE ANTIBODIES
As antipeptide antibodies possess the advantage of 
having pre-determined specificity they have also proved 
useful for answering a variety of biological questions 
e.g. For establishing the orientation of proteins in 
plasma membranes (Schneider et al. , 1983), for 
distingushing between closely related proteins that
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differ by only a single or few amino acids (Alexander et 
al. , 1983), for designing immunodiagnostic reagents 
(Gerin et al., 1983) and for analysing the molecular 
basis of viral and microbially induced immunity (Dryberg 
and Oldstone, 1986).
In recent years the availability of regions of, and 
subsequently the complete, DNA sequence of HSV-1 
(Davison and Wilkie, 1981; Murchie and McGeoch, 1982; 
McGeoch et al., 1985, 1986, 1988; Perry and McGeoch, 
1988) has allowed this technique to be applied to the 
attempted identification and characterisation of the 
predicted products of the identified HSV-1 open-reading 
frames. Palfreyman et al. , (1984b) using synthetic 
oligopeptides conjugated to BSA to produce rabbit 
antisera reactive with the products of HSV-1 immediate 
early genes, 5 and 3, namely Vmwl2 and Vmwl75 were the 
first to successfully generate antisera to synthetic 
peptides which was reactive with HSV-1 gene products. 
This led to numerous successful uses of the technique 
with HSV-1 polypeptides.
To date some 14 HSV-1 genes have either had their 
products identified or known proteins assigned to them 
using this method: The 21K product of gene US11, a DNA 
binding protein which interacts with the a sequence, and 
is localised in nucleoli (Dalziel and Marsden, 1984; 
MacLean et al., 1987); the 38K product of gene UL40, the 
small sub-unit of ribonucleotide reductase (Frame et 
al., 1985); the products of genes US3, US4 and US9, 
which encode a protein kinase, glycoprotein G and a 10K 
tegument phosphoprotein respectively (Frame et al.,
1986a, 1986b and 1987). Confirmation of the products of 
the genes required for DNA replication namely, UL5, UL8 , 
UL9, UL42 and UL52 was also made by this technique 
(Olivo et al., 1989). Identification of the products of 
genes UL31, UL45, UL46 and UL47 using antisera generated 
with synthetic oligopeptides is described in this 
thesis.
In recent years the majority of interest
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surrounding the production of immune responses to 
synthetic peptides has focused on the possibility that 
they may provide useful immunogens in the development of 
synthetic vaccines to a range of viral and microbial 
diseases (reviewed by Brown, 1990). The first 
description of a protective effect induced by 
immunisation with a synthetic peptide was with Foot and 
Mouth Disease Virus (FMDV) (Bittle et al. , 1982), this 
group demonstrated a protective immune response in 
Guinea-Pigs using the amino acid sequence from 141-160 
of the VP1 protein of FMDV, other examples of 
demonstrated neutralising antibodies have been described 
to poliovirus (Eminin et al., 1983), in cows with FMDV 
(DiMarchi et al., 1986), protection against experimental 
infection of malaria in monkeys (Patarryo et al. , 1987), 
and also to gp41 of a bovine rotavirus (Frenchick et 
al. , 1987) so raising hopes that synthetic epitopes in 
the form of peptides may provide some answers to as yet 
unsolved vaccine problems.
Before peptides can be considered as suitable 
vaccines a number of problems will have to be 
surmounted: It is unlikely that any peptide based 
vaccine that contained a carrier protein (nec-e5 5ary to 
enhance immunogenicity, see section 9.2) would be 
acceptable for use in humans or animals due to the 
undefiriable nature of the immunogen and the possibility 
of adverse reactions that might be induced by such a 
carrier. Also, many of the conjugation methods used 
contain compounds that would be unsuitable for human use 
or introduction into the food chain because of their 
toxic or carcinogenic properties. There would be a 
particular problem if a series of injections proved 
necessary as it has been demonstrated that pre-existing 
immunity to carrier proteins can severely reduce their 
efficiency in stimulating a response (Schultze et al., 
1985; Frenchick et al., 1987). Furthermore a peptide- 
protein conjugate would be almost impossible to 
quantitate accurately in terms of dose and alternative
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adjuvants would also have to be developed as those 
currently available are too harsh for vaccine 
development.
9.2 FACTORS INFLUENCING THE ANTIGENICITY OF PEPTIDES
There are a large number of factors which have been 
shown to influence the success of antipeptide antibody 
production. The choice of peptide sequence was thought 
to play an important role in determining the response 
against the antigen; with the inclusion of a variety of 
amino acids on the basis of charge or size suggested as 
influencing immunogenicity (Lerner,1984). In particular 
inclusion of a proline residue or residues was shown to 
enhance significantly the antigenicity of synthetic 
peptides. Peptides containing proline residues in 
addition to polar or uncharged residues routinely 
produce antibodies that react with the native protein 
(Sutcliffe et al. , 1983). This may be due in part, to 
the the fact that proline residues form imide bonds 
instead of amide bonds creating bends in the polypeptide 
chain. Such regions are often accessible to antibodies 
and may enhance mimicking of the native conformation 
(Sutcliffe et al., 1983).
The length of the immunising sequence is also 
critical: to raise antibodies to a peptide a minimum of 
six amino acids is required (Wilson et al. , 1984) and 
peptides of more than ten amino acids generally induce 
antibodies that bind with high frequency to the native 
protein (Palfreyman et al. , 1984a; Tanaka et al., 1985).
Furthermore, the region of the protein from which 
the immunising sequence is derived is thought to be 
significant. Antibodies raised against an accessible 
epitope have a better chance of binding to the native 
protein than antibodies to an inaccessible site, 
although by its very nature, the process of antibody 
binding itself may also render inaccessible sites 
accessible (Wilson et al., 1984). It would be expected
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that more hydrophilic amino acid residues would be 
located on the surface of the molecule and therefore 
analysis using hydrophilicity plots (Hopp and Woods, 
1981, 1983) and hydropathicity plots (Kyte and 
Doolittle, 1982) make it possible to predict which parts 
of the protein are likely to be surface orientated.
These sites therefore have a better chance of 
corresponding to antigenic determinants and so peptides 
can be chosen accordingly. In addition peptides 
containing hydrophilic amino acids have the added 
advantage of being more likely to be soluble in water 
and are thus much easier to work with.
Terminal peptides, either amino or carboxy, are 
also good candidates as choices for immunising peptides. 
The surface location of many chain termini in proteins 
(Thornton and Sibanda, 1983) provides a rational for 
their inclusion as immunogens. It has also been 
suggested that the higher than average antigenicity of 
chain termini could be due to the fact that they are 
less constrained than other sections of the polypeptide 
chain and show a high relative flexibility (Van 
Regenmortel et al., 1986). Peptides corresponding to 
highly mobile regions of the protein, when used as 
immunogens are able to elicit antibodies which react 
strongly with native proteins (Tainer et al., 1984). 
Other factors such as immunisation dose, choice of 
adjuvant and immunisation schedules can also influence 
the result, but usually to a lesser extent (Shinnick et 
al., 1983; Lerner, 1984; Palfreyman et al., 1984a). 
Although these variables are unlikely to have an 
influence over the success of a given antibody's 
potential to recognise a native protein, their 
alteration can have an strong influence over the titre 
of the resulting response (Shinnick et al., 1983).
As has been mentioned, care is usually taken to 
choose the most antigenic peptide sequence when 
attempting to raise antibodies. However it has been 
suggested, (Lerner, 1984) that unless all that is
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required is to access a protein predicted by a nucleic 
acid sequence, the overriding consideration when 
choosing a peptide should be the precision with which a 
given antibody will be able to answer the experimental 
question posed. It is thought that even if an area 
adjacent to a primary target seems more attractive (i.e. 
more hydrophilic) one should (within reason) serve the 
needs of the experiment rather than relying on the 
theoretical "rules" governing peptide immunogenicity 
(Lerner, 1984).
Studies with the haemaglutfmq protein of 
influenza virus (Green et al. , 1982; Sutcliffe et al. , 
1983) have provided the basis for support of these 
observations. Synthesis of peptides covering the 
majority of the HA1 chain showed that the majority of 
the antibodies produced reacted with the intact molecule 
(Green et al. , 1982). Because the complete DNA sequence 
was available (Min Jou et al. , 1982) and its 
crystallographic structure was available to high 
resolution (Wilson et al. , 1981) it was known that in 
its folded state the HA1 molecule displays a number of 
secondary structures including alpha-helices, extended 
chains and beta-sheets. It was therefore evident that 
reactivity of antipeptide antibodies is in general, 
independent of secondary structure or location in the 
molecule. These observations have been further supported 
by experiments with MuLv: 12/12 peptides selected at 
random across the pol gene of MuLv produced antibodies 
reactive with the native protein (Sutcliffe et al., 
1983). Furthermore 18/18 peptides selected from the 
rabies virus glycoprotein gene were also successful in 
eliciting an antiprotein response (Sutcliffe et al., 
1983). Perhaps more important influencing factors may be 
the relative abundance of the target protein and the 
titre of the antibody probe, rather than its
S • I
To function as a successful immunogen, antigens 
must be presented in such a way that they are
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effectively taken up by macrophages (i.e. not lost by 
excretion or rapidly removed by irrelevant cells such as 
granulocytes or hepatocytes) and can also be processed 
so as to be recognised by T-cells. They must also be in 
a form that makes them stable to enzymes which could 
destroy their immunogenic configuration (Humphery,
1986).
Although some reports indicated that it was 
possible to immunise animals u/ith "free" peptides 
without the need for a macromolecular carrier (Beachy et 
al. , 1981; Lerner et al. , 1981; Dreesman et al. , 1982;
Jackson et al. , 1982; Atassi and Webster, 1983; Young
et al. , 1983; Francis et al. , 1987a), it is generally 
necessary to immumise animals with peptide-carrier 
conjugates. With the use of suitable proteins such as 
KLH, thyroglobulin, ovalbumin and BSA (although if it is 
intended to use antibodies to react with the products of 
cultured cells, it is probably best to avoid BSA as a 
carrier, as the anti-albumin antibodies can give 
spurious results, as so many ligands and proteins bind 
to the albumin contained in the bovine serum in cultured 
cells). Recently there has also been a description of 
the utilisation of the core antigen of Hepatitis B virus 
as a carrier molecule for synthetic peptides (darke et 
al., 1987; Francis et al., 1990). These peptide 
conjugates have produced titres of antibody to a FMDV 
protein almost equal to that elicited by the intact 
protein (Clarke et al.,1987). The coupling of peptides 
to carriers may provide T-cell help to antipeptide 
producing B-cells (Mitchison, 1971) and also help 
improve immunogenicity of the peptide by increasing its 
size, thus enhancing its chances of capture by antigen 
presenting cells and generally delaying its clearance 
from the immune system (Borras-Cuesta et al., 1988).
Although this method has produced many successful 
antisera, there are a number of disadvantages in the use 
of carrier proteins to produce an immune response to 
synthetic peptides:
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1. It is impossible to accurately quantitate the 
dose of peptide as it is only possible to make an 
estimation at coupling efficiencies.
2. Only a very small percentage of the immunogen 
will be the desired antigenic sequence, with the 
remainder being accounted for by sequences derived from 
the carrier.
3. Depending on the peptide sequence it can be a 
time consuming excercise to find suitable reaction 
conditions to couple peptides to carrier proteins and 
these sometimes employ highly carcinogenic compounds 
(e.g. DAB).
4. Most conjugation methods employed to attach 
peptides to carrier proteins: through free amino groups 
using gluteraldehyde (Avrameas and Terynck, 1969; Korn 
et al. , 1972); through either amino or carboxy 
positioned cysteine residues using MSB (Liu et al.,
1979; Green et al., 1982); through tyrosine residues 
using DAB (Gordon et al., 1958; Basseri et al., 1979); 
or employing carbodiimides (Goodfriend et al., 1964), 
have all been shown to have a detrimental effect on the 
antigenicity of either the peptide or the carrier 
protein by altering conformations or blocking important 
side-chains.
Briand et al.(1985) carried out a systematic study 
of the use of different carrier proteins and a variety 
of conjugation methods and demonstrated that although 
the choice of carrier protein did not appear critical 
the choice of conjugation method did, with all 
conjugation methods tested affecting the antigenicity of 
the test peptides to a greater or lesser extent and 
conjugation with gluteraldehyde abolishing completely 
the antigenicity of a lysine containing peptide. It has 
also been shown that in certain circumstances exposure 
of the carrier protein itself to the coupling agent can 
have a detrimental effect on its ability to provide help 
to the antipeptide response (Briand et al., 1985),
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resulting in a dose dependent suppression against the 
synthetic epitope to which it is attached (Jacob et al., 
1985).
5. Carrier protein-peptide conjugates are also 
unacceptable for development of vaccines based on 
synthetic peptides for a variety of reasons described 
earlier.
6 . Although many antibodies have been produced 
using peptides conjugated to carrier proteins not all 
attempts have been successful (Nestorowicz et al. , 1985; 
Tanaka et al., 1985) and many failures occur despite 
attention to pick sequences of the appropriate size and 
charge. Antibodies that are generated are often of low 
titre placing severe restrictions on the range of 
experiments that can be undertaken.
9.3 ALTERNATIVE METHODS OF ANTIPEPTIDE ANTIBODY GENERATION
Due to the constraints mentioned above, much recent 
work has been directed at producing suitable 
alternatives to the use of carrier proteins in eliciting 
responses against synthetic peptides. A variety of 
approaches have been investigated which have been 
successful to a greater or lesser extent in producing an 
immune response to a peptide in the absence of a 
macromolecular carrier.
Attempts have been made to produce large repeating 
polymers by polymerising the short peptides of interest 
into a long chain (Audibert et al., 1982; Jacob et al., 
1985; Bittle et al., 1984; DiMarche et al., 1986; 
Borras-Cuesta et al., 1988). In all cases this method 
has produced good levels of antibody, however it still 
possesses some of the problems associated with the use 
of carrier proteins: There is still the need for a 
coupling reaction during the polymerisation which has 
the problems mentioned earlier, also it is difficult to 
predict the resulting peptide structure after 
polymerisation, as a homogeneous product is rarely
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formed. In addition the procedure may alter the 
immunogenic epitopes of the peptide and in certain cases 
the compound used for polymerisation may be immunogenic 
itself (Briand et al. , 1985).
The association of peptides with lipids has also 
been investigated with the effect of long chain fatty 
acids of particular interest. Already Rude et al. ,
(1971) have shown that attachment of a lipid moiety such 
as lauric acid causes an enhancement of the 
immunogenicity of soluble antigens. Stark et al. , (1980) 
also showed enhanced immunogenicity of lipid-conjugated 
proteins. Efficient anti-hepatitis B surface antigen 
antibodies have been produced using synthetic peptides 
conjugated to dipalmityl-lysine (Hopp, 1984). The 
results indicated that that the dipalmityl conjugates 
were as effective at antipeptide antibody generation as 
the peptide conjugated to KLH (Hopp, 1984; Jacob et 
al.,1985). Successful responses have also been 
demonstrated to FMDV peptides incorporated into membrane 
liposomes (Francis et al.t 1985 and 1987a) although the 
reponse was no greater than that achieved by peptide- 
carrier conjugates.
Jacob et al., (1985), compared the effects of using 
protein carriers, lipid conjugated peptides and 
polymerisation of peptides and demonstrated that 
although all methods were successful, no one method 
performed any better than another.
The generation of an antibody response requires 
that T-helper (Th ) cells recognise antigenic peptides 
associated with the major histocompatability complex 
(MHC) class II molecules and these Th cells interact 
with antigen specific B-cells. To achieve a response to 
peptides in the absence of a carrier-protein, it is 
thought that the immunising peptide must contain 
antibody recognition sites (B-cell epitopes) and sites 
capable of eliciting T-cell help for antibody production 
(TH-cell epitopes)(Mitchison, 1971). These Th- epitopes 
must possess the ability to bind to MHC class II
50
molecules on the surface of host cells and subsequently 
form a complex with the T-cell receptor on the surface 
of TH-cells (Rosenthal, 1978; Babbit, 1985).
It was proposed therefore that assocciation of the 
target sequence (B-cell epitope) with a sequence known 
to stimulate TH-cells in the animal of choice might 
enhance immunogenicity. Two groups first demonstrated 
that conjugation with "natural" TH-cell epitopes (Good 
et al. , 1987) or co-polymerisation using gluteraldehyde, 
with "foreign" T-cell epitopes (Leclerc et al., 1987) 
could enhance the immunogenicity of peptides containing 
B-cell epitopes. More recently, successful linear 
synthesis of B and TH-cell epitopes has also been 
demonstrated ( Borras-Cuesta et al., 1987; Cox et al. , 
1988; Milich et al., 1988; Palker et al., 1989).
Francis et al., (1988) demonstrated that addition 
of a variety of "foreign" TH-cell epitopes to the FMDV 
VP1 peptide 141-160 by co-linear synthesis could 
overcome genetic restricted non-responsiveness in inbred 
mice. Polymers containing repeating units of both B and 
TH-cell epitopes have also been shown to be successful 
in eliciting responses in the absence of carriers 
(Borras-Cuesta et al., 1988). The method by which the 
TH-cell epitope is incorporated into the immunogen seems 
to have a marked effect on the subsequent response. 
Linear synthesis of both epitopes produces high titres 
to the B-cell epitope , whereas chemical conjugation of 
the two epitopes using bismaleimidohexane (BMH) produced 
only a moderate to low response to the B-cell epitopes 
(Nicholas et al., 1990).
Although most of the previously described methods 
have been successful at generating responses to 
synthetic peptides in the absence of carriers, some 
still have the disadvantage of requiring one or more 
conjugation reactions which, as described previously, 
can interfere with antigenicity and make it difficult to 
accurately define the antigen.
Tam (1988), first described a system which provided
FIGURE 3
Diagrammatic representation of the core matrix of 
the branched peptide molecule constructed from lysine 
residues. (A) First level, divalent; (B) second level, 
tetravalent; (C) third level, octavalent; and (D) fourth 
level, hexadecavalent. The black dots represent lysine 
residues except for the free amino groups (NH2 ). This 
figure is taken directly from Tam, (1988).
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an accurately definable immunogen. Termed the multiple 
antigen peptide system (MAP), this utilises a simple 
"back-bone" of a low number of sequential levels (n) of 
a trifunctional amino acid (in this case lysine) as the 
core matrix and 2n peptide antigens to form a 
macromolecule with a high density of peptide antigens.
He described a small core of lysine molecules built up 
by solid phase synthesis of peptide bonds through both 
the alpha and the epsilon carbons of lysine. This 
enabled the construction of a branched lysine core (Fig. 
3) of theoretically unlimited size. In practice a 
structure of 7 lysines were used which provided 8 free 
amino groups onto which copies of the peptide immunogen 
could be synthesised. For a fifteen amino acid peptide 
sequence the resulting structures had Mr s in the region 
of 12,000-15,000 and were therefore thought to be large 
enough to dispense with the need for a carrier protein.
Following immunisation these molecules produced 
high titre antisera in both mice and rabbits, the sera 
having a considerably higher titre of antibodies than 
sera prepared from the same peptides anchored covalently 
to keyhole limpet haemocyanin (KLH) as a carrier. (Tam, 
1988; Posnett et al., 1988). It was further shown that 
none of the antibodies produced were cross-reactive.
This indicates that no response was produced to the 
hepta-lysine core, which would have reduced the 
usefulness of such immunogens. In fact, most of the 
antipeptide response has been shown to be directed 
against residues located distal from the core at the 
amino terminal end of the molecule (Posnett et al., 
1988). These results raise the possibility that the MAPs 
may take up a configuration in solution whereby the 
lysine backbone is "buried" within the molecule and as 
such is innaccessable to the immune system.
These branched peptide molecules produce immunogens 
that can be prepared to give a chemically unambiguous, 
accurately defined dose and if necessary can be purified 
to homogeneity. In addition they contain a very high
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density of the immunogenic sequence of interest (>9 5 %) 
in contrast to the low antigen densities exihibited by 
most peptide-protein conjugates (<5%). They are also of 
predetermined and reproducible structure, and have 
therefore been suggested as suitable candidates for 
synthetic vaccine development (Tam, 1988).
Recently, preliminary experiments with these 
structures in which the peptide sequence corresponding 
to the neutrilizing epitope of FMDV (amino acids 141-160 
from the FMDV protein VP1) were reported. The branched 
structures elicited a 50-fold increase in neutralising 
antibody titre over that achieved with the equivalent 
monomeric peptide (Brown, 1990). It has also been 
suggested that a combination of these branched 
structures with TH-cell epitopes, as has been previously 
shown for monomeric peptides (Section 9.3), may further 
enhance their immunogenic potential (Tam, 1988).
Clearly, branched peptides potentially have advantages 
over previously used techniques for eliciting a useful 
immune response.
A detailed investigation of the immunogenic 
properties of branched peptides, with and without Th 
cell epitopes, is contained within this thesis.
10. THE AIMS OF THE WORK PRESENTED IN THIS THESIS
The work covered in this thesis falls into two 
distinct areas: Firstly to investigate the potential of 
branched peptides for producing antisera to synthetic 
peptides. Secondly, to use the antisera generated to 
identify and characterise putative HSV gene products, 
for which no information existed.
As described earlier in this introduction, 
generation of antisera to synthetic oligopeptides has 
provided a very powerful tool in modern biology. These 
antibodies have many uses, not least of which is the 
ability to detect proteins which previously were only 
predicted to exist by the interpretation of a DNA
FIGURE 4
A diagrammatic representation of the octavalent 
lysine core used for synthesis of branched peptides. 
Amino acids are represented by the one letter code.
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sequence and also to assign previously identified 
polypeptides to known open-reading frames. However, as 
discussed, numerous problems are associated with use of 
carrier proteins to stimulate an immune response to a 
peptide. Moreover, even if successfully produced many 
oligopeptide antisera are of low titre, placing severe 
limitations on experimentation.
Therefore, experiments described in this thesis 
compare the efficacy of the "carrier-protein" method 
with some alternatives that were available i.e. the 
branching peptide immunogens described by Tam (1988)[see 
section 5.3]. This involved modifying the synthesis 
protocols described to use Fmoc chemistry to produce 
batches of the polylysine core (Fig. 4). On the branched 
core immunogens containing the sequence of interest were 
synthesised (Fig. 5). Another method tested was 
retention of the oligopeptide on the synthesis matrix of 
Keise)cj.ur resin, which it was hoped, would then 
subsequently substitute for the macromolecular carrier. 
In addition the potential for transfer of the production 
of these antisera from outbred rabbit strains to Balb/c 
inbred mice was investigated, in order that a system for 
the production of monoclonal antibodies might be 
developed. It was anticipated that conjugation of the 
oligopeptides to synthetic "fore^n" TH-cell epitopes 
(section 5.3) would overcome the genetic restriction 
which might be expected to be encountered in such an 
inbred population.
It was decided to use the techniques described 
above to generate sera against peptides corresponding to 
regions of putative HSV-1 polypeptides. Five such gene 
products were chosen for investigation namely, UL31, 
UL41, UL45, UL46 and UL47. Identification and 
characterisation of the encoded proteins within the 
assigned open-reading frames of these genes would 
confirm the accuracy of the DNA sequence and increase 
our understanding of the molecular biology of HSV.
UL45: Identification of the predicted protein
FIGURE 5
Diagrammatic representation of branched peptide no.161. 
Amino acids contained in the molecule are represented by 
the one letter code.
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product of the UL45 gene /£ described in this thesis. 
The UL45 gene product is potentially membrane associated 
as it contains a highly hydrophobic N-terminus with a 
potential transmembrane spanning region and a predicted 
signal sequence from the second translational start site 
(McGeo h et al., 1988).
UL46 and UL47: The DNA sequence of McGeoQh et al. ,
(1988) has predicted polypeptides of Mr 78,239 and 
73,812 potentially encoded by genes UL46 and UL47 
respectively. It has been suggested that the products of 
these genes are involved in the modulation (positively 
and negatively respectively) of the activity of the 
product of gene UL48 (the 65K trans-inducing factor) 
(McKnight et al. , 1987) although these results remain to 
be confirmed. There are also considerable sequence 
differences between the published sequences of genes 
UL46 and UL47 (McKnight et a l 1987; McGeoch et al. , 
1988) and it was anticipated that generation of protein- 
reactive antisera made against synthetic peptides would 
help to establish the accuracy of these sequences.
Recently reported experiments demonstrate that UL47 
and perhaps UL46 are dispensible for viral growth on 
tissue culture as deletion mutants have been isolated 
that lack the complete UL47 gene and the carboxy 
terminal one third of the UL46 gene, which grow in vitro 
indistinguishably from wild-type, (Barker and Roizman, 
1990). Additionally in vivo studies with two UL46 
deletion mutants have shown the mutants display 
pathogenicity similar to that of wild-type virus in a 
rabbit eye model, although they show a reduced 
neuropathogenicity in mice (Gordon et al., 1990; 
Abstracts: 15th International Herpesvirus workshop).
UL31: DNA sequence analysis indicates that the 
UL31 gene encodes a polypeptide of Mr 33,951. The 
sequence information indicates that there is an overlap 
of 19 codons, in a "tail-to-tail" fashion with gene UL30 
(HSV-1 DNA polymerase), as well as a 3 codon overlap 
with gene UL32 (Quinn and McGecch, 1985; McGeooh et al.,
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1988). Hou/ever this interpretation remains tentative, 
due to the uncertainty of the position of translational 
start sites. It was anticipated that by using a peptide 
sequence contained wholly within the proposed overlap to 
generate an antiserum, it would be possible to confirm 
the existance of the predicted overlap.
UL41: DNA sequence analysis indicates that the UL41 
gene encodes a polypeptide of Mr 54,914. The product of 
this ORF has been identified as being involved in shut- 
off of host macromolecular synthesis (Read and Frenkel, 
1983; Kwong et al., 1988). However no specific antisera 
existed to the UL41 protein. It was hoped that 
generation of an antipeptide serum directed against the 
product of this gene would facilitate the further study 
of its involvment in host shut-off.
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MATERIALS
Unless specifically stated all chemicals were obtained 
from BDH chemicals Ltd., Poole, Dorset or Sigma (London) 
Ltd. and were of analytical grade or better.
A. CHEMICALS AND REAGENTS
TISSUE CULTURE: All reagents used for tissue culture were 
supplies by Gibco-Biocult, Paisley, Scotland.
c.
ELEltROPHORESIS: Acrylamide was supplied by Koch-Light 
Laboratories Ltd., Suffolk, UK. Ammonium persulphate and 
TEMED were obtained from Biorad Laboratories, Richmond, 
California. .
AUTORADIOGRAPHY: Kodak X-OMAT XS-1 and duplicating film 
were obtained from Kodak (London) Ltd. En3hance was 
obtained from New England Nuclear, Boston, Mass., USA.
IMMUNOBLOTTING: Sheets of nitrocellulose were obtained from 
Schleicher and Schull, Dassel, West Germany. Gelatin was 
supplied by Biorad Laboratories. Non-immune rabbit serum 
was obtained from the Scottish Antibody Production Unit 
(SAPU), Scotland.
ELISA: Horseradish peroxidase-protein A conjugate and 
horseradish peroxidase-antimouse IgG conjugates were 
supplied by Biorad Laboratories.
OLIGOPEPTIDE SYNTHESIS: dimethylformamide, acetic acid, 
diethylether, t-amyl-alcohol and piperidine were all 
obtained from Rathburn Chemicals Ltd. F—moc amino acids 
were obtained from LKB Biochrom. Trifluoroacetic acid was 
supplied by Aldrich Chemical Company, England. Fmoc amino 
acids were supplied by LKB Biochrom, England; with the 
exception of Fmoc-Lys (Fmoc) and resin with the first amino 
acid attached which were obtained from Peptide and Protein 
Research, England.
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HIGH PRESSURE LIQUID CHRQMOTOGRAPHY: HPLC grade methanol 
and acetonitrile u/ere obtained from Rathburn Chemicals 
Ltd., Walkerburn, Scotland. Dynamax 300A columns were 
obtained from Dynamax, England.
MISELLANEOUS: Ficoll 400, CNBr-activated sepharose and PD10 
columns were supplied by Pharmacia, Upsalla, Sweden. NP-40 
was obtained from Pierce Chemical Company, Chicago, 
Illinois. All radiochemicals were supplied by Amersham 
International PLC, Buckinghamshire, England.
B. SOLUTIONS
Electrophoresis buffer
52mM Tris, 53mM glycine, 0.1% SDS.
Transfer (Towbin) buffer
25mM Tris pH 8.3, 192mM glycine, 20% (v/v) methanol.
Tris buffered saline (TBS)
20mM Tris pH 7.5, 500mM NaCl.
Phosphate buffered saline (PBS)
170mM NaCl, 3.4mM KC1, lOmM Na2HP04 pH 7.2 supplemented 
with 6.8mM CaCl2 and 4.9mM MgCl2 .
Versene
6mM EDTA dissolved in PBS containing (w/v) phenol red. 
Trypsin-Versene
One volume 0.25% (w/v) Difco trypsin (dissolved in 25mM 
Tris, 140mM NaCl, 5mM KC1, 0.7mM Na2HPC>4, lmg/ml dextrose, 
0.0015% phenol red pH 7.4 supplemented with 100 units/ml 
penicillin and 100 micrograms/ ml streptomycin plus 4 
volumes versene.
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Gte.msa
1.5% (v/v) suspension of Giemsa in glycerol, heated at 
56° C for 90-120 minutes and diluted u/ith an equal volume of 
methanol.
Denaturing buffer
50mM Tris-HCL pH 6.7, 2% SDS, 700mM 2-mercaptoethanol, 10% 
glycerol, bromophenol blue (to colour).
Blocking buffer
1 x TBS plus 3% gelatin heated to 37°C.
Antibody buffer
1 x TBS + 1% BSA + 0.01% Sodium azide.
METHODS
11. GROWTH OF CELLS AND VIRUS STOCKS
11.1 GROWTH OF CELLS
Cells were grown in 80oz roller bottles in Eagle's 
medium supplemented with 5% v/v tryptose phosphate and 
10% newborn calf serum (ETC-10),in an atmosphere of 90% 
air and 10% carbon dioxide. Once confluent the cells were 
harvested by washing twice with 2 0 ml of trypsin/versene 
(1:4). The cells were then harvested in 20ml of ETC-10 
and resuspended at a concentration of lxlO7 cells/ml and 
stored at 4°C for up to 3 days. Petri dishes were seeded 
at 3xl06 cells/50mm dish or 8xl06 cells/90mm dish for use 
the following day.
11.2 GROWTH OF VIRUS STOCKS
HSV-1 strain 17 syn+ (Brown et al., 1973) was used 
in these studies. In addition the phosphonoacetic acid 
resistant mutant PAAr-1 was used, this was derived from 
HSV-1 17syn+ (Hay and Subak-Sharpe, 1976); the mutation 
has been mapped within the DNA polymerase gene 
(Crumpacker et al.y 1980). Elite virus stocks (virus with 
a low serial passage number) was used to infect BHK 
monolayers which were approximately 90% confluent at a 
mutiplicity of 1 plaque forming unit (pfu) per 300 cells 
in 40ml of ETC-10. Virus was grown at 31°C and harvested 
when maximum cytopathic effects (cpe) were observed.
Infected cells were pelleted at 2,000rpm for 10 
min in a Fisons Coolspin. The supernatant was spun in a 
Dupont Sorvall GSA rotor at 12,000rpm for 2h and the 
virus containing pellet resuspended in 5ml of supernatant 
and son icated until homogeneous. This was termed the 
supernatant virus stock (SV).
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The cell pellet was sonicated until homogeneous, 
freeze thawed, resonicated and then spun at 2 0 0 0 rpm for 
lOmin. The supernatant was kept and the pellet 
resuspended in 5ml of fresh ETC-10 and the above 
procedure repeated. The two supernatants were pooled and 
this represented the cell—associated virus stock (CV).
Virus stocks were checked for sterility by 
streaking on brain heart infusion blood agar plates and 
incubated at 37°C for 7 days. If no contamination was 
evident stocks were stored at -70°C.
Virus stocks were also titrated at both 31°C and 
38.5°C : Virus was serially diluted 10-fold in PBS and 
used to infect BHK monolayers on duplicate plates. Virus 
was allowed to absorb for lhr at 37°C then overlayed with 
3% methyl cellulose and ETC-10 (1:1) to prevent 
extracellular spread of the virus and the plates 
incubated at 31°C for 3 days or 38.5°C for 2 days. The 
monolayers were fixed and stained with Giemsa stain and 
plaques counted using a dissection microscope.
12. PREPARATION OF INFECTED CELL EXTRACTS
12.1 PREPARATION OF LABELLED EXTRACT FROM CELLS LATE IN 
INFECTION
Monolayers of BHK cells at about 90% confluency 
were infected with stock virus at a multiplictiy of 2 0  
pfu per cell in ETC-10. Virus was allowed to absorb at 
37° C for lhr and the plates were then washed twice in 
Eagle's medium containing one fifth the normal 
concentration of methionine and 2% calf serum. They were 
then further incubated in 5ml (90mm dish) of this medium 
for two hours. 3 3 S-methionine was then added at 50uCi/ml 
and the cells then reincubated at 37°C. Infected cells 
were harvested at 16—24hpost—infection.
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12.2 PREPARATION OF EARLY LABELLED EXTRACTS
Cell extracts prepared in the absence of viral DNA 
replication were prepared by first pre-treating the cell 
monolayer with phosphonoacetic acid (PAA) at 300ug/ml for 
1 h, then infected, maintained and labelled as for a 
normal infection but with the continuous presence of PAA.
12.3 HARVESTING OF INFECTED CELL EXTRACTS
Infected cell extracts were harvested in 2.5ml (for 
a 90mm dish) and 20ml (for a roller bottle) of denaturing 
buffer containing 50mM Tris.HCl pH 6.7, 0.1% SDS, 700mM 
2—mercaptoethanol and 1 0 % glycerol, containing 
bromophenol blue. Samples were heated to 70°C for 5 min 
then alliquoted and stored at -70°C until required.
13. PREPARATION OF PURIFIED LABELLED VIRIONS
Monolayers of BHK cells in 80oz roller bottles were 
infected when 90% confluent with virus at a multiplicity 
of 0.05 in ETC-10. Following overnight incubation at 37°C 
the culture medium was removed and replaced with Eagle's 
medium containing one fifth the normal concentration of 
methionine and reincubated for a further 5-6 hours. 3 5 S— 
methionine was then added to each roller bottle to give a 
final concentration of 25uCi/ml, the cells were then 
reincubated for a further 3—4 days until maximum cpe was 
observed.
The cell culture was clarified by centrifugation at 
2500rpm for 30 min, the supernatant was then collected 
and the free virus was pelleted by centrifugation in a 
Sorvall GSA rotor for 2 h at 12,000rpm and 4°C. The 
pelleted virus was resuspended in a minimal volume of 
Eagle's medium without Phenol—red and stored at —70°C
until required.
5-15% Ficoll 400 gradients were prepared with 
Eagle's medium without phenol red in cellulose nitrate
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centrifugation tubes (Beckman AH627) and chilled to 4<>C. 
Virus samples u/ere then layered gently onto the top of 
the gradients, and spun at 1 2 ,0 0 0 rpm for 2 h at 4°C in a 
Sorvall OTDO-50 ultracentrifuge using an AH627 rotor.
Following centrifugation the virion band was 
visualised by shining a high intensity light from above 
and removed by insertion of a 18 gauge needle through the 
wall of the tube. The virion particles were then pelleted 
in Eagle's medium without phenol-red by centrifugation in 
a AH627 rotor for 2 h at 21,000 rpm. (J.F. Szilagyi and
C. Cunningham, personal communication). The virion pellet 
was resuspended in 500ul of Eagle's medium without 
phenol-red and stored at -70°C until required. For 
electron microscopy of virions, the purified virions 
(2 ul) were applied to a parlodion—coated copper grid, 
allowed to absorb for 5min., blotted dry and stained with 
3% phosphotungstic acid pH 7.0. Electron microscopy was 
carried out by Dr.F.J. Rixon.
13.1 IODINATION OF VIRION PROTEINS
Virion proteins were iodinated essentially as 
described by Markwell and Fox, (1978). Briefly, 2mg Iodo- 
gen (Pierce)[1 ,3,4,6-tetrachloro-3,6 ,-diphenylglyclouril] 
was dissolved in 2ml chloroform immediately before use, 
25ul was transferred to an Eppendorf tube, dried and 
stored under nitrogen. 125I (200uCi)(Amersham; IMS.30) 
was added, followed by 30ul of Percoll-purified virions 
which had been diluted in phosphate buffer (pH 7.4) to a 
final buffer concentration of lOmM. Incubation was 
performed for lOmin at between 0 and 4°C and the reaction 
stopped by transferring the solution to another tube 
without Iodo-gen. Iodination of virion proteins was 
carried out by Dr. N.Langeland and Dr. L. Haarr.
14. DETERGENT EXTRACTION OF VIRION PARTICLES
For detergent extraction of virion particles, NP-40
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was diluted to the desired concentration in a buffer 
containing, 20mM Tris/ 5M NaCl pH 7.5. Virion particles 
in Eagle's medium without phenol-red were added to lOOul 
of a solution of NP-40 of the desired concentration , 
covered and incubated for 30 min at 31°C. Samples were 
then gently mixed and spun for 1 h. at 50,000 rpm and 4°C 
in a TLA 100.2 rotor using a Beckman table top 
ultracentrifuge. Following centrifugation both pellet and 
supernatant were resuspended in denaturing buffer at a 
ratio of two parts sample to one part buffer and boiled 
at 100°C for 5 min. Samples were then loaded on an SDS- 
polyacrylamide gel and separated by electrophoresis. For 
experiments involving the iodination of virion proteins 
the centrifugation step was ommited.
15. SDS—POLYACRYLAMIDE GEL ELECTROPHORESIS (SDS-PAGE)
15.1 GEL ELECTROPHORESIS
For protein analysis vertical acrylamide gels were 
used: These were either single concentration or 5-12.5% 
gradient gels. Stocks of 30% acrylamide were prepared in 
water, the ratio of acrylamide to the crosslinking agent 
(N, N'-methylene bisacrylamide or N, N'—
Diallyltartardiamide ) was 20:1 and 40:1 for gradient and 
single concentration gels respectively. After filtering 
through Whatman No.l filter paper these solutions were 
used to prepare the appropriate gel concentration in a 
buffer of final concentration of 375mM Tris.HCl, pH 8.9, 
0.1% SDS.
For gradient gels the higher concentration 
acrylamide solution also contained 15% glycerol to 
stabilise the gradient. The gel solutions were 
polymerised with a final concentration of 3.65mM ammonium 
persulphate and 2.75mM TEMED. Following polymerisation of 
the acrylamide, a stacking gel consisting of 5% 
acrylamide in 122mM Tris.HCl, pH6 .7, 0.1% SDS was added, 
along with a teflon comb to form the sample wells. Before
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electrophoresis protein samples u/ere boiled for 5 min in 
buffer of a final concentration of 50mM Tris.HCl, pH 6.7, 
2% SDS, 700mM 2-mercaptoethanol and 10% glycerol, with 
sufficient bromophenol blue to visualise the dye front. 
Electrophoresis was carried out in a buffer containing 
52mM Tris.HCl, 53mM glycine and 0.1% SDS, at either 10mA 
overnight at room temperature or 70mA for 3-4 h at 4°C.
15.2 STAINING OF SEPARATED PROTEINS
15.2.1 Coomassie brilliant blue staining
Following electrophoresis gels were fixed for 30 
min. in methanol: acetic acid :water (50:7:50) containing 
0.2% Coomassie brilliant blue R250, followed by 
destaining for at least lh, in 5% methanol and 7% acetic 
acid. If required gels were the dried under vacuum onto 
Whatman 182 filter paper and exposed to Kodak XS-1
film at -70° C.
15.2.2 Silver staining
Following electrophoresis gels were fixed for 30 
min in 30% ethanol/ 10% acetic acid. Gels were then 
removed from the fix solution and incubated for a further 
30 min in a solution containing: 30% ethanol, 0.5M acetic 
acid, 0.5% gluteraldehyde and 0.2% sodium thiosulphate. 
The fixed gels were then rinsed thoroughly in water for 
3x10 min, and then soaked in 0.1% silver nitrate/ 0.02% 
formaldehyde for 15-30 min. Gels were then developed in a 
solution containing 2.5% sodium bicarbonate/ 0.01% 
formaldehyde, pH 11.8, for 5-15 min. until all bands were 
visible. Development was then stopped by addition of 
0.05M EDTA for 5 min followed by a further wash in' 
dionised water. All solutions for siver staining were 
prepared using high purity filtered HPLC grade water.
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16. SYNTHESIS AND PRODUCTION OF SYNTHETIC OLIGOPEPTIDES.
16.1 SYNTHESIS OF SYNTHETIC OLIGOPEPTIDES.
Synthetic oligopeptides u/ere synthesised, using 
continuous flow Fmoc chemistry (for reviews, Atherton et 
al, 1979, Sheppard 1983) using a LKB Biolynx automated 
peptide synthesizer. This involved sequential addition of 
of F-moc protected amino acids, in line with the required 
sequence onto a polyamide resin to which the first amino 
acid had been coupled via an acid labile bond (obtained 
from Peptide and Protein Research, Reading, UK) or 
directly onto Ultrasyn C resin (Pharmacia).
The peptides were synthesised both directly onto 
the resin and onto a branching lysine core (Fig. 4) to 
generate a peptide with eight identical branches (Fig. 5; 
Possnett et al., 1988; Tam 1988) using two columns of the 
synthesiser in series. The lysine core was synthesised 
(onto an alanine residue coupled onto the resin) using 
Fmoc-Lys (Fmoc) pentafluorophenyl ester (purchased from 
Peptide and Protein Research, Reading, UK). The 
protecting F-moc group was removed at the end of every 
cycle using 20% piperidine in dimethylformamide (DMF) for 
15-20 min. Following synthesis the peptide containing 
resin was dried down using alternate washes of DMF, t- 
amylalcohol, acetic acid (Sequencer grade), t— 
amylalcohol, DMF and finally diethyl ether and stored at 
-20°C until cleavage.
16.2 CLEAVAGE OF PEPTIDES FROM SYNTHESIS RESIN.
Following final deprotection and removal of the 
terminal F-moc group, the oligopeptides were cleaved from 
the synthesis resin using different protocols according 
to the types of amino acids in the oligopeptide. These 
protocols were taken from the Biolynx Peptide Synthesis 
Manual and were based on advice from Dr. P White 
(Pharmacia), Mr. P.Seale (Glaxo Group Research Ltd.), Dr.
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M.Munns (Peptide and Protein Research Ltd.) via Miss
A.Owsianka.
16.2.1 Cleavage of peptides attached to the resin via an 
acid labile linkage.
16.2.1.1 Cleavage of peptide 161 (Table 1).
This peptide contained no arginine residues: it was 
simoultaneously cleaved from the resin and side-chain 
protecting groups removed with a mixture of 95%TFA/5%H20. 
The dried down peptide bound resin was added to the 
TFA/H2 O mixture in a 100ml round bottom flask, stoppered 
and left at room temperature for 2 h. The mixture was 
then filtered slowly through a scintered glass funnel and 
then washed through with a further 25ml of 95%TFA/H2 0 
The peptide containing solution was then rotary 
evaporated at 35°C to remove the TFA. The remaining 
peptide containing solution was mixed with 50ml of water 
and shell-frozen in an acetone/dry ice bath, followed by 
freeze drying overnight. The resulting peptide was 
weighed and then stored at -20°C until required. The 
linear, monomeric form of peptide 161 was purchased from 
Cambridge Research Biochemicals Ltd.
16.2.1.2 Cleavage of peptides 172. 173. 175. 177 and 202 
(Table 1)
These peptides contained one or more arginine 
residues. Removal of the Mtr (4-methoxy-2,3,6- 
trimethylphenylsulphonyl) protecting group is relatively 
slow and phenol is added as a scavenger to protect'' 
against unwanted side-chain reactions. The dried down 
peptide bound resin was added to 25ml of the TFA/phenol 
solution in a 100ml round bottom flask, stoppered and 
left at room temperature overnight. The solution was then 
filtered slowly through a scintered glass funnel and then 
washed through with a further 25ml of the cleavage
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solution. The TFA was then removed by rotary evaporation 
at 35° C and the flask attached to a vacuum pump for two 
hours until the peptide solution was a crystalline solid. 
100ml of 50% diethylether was then added to the flask, 
the solution was thoroughly mixed and added to a 500ml 
separation flask from which the aqueous phase was 
collected and subjected to a further round of ether 
exaction, the resulting aqueous phase was then rotary 
evaporated to remove any excess ether. The peptide 
mixture was then mixed with 50ml of H2 O, shell frozen and 
freeze dried as before.
16.2.1.3 Cleavage of peptide 258 (Table 1)
Peptide no.258 contains within its sequence both 
tryptophan, and arginine residues. This combination poses 
special problems as the Mtr side-chain protecting group 
from arginine can covalently attach to tryptophan 
especially during the long deprotection time needed for 
removal of the Mtr group. Furthermore methionine needs 
protection against oxidation. Finally tryptophan can 
irreversibly, covalently attach to the resin during 
cleavage of the peptide.
Cleavage and deprotection strategy involved 
blocking the reactive group on tryptophan with 
trimethylsiyl bromide (tmsb), which could later be 
removed. In addition the peptide was first cleaved from 
the resin under conditions in which side-chain protecting 
groups were not removed. The detailed protocol was as 
follows: The resin used for synthesis was Ultrasyn C., 
therefore the protected peptide was removed using 5% TFA 
in DCM, which was slowly dripped through the resin'for 60 
mins. The TFA and DCM was then removed by evaporation 
using nitrogen.
Following cleavage the side-chain protecting groups 
were removed using: TFA + 1M thioanisole, 1M 
trimethylsiyl bromide (tmsb), 20 molar eqiv. cresol and 
20 molar equiv. ethanedithiol (EDT)[5mls of TFA +
FIGURE 6
Gel of molecular u/eight estimation of branched 
peptide 161. Peptides were separated on an SDS- 
polyacrylamide single concentration (15%) gel. Lanes 1 
and 2 represent molecular weight markers (lug and 0.5ug) 
respectively. Lanes 3 and 4 contain 5ug and lug of 
peptide 161B respectively. Peptides were visualised by 
staining with coomassie brilliant blue.
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scavengers per lOmg resin]. The above mixture was added 
to the protected peptide at 0°C, under an atmosphere of 
nitrogen and incubated at 0°C for 25mins. Following 
incubation the TFA + scavengers were removed using 
nitrogen evaporation. Sufficient diethylether was added 
to precipitate the peptide, following centrifugation 
ether extraction was repeated followed by freeze-drying. 
(Note: tmsb is a highly reactive chemical, special 
precautions were taken during the use of this chemical, 
including use of protective clothing and full face- 
protection and carrying out all manipulations under an 
atmosphere of nitrogen).
16.2.2 Cleavage of peptides attached via base-labile 
linkage agent
Side-chain protecting groups of peptides covalently 
attached to the synthesis resin via a base-labile handle 
were removed while leaving the peptide attached to the 
synthesis resin. Cleavage was performed identically as 
descibed in section 16.2.1 except following reaction with 
the cleavage solution, a futher 100ml of cleavage 
solution was dripped through the resin very slowly in a 
scintered glass funnel to ensure complete removal of all 
side-chain protecting groups.
16.3 ANALYSIS OF SYNTHETIC OLIGOPEPTIDES
Following continuous-flow sythesis in three columns 
linked in series, peptides were cleaved from the 
synthesis resin as described above and subjected to 
analysis in order to determine their composition with 
respect to homogeneity, amino acid content and Mr as 
follows:
Monomeric, linear, peptides were subjected to HPLC 
analysis using a Beckman System Gold HPLC and a Dynamax 
analytical column (4.6mm internal diameter x 25cm length, 
300A C8 resin, catalogue no. 83-3-03-C), and a gradient 
of 0% to 95% acetonitrile (Rathburn Chemicals) in water,
FIGURE 7
HPLC profile of peptide No.258 (Table 1). 50ug of 
peptide 258 was analysed using a Beckman System Gold 
HPLC and a Dynamx analytical column as described in 
Methods section 16.3. The peptide is represented by the 
large single peak which was 94% of the material 
analysed. The Y-axis represents absorbtion (225nm) while 
the X-axis represents time in minutes.
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ABSORBANCE 
1.000 0.500 0.000
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of duration 20 minutes and flow rate 0.5ml/min 
(wavelength 225nm). In addition they were also routinely 
tested for the correct Mr using Fast atom bombardment 
spectroscopy (Fab-mass) by M-Scan Ltd. The results of 
these analysis are summerized in Table 2.
Branched peptides, because of their high molecular 
weight can be visualised using polyacrylamide gel 
electrophoresis as an initial test of homogeneity and 
estimation of Mr , an example of which is shown in Fig. 6, 
where the branched form of peptide 161 (Table 1) with a 
predicted Mr of 12,641 was shown to have a mobility of 
around Mr 14,000 and an appearance of a single 
homogeneous band. All other branched peptides were also 
analysed in this way and gave the expected results. 
Branched peptides were also subjected to HPLC analysis as 
described (an example of which is shown in Fig. 7) above 
with the results summ&riaed in Table 2. Finally all 
branched peptides were subjected to amino acid analysis 
t© determine their amino acid composition (carried out by 
Cambridge Research Biochemicals Ltd.). All branched 
peptides gave the expected amino acid compositions.
Analysis was not carried out on the resin-linked 
peptides. As synthesis was carried out on three columns 
of the synthesiser in series, peptides which remained 
attached to the sythesis resin by the base-labile linkage 
were assumed to be identical in composition to the 
monomeric peptides. By the nature of the structure of 
resin-linked peptides HPLC and Fab-mass analyses were 
not possible.
Throughout this thesis peptides are referred to by 
their number as given in Table 1. In addition, branched 
peptides are referred to by 'B ' e.g. 161B, whereas''R' 
represents resin-linked peptides and *H1 represents 
peptides conjugated to the ThCE e.g 161R and 161E 
respectively.
TABLE 2
Analysis of peptides as cleaved from the resin: Nt 
values (a) determined by fast-atom bombardment 
spectroscopy (M-Scan Ltd.); % purity (b) determined by 
HPLC analysis as described in Section 16.3; amino acid 
composition (c) determined by amino acid analysis 
(Cambridge Research Biochemicals Ltd.)
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16.4 COUPLING OF PROTECTED PEPTIDES TO RESIN-BOUND 
BRANCHING PEPTIDES.
Protected 17-mer SWM-1 peptide (Peptide and Protein 
Research, Reading; Fig. 11) u/as coupled to resin bound 
branching peptides using diisopropylcarbodiimide (DIPCI): 
0.1 mM Of peptide bound resin was mixed with a solution 
containing 0.2mM of protected peptide and 0.22mM 1- 
hydroxylbenzotriazole (HOBT) in a minimal volume of DMF, 
(in practice 1 ml) in a 10ml glass stoppered test tube. 
This mixture was then added to an equal volume of 
dichloromethane (DCM) and placed on ice. 0.22mM of DIPCI 
was added dropwise by syringe and the solution agitated 
for 60 sec. then allowed to stand on ice for 15 min. The 
mixture was then rotated gently overnight using the motor 
of a rotary evaporator at room temperature. The resulting 
peptide bound resin was cleaved as described previously 
(Section 16.2).
17. GENERATION OF ANTIBODIES
17.1 LINKAGE OF PEPTIDES TO CARRIER PROTEINS
17.1.1 Preparation of bis-diazotised benzidine(DAB)
DAB was prepared by Dr.Howard S. Marsden according 
to the method of Likhite and Sekar (1967). Briefly, 0.23g 
benzidine hydrochloride was dissolved in 45ml 0.2M HCl, 
5ml of 0.5M sodium nitrate was added and the solution 
stirred slowly at 0°C for 1 h. The DAB was then aliquoted 
into 2ml amounts and stored at -70°C.
17.1.2 Coupling reaction
The coupling reaction was carried out according to 
the method of Basseri et al., (1979). 30mg of appropriate 
carrier protein: either bovine thyroglobulin, bovine 
serum albumin, were added to lOmg of appropriate peptide 
dissolved in 0.16M borate pH 9.0, 0.13M NaCl. 1ml of DAB 
was added slowly dropwise stirring continuously and the
70
solution was left on ice for 1 h. The resulting solution 
was dialysed against PBS-A to remove excess DAB and 
stored at -70°C.
17.2 PRODUCTION OF ANTISERA TO SYNTHETIC OLIGOPEPTIDES
17.2.1 Quantitation of peptide used to immunise animals
The amount of peptide used for immunisations was
quantitated in the following ways. For protein-conjugated 
peptides the extent of coupling wa>determined in a series 
of independent experiments in which peptides were first 
iodinated via the tyrosine residue (Hunter and Greenwood, 
1962) and the radioactivity both attached to the carrier 
protein and remaining as free peptide was measured 
following separation on a Sephadex G25 column 
(Pharmacia). The extent of coupling varied between 20% 
"and 30%. Branched peptides were weighed directly. For 
resin-linked peptides the amount of peptide was estimated 
'by first measuring colormetrically the amount of the 
first amino acid attached per gram of resin as described 
in the Pharmacia peptide synthesis manual and then 
assuming 100% coupling of each amino acid during the 
synthesis.
17.2.2 Preparation of antisera in rabbits
Female New Zealand White and Sandy-Half Lop rabbits 
were used for all immunisations. Rabbit sera was 
prescreened for low reactivity on western blots before 
immunisation. Initial screening was performed for each 
animal on 1ml of serum obtained from the supplier 
(HyLine) who tagged each animal. Animals with low 
reactive serum were then purchased for the study arid 10ml 
of pre-immune serum obtained and stored as described in 
section 17.3. Rabbits were given an intramuscular 
immunisation on day 0 and then a further three injections 
on days 10, 30 and 40. Test bleeds were taken 7 days 
after every injection and rabbits were bled out on day 
50. All immunisations contained lOOug peptide emmulsified
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in either Freund's complete adjuvant (FCA) for the 
primary injection or Freund's incomplete adjuvant (FIA) 
for all subsequent injections.
17.2.3 Preparation of antisera in mice
Female Balb/c mice were used for all immunisations. 
Mice were immunised either intramuscularly, 
intraperitoneally or subcutaneously on day 0 and day 30 
and test bleeds taken 7 days after each injection. 
Immunisations contained either lug or 50ug of peptide 
emmulsified in FCA, for the primary and FIA for the 
subsequent immunisations.
17.3 PREPARATION OF ANTISERA
Following collection, rabbit and mouse serum was 
placed at 37°C for lh, in order to aid clotting. Released 
serum was then removed by aspiration using a glass 
^pipette. The blood clot was then broken down using a 
sterile glass rod and the blood subjected to 
centrifugation (2000rpm for lOmin); followed by removal 
of the remaining serum by aspiration. The resulting serum 
was aliquoted and stored at -20°C.
For antiserum generated against peptides conjugated 
to BSA, the collected serum was passed through a BSA- 
Sepharose column to remove any BSA reactive antibodies.
To do this BSA was coupled to cyanogen bromide activated 
Sepharose 4B (Pharmacia Laboratories) according to the 
manufacturers instructions, lg of dried beads was swollen 
for 15-30 min using ImM HC1, in a scinted glass funnel 
and then rinsed with coupling buffer (0.1M NaHCCfe pH 8.3, 
0.5M NaCl). BSA (5-10mg/ml of gel) was dissolved ih 
coupling buffer adjusted to a volume of 5ml and mixed 
end-over-end with the Sepharose for 2 h at room 
temperature. The beads were then washed with coupling 
buffer.
Any remaining active groups on the beads were 
blocked by incubating end-over-end with 15ml of 1M
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ethanolamine pH 8.0 for 2h at room temperature. Non- 
covalently absorbed proteins were removed by washing 
three times in 0.1M acetate, 0.5M NaCl, pH 4.0, then 
three times in 0.1M NaCCfc , 0.5M NaCl, pH 8.3. The beads 
were then given a final rinse in PBS and stored at 4°C in 
PBS containing 0.01% sodium azide until required. 
Following passage through the column the resulting serpv^ 
was aliquoted and stored as described previously.
18. IMMUNOASSAYS
18.1 ENZYME LINKED IMMUNOSORBANT ASSAY (ELISA)
ocT~
ELISA assays were carriedtto determine the titre of 
antipeptide sera obtained from mice and rabbits. The 
appropriate antigenic peptide was diluted in PBS to a 
final concentration of 20ug/ml. lOOul of antigen solution 
was added to each well of a 96 well microtitre plate 
^giving 2ug of peptide per well.
Peptides were allowed to adsorb to the plate at 
37°C overnight. Antigen solution was then removed and the 
plates blocked in a solution containing 1% BSA for 1 h. 
at 37°C, the plates were washed three times in PBS 
containing 0.01% Tween-20 (PBS-Tween) and incubated with 
lOOul of the the appropriate antibody dilution at 37°C 
for 1 h. For detection of bound antibody plates were 
washed five times in PBS-Tween and incubated with lOOul 
per well of either horseradish peroxidase-protein A 
conjugate (for rabbit antisera) or horseradish 
peroxidase-antimouse IgG conjugate (for mouse antisera) 
at a 1/1000 dilution in PBS for lh at 37°C. Plates were 
then washed seven times in PBS-Tween and incubated in a 
50mg/ml solution of 2'2 azino-bis(3-ethylbenzthazoline-6- 
sulphonic acid) [ABTS] in citrate phosphate buffer 
containing 0.01% hydrogen peroxide. After 15 min of 
colour development reaction the plates were read on a 
Titretek Multiscan plate reader at 405nm. All ELISA 
results were the means of duplicate parallel
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determinations. Appropriate controls of pre-immune sera 
and unrelated peptides were included in all ELISA 
experiments.
18.2 IODINATION OF PROTEIN A
Protein-A was reconstituted in PBS at a 
concentration of 0.5mg/ml, aliquoted into 20ul amounts 
and stored at -70°C until required. To lOug (20ul) of 
protein A was added, lOul of 1M potassium phosphate 
buffer pH 7.5, 200uCi of 125I (Nal12s, Amersham 
International) and 20ul of chloromine T (0.5mg/ml in 
PBS). This mixture was allowed to react for 20sec. at 
room temperature, then 20ul of sodium metabisulphite 
(lmg/ml in PBS) was added to stop the iodination 
reaction. Removal of free Nal125 was achieved by passage 
through a Sephadex G25 PD10 column (Pharmacia).
Pre-packed PD10 columns containing 9ml of 
'Sephadex G25 were obtained from Pharmacia laboratories. 
Non-specific protein binding sites were blocked with 20ml 
of buffer containing 0.1% BSA, and then equilibriated 
with the required buffer.
The iodinated protein A was eluted from the column 
using PBS, 0.5ml fractions were collected and lOul was 
assayed for radioactivity in a gamma counter. Two peaks 
were observed, the first containing the protein A and the 
second the free iodide. Fractions containing the 
iodinated protein A were pooled and stored at 4°C, in the 
presence of 0.1% sodium azide.The iodination reactions 
were carried out by Mrs. Mary Murphy.
18.3 IMMUNOBLOTTING
The immunoblotting technique was that of Towbin et 
al. (1979), with several modifications. Cells were 
harvested in denaturing buffer at a concentration of 
107cells/ml.(Methods section 12.3). Samples were boiled 
for 5 min and were loaded onto SDS-polyacrylamide gels,
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at approximately 106 cell equivalents per cm. Following 
electrophoretic separation at 10mA overnight, proteins 
were then transferee! to nitrocellulose using a Biorad 
transblot apparatus. Three foam pads and two sheets of 
Whatman no. 182 filter paper were pre-soaked in transfer 
buffer (192mM glycine, 25mM Tris.HCl pH 8.3 and 20% 
methanol) along with the nitrocellulose sheets to be used 
in the transfer. The gel was layed down on one sheet of 
the filter paper on top of two of the pre-soaked foam 
pads and then covered with nitrocellulose. This 
assemblage was rolled with a glass rod to exclude air 
bubbles. The nitrocellulose was then covered with the 
other sheet of filter paper and a further foam pad and 
the plastic holder was closed tightly over the sandwich. 
This sandwich was placed in the transfer tank with the 
gel towards the cathode and the nitrocellulose towards 
the anode. Proteins were transfered onto nitrocellulose 
electrophoretically in transfer buffer at 250mA for a 
'minimum of 3 h. at room temperature.
Following electrophoretic transfer nitrocellulose 
was removed from the sandwich and blocked for 2 x 30 
mins. at 37°C in blocking buffer (3% gelatin, ImM 
Tris.HCL pH 7.4, 15.4mM NaCl, and 0.05% Tween-20). Sheets 
were then washed 2 x 5  min. in wash buffer (1M Tris.HCL 
pH 7.4, 15.4mM NaCl with 0.05% Tween-20). Antibody 
solutions were made up to the desired concentrations in 
wash buffer containing 1% BSA and 0.01% sodium azide and 
added to the nitrocellulose in perspex wells or plastic 
dishes, depending on the size of the nitrocellulose and 
incubated overnight at room temperature.
Following overnight incubation in the antiserum, 
nitrocellulose was washed thoroughly in wash buffet for 4 
x 5 min. 123I-protein A was diluted to 1.5 x 10scpm/ml in 
wash buffer containing 3% BSA and incubated with the 
nitrocellulose for 2h at 37°C, then washed in wash buffer 
containing 1M potassium iodide for 2 x 60 min. The 
nitrocellulose was then given a final rinse in wash 
buffer without Tween-20 and dried on tissues, before
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being taped to cardboard sheets for autoradiography.
For autoradiography the procedure of Haarr et al,% 
(1985) was used, to align the 38S-methionine labelled 
protein tracks with the 123I-protein A signals. This 
involves simultaneously exposing the nitrocellulose to 3 
sheets of Kodak XS-1 film. The first film is placed 
directly on top of the membrane followed by a sheet of 
black paper then the further two sheets of film and an 
image intensifying screen (Dupont). The first film 
detects electrons from the decay of 35S—methionine which 
are unable to transfer to the second film. The high 
energy gamma emmisions from the 123I-protein A pass 
directly through all three films with little absorjption 
and interact with the image intensifying screen producing 
photons which are directed mainly onto the third film and 
to a lesser extent onto the second film: the signal is 
prevented from reaching the first film by the sheet of 
black paper. Thus the 33S-methionine signals on the first 
-film remain largely independent of the 125I signal. 
Radioactive ink containing 14C and 123 I spotted onto the 
cardboard produces images on the three films allowing 
them to be aligned (14C on the first and 125I on the 
second and third).
18.4 VIRAL NEUTRILISATIQN ASSAY
Virus was diluted to the desired concentration and 
mixed with the antiserum under test at the desired 
concentration diluted with various concentrations of 
guinea-pig complement (SAPU). Virus was incubated with 
antibody at 31°C for 1 h. Following incubation, virus 
samples were then plated onto 80% confluent BHK cells in 
50mm dishes (200pfu and 2000pfu) and overlayed with 
Eagle's medium containing methyl cellulose as described 
in section 11.2 . Plates were incubated for three days at 
31°C and then plaques counted.
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RESULTS
19. GENERATION OF OLIGOPEPTIDE INDUCED ANTISERA
For generation of antisera to put tive HSV 
polypeptides, oligopeptides were synthesised which ranged 
from 13-35 amino acids in length. The sequence and 
nomenclature of peptides is shown in Table 1. Three types 
of oligopeptides were synthesised:
A. Linear, monomeric peptides.
B. Branched peptides (Tam, 1988; Posnett et al. , 1988; 
see Section 9.3; Fig. 5).
C. Linear, monomeric peptides covalently attached to the 
synthesis matrix.
To investigate the immunogenic properties of the 
three peptide forms. Six different peptide sequences were 
presented in each of the three forms (monomeric, branched 
and resin-linked) to rabbits. Petides 161, 172, and 173, 
(Table 1) were used to immunise female New-Zealand White 
rabbits, whereas peptides 175, 177 and 202, (Table 1) 
were used to immunise female Sandy Half-lop rabbits. 
Immunisations of lOOug peptide were made intramuscularly 
to the schedule described in Methods section 17.2.1.
Seven days after each injection approximately 20ml of 
blood was taken from rabbits, serum was prepared as 
described (section 17.2.3) and tested for antipeptide 
antibodies.
Table 1, shows the sequences of the synthetic 
peptides and the predicted HSV-1 gene products containing 
those sequences (McGeoLh et al., 1988). These peptides 
were selected from predicted protein sequences on the 
basis of their proximity to their amino- or carboxy- 
terminus or because they correspond to hydrophyillic 
regions, criteria which are considered favourable to 
generation of antisera reactive with the protein of which 
the peptide forms a part (Palf^^mian et al.y 1984;
Lerner, 1984; Introduction section 9.2). These six 
peptides, each protein-conjugated, resin-bound and in
FIGURE 8
ELISA determination of anti-peptide response. Rabbit 
serum was tested in 2-fold dilutions against the 
immunising peptide sequence. Results are plotted as 
A4oshb vs dilution of serum. Results shown are for the 
final sera obtained on day 50 of the experiment and 
represent the mean values of duplicate plates. Panels a- 
f represent the data obtained with the six peptide 
sequences, 161, 177, 172, 202, 175 and 173 respectively.
O O O  represents rabbits immunised with peptides 
coupled to a carrier protein, -■— ■— ■- represents
rabbits immunised with branched peptides. Animals 
immunised with the resin-linked peptides are represented 
by -A— A— A—
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branched form, were used to immunise rabbits.
19.1 ANTIPEPTIDE TITRE OF THE RABBIT SERA
Enzyme-linked immunoabsorbant assay (ELISA) was 
used to determine the antipeptide titre of the five sera 
obtained from each of the 36 rabbits used in the 
experiment. Fig. 8, shows the titres of sera from the 
final bleed (day 50) taken from the rabbits. Each panel 
represents the sera from rabbits immunised with one 
peptide sequence.
Several interesting features are evident from this 
data. First, all rabbits immunised with branched peptides 
produced sera which was reactive with the immunising 
peptide. Whereas in contrast, some rabbits immunised with 
either the protein-conjugated peptides (Panel f) or the 
resin-linked peptides (Panels b, c, d and e) failed to 
give any detectable response. Secondly the sera of 
animals immunised with the branched peptides are 
consistently of higher titre than sera of animals 
immunised with protein-conjugated or resin—linked 
peptides. In fact, in only one case was a serum obtained 
(following immunisation with a protein-conjugated 
peptide) with a titre which was equal to that obtained 
using a branched peptide (Panel a).
The data were quantified (Table 3) in the following 
manner. First, the dilution of antiserum required to give 
an optical density of 0.2 was obtained from the data in 
Fig. 8. Non-reactive sera were given a value of zero. 
These values were summed for rabbits immunised with each 
of the three forms of peptide and this sum divided by the 
number of rabbits in each group. The values so obtained 
were 49.7, 394 and 6.6 for protein-conjugated, branched 
and resin-linked peptides respectively. This data shows 
that the antipeptide titre of sera generated using 
branched peptides was 9—fold higher than that generated 
by protein—conjugated peptides or about 58—fold higher 
than that generated by resin-linked peptides.
FIGURE 9
ELISA determination of anti—peptide response u/ith time. 
Rabbits were immunised as described, on days 0, 10, 30, 
and 40. Results shown are a 1/10 dilution of serum 
collected on days 7, 17, 37, and 50. Results are plotted 
as A4 0 3 n m vs time (in days) and are the means of 
duplicate plates. Panels A-F represent the data obtained 
with the six peptide sequences, 161, 177, 172, 202, 175 
and 173 respectively. The symbols are identical to those 
for Figure 8.
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To determine the rate at which the rabbits 
responded to immunisation with the differently presented 
peptides, a similar analysis was performed on sera 
obtained on days 0 (pre-immune), 7, 17, 37 and 50. Figure 
9, shows a part of the data; namely the ELISA titre of 
ten-fold dilutions of antisera. Several features are 
obvious: First, the response against immunisation with 
the branched peptides is both more rapid and of greater 
magnitude than that against either protein-conjugated or 
resin-linked peptides. Second, the sera of all animals 
immunised with branched peptides has elevated peptide 
titres after only a single injection. This is in contrast 
to animals immunised with both protein—conjugated 
peptides (in which only 3 out of 12 sera had antipeptide 
antibodies and these were of low titre) and resin-linked 
peptides (in which only 2 out of 10 sera had antipeptide 
antibodies, again of low titre). Third, the titre of 
almost all positive sera increased with each immunisation 
suggesting that continued immunisations might produce 
more protein reactive sera.
19.2 ANTI-PROTEIN TITRE OF THE RABBIT SERA
Western blotting was used to determine the anti­
protein titre of the final bleeds from each of the 
rabbits. Sera were serially four-fold diluted and 
screened together with the pre-immune sera on both mock- 
infected BHK cells and cells infected with HSV-1. The 
results for one serum 94497, from a rabbit immunised with 
peptide 173 are shown in Figure 10. The important 
features of this figure are the folowing: First, a 
polypeptide not recognised in extracts from uninfected 
cells or by pre-immune serum is recognised by the immune 
serum in extracts of infected cells. The Mr of this 
polypeptide is 82,000 and its properties are described in 
detail later in this thesis and elsewhere (Section 21.1; 
McLean et al., 1990). Second, the polypeptide is 
recognised by this serum diluted up to 160-fold. Data for
FIGURE 10
Western blotting for determination of anti-protein 
titre of rabbit serum. HSV-1 infected cell polypeptides 
u/ere separated by SDS-PAGE and western blotted. Lanes 1- 
4 are 1/10, 1/40, 1 /16,0 and 1/640 dilutions respectively 
of antiserum 94497 raised against the branched peptide 
173B, known to recognise a HSV-1 protein of Mr 82,000 
(McLean et al., 1990). Lane 5 shows the reactivity of 
the 94497 pre-immune serum and lane 6 shows the 
reactivity of 94497 with mock-infected cells.
1 2  3 4
Vm w81,8 2 -
FIGURE 11
Diagramatic representation of the 161 branched 
peptide following attachment of the SWM-1 TH-cell 
epitope to all eight amino terminal tyrosine residues. 
The portion of the immunogen which represents the Th CE 
is shown within the broken lines. All amino acids are 
represented by the one-letter code.
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TABLE 5
Antipeptide response to SWM-1
a
PEPTIDE ANTIPEPTIDE TITRE TO THCE
NUMBER
161 256, 256, 512, 512, 512
173 256, 1024 , 1024 , 1024, 1024
175 128, 512, 512, 512, 1024
177
00
, 0 ,
00
242 256, 512, 1Q24, 1024, 1024
244 512, 512, 512, 1024, 2048
0 No detectable reactivity.
a Titre expressed as the greatest dilution 
giving an OD4 0 5  greater than 0.2 in ELISA.
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this serum and that of the other rabbit sera were 
quantitated as described for the antipeptide sera and are 
shown in Table 4.
These data show that branched peptides produced a 
much better anti-protein response than did either 
protein-conjugated or resin-linked peptides. None of the 
resin linked peptides yielded a serum reactive with 
protein. The mean titres of the sera produced by the 
branched and protein—conjugated peptides were 8 6 . 2  and
20.0 respectively (Table 4). No sera from animals 
immunised with peptide 177, from the predicted product of 
gene UL41, was reactive with a virus-specific protein.
19.3 COUPLING OF "FOREIfrN" T-CELL EPITOPE TO BRANCHED 
PEPTIDES
The 17 amino acid "foreign" T-cell epitope (ThCE) 
SU/M-1 (Berkower et al. , 1985), from sperm whale myoglobin 
was coupled via carbodiiami.de to the amino termini of the 
^branched peptide molecules, to produce a large immunogen 
containing both B and TH-cell epitopes (Fig. 11). This 
procedure is described in detail in Methods section 16.4. 
Four branched peptides, were used namely: 161B,
177B, 173B and 175B (Table 1). Two additional branched 
peptides were included in these experiments. Although 
unrelated to the other work described in this thesis they 
were used to further increase the number of sample 
antigens in the experiment and so provide a more 
comprehensive investigation. They were 242B: 
(MATDIDMLIDLGLDLSJsK?A from HSV-1 gene UL54 (IE63), 
representing amino acids 1-16 and 244B:
(TGAPDVSALGAQGVL)a K7 A from HSV-1 gene IE175, representing 
amino acids 985-999. These peptides were synthesised and 
coupled to the ThCE by Miss A.M. Owsianka and 
Dr.H.S.Marsden.
To confirm that the ThCE was attached and was 
being introduced into the mice; the resulting mouse sera 
we/<& tested via an ELISA assay for the presence of
FIGURE 12
Titration of antiserum raised in ten Balb/c mice.
The data presented is for mice immunised with branched 
peptide 173, either alone or conjugated to the SU/M-1 T— 
cell epitope. Those sera raised against 173 alone are 
represented by -o— O— o— while those sera raised against 
173 + SWM-1 are represented by B
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antibodies to the SWM-1 sequence. All mouse sera, with 
the exception of those mice injected with peptide 177E, 
contained high titres of antibodies to this sequence 
(table 5), providing evidence of attachment of the ThCE , 
to at least one "arm" of the immunogen. This was 
confirmed by examination of the products of coupling 
reactions using SDS-PAGE analysis which showed coupling 
effi ciencies ranging from 0-100% attachment of SWM-1 (not 
shown).
19.4 ANTIPEPTIDE TITRE OF BRANCHED PEPTIDES + SUM-1
Balb/c mice were immunised with two 50ug injections 
of the branched peptide, either alone or in combination 
with ThCE molecules, as described in detail in Methods, 
section 17.2.2. Bleeds were taken 7 days after the second 
immunisation and tested for antipeptide titre in an ELISA 
assay. Sera were screened against the appropriate 
branched peptide in the absence of the ThCE to exclude 
measurment of antibodies generated against the ThCE 
sequence.
Figure 12, shows the titres of sera from the bleed 
taken 7 days after the second immunisation of one peptide 
sequence. The panel represents the sera from mice 
immunised with one peptide sequence. Several interesting 
features are evident from this data (Table 6 ). First, of 
the 30 mice immunised with branched peptides in 
combination with the ThCE only two mice failed to respond 
to the immunogen, whereas when the corresponding branched 
peptides were used without the presence of the ThCE, 17 
mice out of a possible 30 failed to give any detectable 
antipeptide response. Second, using criteria to determine 
antipeptide titre identical to those described earlier 
(section 19.1), the data shows that of the 13 mice that 
responded to the branched peptides in the absence of the 
ThCE only one achieved a titre of greater than 1000 (8 %). 
Whereas, of the 28 positive antisera raised using the 
branched peptides in combination with the ThCE, 15 had a
FIGURE 13
Bar graph representing the mean titres for 12 
groups of 5 mice immunised with branched peptides either 
alone (-), or in combination with the ThCE (+). Peptide 
numbers are shown along the X-axis while mean titres 
were determined from the data presented in Table 6 .
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FIGURE 14
Graph representing increasing concentrations of both 
branched and monomeric peptide (X—axis), tested via an 
ELISA assay against one single concentration of 
antiserum 94497 (1/40). Branched peptide 173B is 
represented by 4F j j  , while the monomeric peptide 
173 is represented by #  %
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titre of greater than 1000 (54%) (Table 6 ). Third, the 
only branched peptide/TiiCE molecule that failed to 
produce 5 positive mice, giving only 3 positives of low 
titre, was 177 and this peptide produced a generally poor 
response in rabbits (Figures 8 and 9).
The antipeptide titre for mice immunised either 
with or without the ThCE were summed, and these sums were 
divided by the total number of mice in each group (30) 
(Table 6 ). The values so obtained for branched 
peptide/TnCE immunogens was 968.8, whereas the value for 
branched peptides alone was 58. Showing that the 
antipeptide titre of sera generated by branched peptides 
in combination with the SU/M-1 ThCE was about 17—fold 
higher than that generated when the ThCE was absent.
The mean titres of antisera raised with both immunogens 
either with or without the ThCE are summerised in Figure 
13.
20. SENSITIVITY OF BRANCHED AND MONOMERIC PEPTIDES IN
ELISA ASSAYS  ^ '
Both monomeric and branched peptides were tested in 
ELISA assays to determine the minimum amounts of each 
that was neseccary to detect a given antibody, the 
results from one example are shown in Figure 14. The 
results presented in this figure show that a 
concentration of lug of monomeric peptide per well of a 
microtitre plate was required to obtain an absorbance of 
>0.2. Whereas in contrast as little as O.Olng of the 
branched peptide form was required. This result held true 
whether the antiserum had been raised against either the 
branched or monomeric peptide. The results presented in 
Figure 14, are typical of those observed for all peptide 
sequences tested; these results are summerized in Table 7 
and the values demonstrate that the amounts of branched 
peptide required to elicit a given absorbance in an ELISA 
assay ranged from 1 0 2 to 1 0 4 less than the amount of 
monomeric peptide required.
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FIGURE 15
A schematic presentation of the predicted protein 
product of gene UL47 of HSV-1 strain 17 with the 
location and sequence of the peptide against which the 
antiserum 94497 was raised. The HSV-1 genome is shown 
with the unique long (Ul ) and unique short (Us ) regions, 
the terminal repeats (TRl and TRs ), internal repeats 
( I R l and IRs ) and the locus of gene UL47 (McGeoch et 
al., 1988). The fractional length of the genome is shown 
at the top of the figure. The numbers at the end of the 
open reading frame and peptide refer to amino acid 
numbers in the predicted sequence. The amino-terminal 
tyrosine (Y) residue in parenthesis is not part of the 
predicted amino acid sequence of UL47 (see text).
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FIGURE 16
Western blotting with the 94497 serum showing 
specific recognition of an 82K polypeptide in HSV-1 
infected cells. The first lane (3 5 S) shows 3 sS-labelled 
HSV—1 infected cell proteins transferred to 
nitrocellulose. The second and third lanes (l2 3 I) shows 
polypeptides on the nitrocellulose that were detected by 
the pre-immune (PI) or immune (I) 94497 serum (1/100 
diln.) respectively. In this and subsequent figures, 
unless otherwise stated, polypeptides were separated on 
5-12.5% SDS polyacrylamide gels and alignment of the 
3 3 S—labelled and 1 23 I—labelled lanes was as described by 
Haarr et al., (1985).
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22. IDENTIFICATION OF HSV-1 GENE PRODUCTS 
22.1 IDENTIFICATION OF THE PRODUCT OF GENE UL47
Identification of the product of gene UL47 using 
antiserum 94497: Figure 15, shou/s the position df the 
open reading frame of gene UL47 on the prototype 
arrangment of the HSV-1 genome (McGeoch et al.9 1988) 
together with the position and sequence of the peptide 
against which antiserum 94497 was raised. The reactivity 
on western blots of this antiserum with proteins from 
HSV-1 infected cells is shown in Figure 16. The immune 
serum specifically detects a strong polypeptide band of 
apparent Mr 82,000 in 5-12.5% gels which is not detected 
by a sample of the pre-immune serum (Fig. 16) and is also 
shown to be absent from a mock-infected cell extract 
(Fig. 21; Panel A, lane 1). This band was therefore 
considered to be the protein product of gene UL47.
To test whether the protein product of gene UL47 is 
a structural component of the HSV-1 virus particle, 
virions were first purified from the supernatant of 3 5 S- 
met labelled cells (Rixon et al., 1988). Figure 17, is an 
electron micrograph of such a preparation and shows it to 
be substantially free of any visible contaminating 
cellular debris. Virion proteins were subjected to gel 
electrophoresis, transferred to a nitrocellulose membrane 
and probed with serum 94497. Both 5-12.5% gradient gels 
crosslinked with BIS (Figure 18, lanes 1-6) and 6 % gels 
cross-linked with DATD (lanes 7-9) were used because in 
earlier experiments (Marsden et al., 1976), a polypeptide 
doublet of apparent Mr s 82K and 81K had been observed in 
purified virions and it was anticipated that one of the 
gel systems might resolve the UL47 gene product as a 
doublet. Figure 18 (lanes 1 and 7), show the methionine- 
labelled virion polypeptides which were transfered to the 
membrane. The profile is similar to that reported earlier 
(Heine et al., 1974; Marsden et al., 1976; Dargan, 1986., 
Rixon et al., 1988) in that the major proteins seen
FIGURE 17
Electron micrograph of the virion preparation used for 
the experiment shown in Fig 18. Virions were prepared as 
described in the text. 2 ul of virion sample was applied 
to a parladion-coated copper grid, allowed to absorb for 
5 min, blotted dry and and stained with 3% 
phosphotunstic acid (pH 7.0). Preparation of the virions 
used for this electron micrograph and the 
electronmicroscopy was kindly carried out by Dr.F.J. 
Rixon.

FIGURE 18
The 82/81K polypeptide products of gene UL47 are virion 
proteins. HSV-1 virions, labelled with 3 3 S-methionine, 
were separated by SDS-PAGE using either 5-12.5% gels 
crosslinked with BIS (lanes 1-6) or b% gels cross-linked 
with DATD (lanes 7-10), then transferred to 
nitrocellulose membrane strips. Lanes 2—6, 8 and 9 were 
probed with serum 94497 [1/100 diln.] in the absence of 
polypeptide (lanes 2, 8 and 9) or in the presence of 
lug/ml (lane 3), lOug/ml (lane 4) and lOOug/ml (lanes 5 
and 10) of branched peptide (YGAAALRAHVSGRRA)aK?A 
against which the antisera was raised or lOOug/ml of the 
unrelated branched peptide (YLTPANLIRGDNA)oK7 A (lane 6 ). 
Bound antibody was visualised with 1 2 3 I-protein-A 
(tracks 2—6, 8 , 9 and 10). Lane 9 is a shorter exposure 
of lane 8 . The major virion proteins transferred to 
nitrocellulose are indicated on the left.
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FIGURE 19
Localisation of Vmu/82/81 within the virion by 
treatment of virions with NP40. Following treatment of 
virions with various concentrations of NP40, solubilised 
proteins were identified as those remaining in the 
supernatant following ultracentrifugation as described. 
Proteins in the pellet (P) and supernatant (S) were 
separated by SDS-PAGE and silver stained.
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include the major capsid protein (Vmw 155), gB, Vmw 82, 
the 65K transinducing factor (Vmw65 or 65Kt i f ), gD, Vmw51 
(VP19c) and Vmw37. It lacks the large tegument protein 
Vmu/273 because Vmu/273 is too large to be electroeluted 
from the gel and transfered to the nitrocellulose 
membrane (Rixon et al.t 1988).
Serum 94497 reacts specifically with Vmw82 (lane 2) 
and Vmw82/81 (lanes 8 and 9) and this reaction is blocked 
by the peptide against which the antiserum was raised 
(lanes 3-5 and lane 10) but not by an unrelated peptide 
(lane 6 ). Lane 7 shows virion proteins blotted from a 6 % 
gel cross-linked with DATD in which Vmw82/81 has been 
resolved as doublet. Two seperate exposures of a strip 
probed with antiserum 94497 show that both the 82K and 
the 81K polypeptides are recognised by the serum (Lanes 8 
and 9) and that the reactions are blocked by the 
oligopeptide against which the antiserum was raised. This 
experiment identifies the UL47 82/81K gene product as the 
previously recognised Vmw82,81 major component of HSV-1 
virions.
To investigate where in the virion the 82/81K 
protein is located, purified virions were treated with 
various concentrations of NP-40 and solubilised proteins 
separated from larger virion structures by 
centrifugation. Proteins in both pellet (P) and 
supernatant (S) were resolved by SDS-PAGE using a 5-12.5% 
gradient gel and proteins visualised by silver staining 
(Fig. 19). The data show that in the absence of NP-40 or 
with 0.01% NP-40 the virions appear intact as no proteins 
are found in the supernatant. With 0.1% and 1.0% NP-40 
both gB (an envelope glycoprotein) and Vmw65 (a tegument 
protein) were solubilised as was Vmw82,81. In contrast, 
concentrations of NP-40 as high as 1% failed to 
solubilise Vmwl55 (the major capsid protein) showing that 
the capsids remain intact. This data suggests that 
Vmw82,81 is located in the virion tegument 
or envelope.
To determine whether the product of gene UL47 was
FIGURE 20
Vmw82,81 is located in the tegument. Percoll-purified 
virions were incubated at 0-4°C either in the absence 
(lane 2) or the presence (lane 1) of 1% NP40. All 
samples were then iodinated: Acid insoluble 
radioactivity from 123-iodine varied from 2 0 , 0 0 0  to
600,000 per ul. Polypeptides were then separated by SDS— 
PAGE slab gels of 9% acrylamide cross-linked with DATD. 
The heavily labelled band just above Vmw65 in lane 1 was 
also present after iodination of the BSA-containing 
Percoll solution and most likely represents BSA. This 
experiment was carried out by Drs. N. Langeland and L. 
Haarr.
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FIGURE 21
The 82K product of UL47 is expressed late (Panel A) 
and the 38K product of gene UL45 is expressed early 
(Panel B) in HSV-1 infected cells. BHK cells u/ere 
infected with HSV-1 strain 17, harvested at times shown 
(in h), separated by SDS page and probed with serum 
94497 [1/100 diln.] (Panel A) and antiserum 23311 [1/50 
diln.] (Panel B). Proteins from mock-infected (MI) cells 
were included for comparison. The figure shows 
autoradiographic images of the 1 2 3 I-protein A used to 
detect bound antibody; which have been trimmed to show 
only the relevant region.
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located on the surface of the virion Percoll-purified 
virions were surface—labelled with 123 Iodine, after being 
subjected to treatment with 1% NP-40, (Fig. 20). Surface 
labelling with 123 I following NP-40 treatment shows the 
iodination of gB, Vmw82,81, gD, and Vmw65 (lane 1).
Without pretreatment with NP—40, Vmw82,81 and Vmw65 were 
not iodinated (lane 2). This indicates that the UL47 
protein is unlikely to be located on the surface of the 
virion particle. Together with the results of the 
previous experiments this suggests Vmw82, 81 are located 
in the tegument.
The regulation of expression of Vmw82,81 was then 
investigated. Cells were harvested at various times after 
infection and polypeptides were separated by SDS-PAGE, 
transferred to a nitrocellulose and probed with antiserum 
94497 (Fig. 21, Panel A). The protein was first just 
detectable at low levels at 6 hours and 8 hours after 
infection. However it was then strongly upregulated at 10 
hours and produced in higher amounts at 12 hours, its 
production then declined slightly after 24 hours (Fig.
21, Panel A). This dramatic up-regulation was 
reproducibly observed and suggests that UL47 is regulated 
as a late gene.
An operational definition of a true-late gene was 
suggested by Johnson et al.y (1986) to be those genes 
whose expression is most severely reduced, compared to 
all other groups of genes, under conditions of severely 
inhibited viral DNA replication. To determine whether 
gene UL47 was regulated as a true-late gene according to 
this definition the expression of the 82,81K protein was 
examined in the presence of 300ug/ml phosphonoacetic acid 
(PAA), as described in Methods section 12.2. This 
concentration reduces virus DNA replication to 
undetectable levels (<5% of the no drug control) in cells 
infected with HSV-1 strain 17 (Johnson et al.9 1986). The 
PAA-resistant mutant PAAr-1 (Hay and Subak-Sharpe, 1976), 
which induces wild-type levels of viral DNA synthesis in 
the presence of 300ug/ml PAA, was included in the
FIGURE 22
The 82K product, of gene UL47 is regulated as a true- 
late protein. Proteins were extracted from BHK cells 
infected with HSV-1 strain 17 in the absence (17+ -PAA) 
or presence (17+ +PAA) of 300ug/ml phosphonoacetic acid 
(PAA). A third set of cells were infected with a PAA- 
resistant mutant in the presence of 300ug/ml PAA (PAAr-l 
+PAA). Cells were harvested at 0, 6, 12, and 24 hours 
after infection, as indicated above the lanes and 
separated by SDS-PAGE. Three identical gels were run, 
polypeptides were transfered to nitrocellulose membranes 
and probed with serum 94497 [1/100 diln.] to detect the 
product of gene UL47 (panel A), serum 14327 [1/50 diln.] 
to detect the product of gene US11 (panel B), and serum 
18826 [1/100 diln.] to detect the product of gene UL42 
(panel C). Panel D shows an immunoblot with serum 94497 
of doubling dilutions extracted from BHK cells infected 
with HSV-1 strain 17 in the absence of PAA and harvested 
18 hours after infection. The autoradiographs have fceen 
trimmed to show only the relevant region.
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FIGURE 23
A schematic presentation of the predicted protein 
product of gene UL45 of HSV-1 strain 17 with the 
location and sequence of the peptide against which the 
antiserum 23311 was raised. The HSV-1 genome is 
represented as previously described for Fig. 15.
YR
PL
GP
T 
PP
M
RA
RL
PA
85
experiment as a control.
For comparison the behaviour of two other proteins 
was also examined: 21K, a true-late protein (Johnson et 
al.y 1986) and 65Kd b p , an early protein (Schenk and 
Ludwig, 1988; Goodrich et al.t 1988) whose synthesis is 
reduced 3-4 fold in the presence of PAA (Goodrich et al.> 
1988). The reactivity on Western blots of the rabbit 
antisera 18826 and 14327 used to detect the presence of 
65Kd b p and 21K respectively have previously been 
described (Parris et al. , 1988; MacLean et al.t 1987). 
Antiserum 18826 reacts with only a single protein 65Kd b p 
(Parris et al.9 1988) whereas antiserum 14327 reacts with 
predominantly 21K and proteins of apparent Mr 22K, 17.5K, 
14K and 11K which are related to 21K (MacLean et al.y
1987).
The results of this experiment are shown in Figure 
22, in which infected cells were harvested at 0 hours, 6 
hours, 12 hours and 24 hours after absorption. The 
82,81K polypeptide was first detected at 12 hours after 
absorption both in the wild-type virus-infected cells in 
the absence of PAA and in PAA-resistant virus in the 
presence of PAA: In cells infected with wild-type virus 
in the presence of PAA no synthesis of 82,81K could be 
detected by antiserum 94497 at any time after infection 
(Panel A, Fig. 22). This finding is exactly what would be 
expected for a true-late protein and essentially 
parallels the result obtained with 21K (Panel B, Fig.
22), previously found to be a true-late (Johnson et ai., 
1986). In contrast 65Kd b p is clearly detectable by 6 
hours post-infection and is only slightly inhibited by 
PAA in the wild-type virus-infected cells (Panel C, Fig 
22) .
The sensitivity of detection of 82,81K by antiserum 
94497 was quantitated by Western-blotting two-fold serial 
dilutions of HSV-1 infected cells. The antiserum was able 
to detect 0.5% (i.e. 1 to 256 dilution) of the level of 
polypeptide induced in cells infected with wild—type 
virus in the absence of PAA (Panel D, Fig. 22). These
FIGURE 24
Western blotting u/ith the 23311 serum showing specific 
recognition of a 38K polypeptide in HSV-1 infected 
cells. The first lane shows 38S-labelled HSV-1 infected 
cell proteins transferred to nitrocellulose. The second 
and third lanes show polypeptides on the nitrocellose 
that were detected by pre-immune rabbit serum (PI) or 
immune (I) 23311 serum respectively.
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FIGURE 25
The 38K product of UL45 is a component of HSV-1 
virions. Purified HSV-1 virions, labelled with 3SS- 
methionine, were separated by SDS-PAGE. Lane 1. shows 
the 33S—labelled virion polypeptides transferred to 
nitrocellulose. Lanes 2 and 3 show polypeptides detected 
by pre-immune and immune 23311 serum [1/50 diln.] 
respectively.
1 2 3
Vmw155-
gB-
Vmw81,82- pv
Vmw65-
9°'
Vmw37- -UL45
86
experiments show that in the absence of viral DNA 
synthesis the expression of gene UL47 is reduced to less 
than 0.5% of normal. The conclusion reached is that the 
UL47 gene, encoding the 82,81K polypeptides requires 
replication of viral DNA for expression.
21.2 IDENTIFICATION OF THE PRODUCT OF GENE UL45
Identification of the product of gene UL45 was 
achieved using antiserum 23311. Figure 23, shows the 
position of the open reading frame of gene UL45 on the 
prototype arrangment of the HSV-1 genome (McGeoch et al., 
1988) together with the position and sequence of the 
peptide against which antiserum 23311 was raised. The 
reactivity on western blots of this antiserum with 
proteins from HSV-1 infected cells is shown in Figure 24. 
The immune serum specifically detected a strong 
polypeptide band of apparent NL 38,000 in 5-12.5% gels 
which was not detected by a sample of the pre-immune 
serum (Fig. 24) and which was also/,from a mock-infected 
cell extract (Fig. 21; Panel B, lane 1). This band was 
therefore considered to be the protein product of gene 
UL45.
Antiserum 23311 was also used to detect the 
presence of the UL45 gene product in purified HSV-1 
virions. Figure 25 shows the result of a western blotting 
experiment in which purified HSV-1 virions were separated 
by SDS—PAGE and transferred to nitrocellulose, where they 
were probed with antiserum 23311. This antiserum detected 
a polypeptide band of Mr 38,000, which was the same Mr as 
the protein detected by this antiserum in HSV-infected 
cell extracts (Fig. 24). This polypeptide is a minor 
component of HSV-1 virions as the polypeptide is not 
visible in a normal profile of methionine labelled 
virions (Fig. 25, Lane 1).
A time course of protein production during viral 
infection was then carried out to investigate the 
regulation of expression of Vmw38. Cells were harvested
TABLE 8
Effect of pre-incubation of HSV-1 strain 17+ with 
antisera: 10555 (anti-HSV—1 serum, Column 1); 23074 
(anti-carboxy—amino acids 156-168 of UL45, Column 2); 
antisera 23311, immune and pre-immune (columns 3 and 4 
respectively). Antisera we(^ diluted to the desired 
concentration shown, with PBS containing 4% guinea-pig 
complement and pre—incubated with virus for lh at 31°C, 
followed by infection of cells with 200pfu virus (as 
described in Methods section 18.4).
TABLE 8
Neutralization of HSV-1 by serum 23311
ANTI SERUM _______ PLAQUES COUNTED
DILUTION
1 0 223 69 236
1/2 0 211 94 242
1/4 0 205 173 210
1/8 5 234 212 197
1/16 23 220 219 247
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and probed u/ith antiserum 23311 as previously described.
w/Hm* I
The protein was first just detectable at low levels7hour 
immediately after infection (Fig. 21, Panel B). However *+ 
it then began to be produced in greater amounts reaching 
a peak around 12—24 hours. These kinetics are those of an 
early protein.
Due to the possibility that UL45 may be included in 
the virus membrane (for reasons discussed earlier, 
section 10); antiserum 23311 was also tested for its 
ability to interfere with HSV-1 infection of BHK cells. 
Virus was pre-incubated with 23311, in addition to a 
serum (23074) raised against a carboxy—terminal peptide 
(172, Table 1) from UL45 and a polyclonal anti-HSV-1 
rabbit serum (10555, prepared by Dr.H.S. Marsden).
Initial experiments were performed to determine the 
concentration of guinea-pig complement which produced 
maximum neutrilisation of virus by serum 10555 and 4% was 
chosen (data not presented). Antiserum 23311 was observed 
to give a slight (3-fold) reduction in the number of 
plaques produced when compared to pre-incubation with 
antisera 23074, 10555 and the 23311 pre-immune serum 
(Table 8).
To investigate this observation further, an 
oligopeptide was synthesised corressponding to the amino- 
terminal 35 amino acids of the predicted product of gene 
UL45: a sequence which includes the entire region 
predicted to be external to the potential membrane 
spanning domain. This peptide was synthesised as a 
monomer because peptides of this length would be expected 
to elicit a good immune response in the absence of a 
carrier protein and because uncertainty existed as to 
whether difficulties such as stearic hinderance might be 
encountered in synthesising a branched peptide of this 
size. Although this peptide (no. 258, Table 1) was 
successfully synthesised, had the correct Mr (Table 2), 
and was 94% pure (Fig. 7), it surprisingly failed to 
induce either an antipeptide or antiprotein response in 
rabbits (data not shown). Thus disappointingly, the sera
FIGURE 26
A schematic presentation of the predicted protein 
product of gene UL46 of HSV-1 strain 17 with the 
location and sequence of the peptide against which the 
antiserum 94490 was raised.The HSV-1 genome is 
represented as previously described for Fig. 15.
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FIGURE 27
Western blotting u/ith the 94490 serum showing specific 
recognition of a 100K polypeptide in HSV-1 infected 
cells. The first lane shows 35S-labelled HSV—1 infected 
cell proteins transferred to nitrocellulose. The second 
and third lanes show polypeptides on the nitrocellose 
that were detected by pre-immune (PI) or immune (I)
94490 serum respectively.
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FIGURE 28
The products of genes UL46 and UL31 are not detected 
in HSV-1 virions. 35S-methionine labelled virion 
polypeptides transferred to nitrocellulose are shown in 
Lane 1. Lanes 2 and 3 show polypeptides detected by 
antisera 94490 [1/100 diln.] and R85/1 [1/10 diln.] 
respectively. Lane 4 shows specific recognition of the 
82,81K products of gene UL47 by antiserum 94497 as a 
control.
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could not be used to further investigate whether 
antibodies directed against the amino-terminus of UL45 
could neutr lise virus.
21.3 IDENTIFICATION OF THE PRODUCT OF GENE UL46
Identification of the product of gene UL46 u/as 
ach*a ved using antiserum 94490. Figure 26 shows the 
position of the open reading frame of gene UL46 on the 
prototype arrangment of the HSV-1 genome (McGeoch et al. ,
1988) together with the position and sequence of the 
peptide against which anti serum 94490 was raised. The 
reactivity on western blots of this antiserum with 
proteins from HSV-1 infected cells is shown in Figure 27. 
The immune serum specifically detected a polypeptide band 
of apparent Mr 100,000 in 5-12.5% gels which was not 
detected by a sample of the pre-immune serum (Fig. 27) 
and was also absent from a mock-infected cell extract 
(Fig. 29; Panel A, lane 1). This band was therefore 
considered to be the protein product of gene UL46.
Antiserum 94490 was also used to attempt to detect 
the presence of the UL46 gene product in HSV-1 virions. 
The result of a western blotting experiment are shown in 
Figure 28: Antiserum 94490 failed to detect any 
polypeptide band in purified HSV-1 virions (Fig. 28, lane 
2 ).
A further time course of protein production during 
viral infection was then carried out to investigate the 
regulation of expression of VmwlOO. Cells were harvested 
and probed with antiserum 94490 as previously described. 
The protein was first just detectable at low levels at 2 
hours and 3 hours after infection (Fig. 29, Panel A). 
However it then began to be produced in larger 
amounts reaching a peak around 12-24 hours, again these 
kinetics are typical of an early protein.
FIGURE 29
The 100K product of UL46 is expressed at early times 
(Panel A) and the 30K product of UL31 is expressed late 
(Panel B) in HSV—1 infected cells. BHK cells u/ere 
infected with HSV-1 strain 17, harvested at times shown 
(in h), separated by SDS page and probed with serum 
94490 (Panel A) or antiserum R85/1 (Panel B). Proteins 
from mock-infected (MI) cells were included for 
comparison. The figure shows an autoradiographic image 
of the 123 I—protein A used to detect bound antibody.
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FIGURE 30
A schematic presentation of the predicted protein 
product of gene UL31 of HSV-1 strain 17 with the 
location and sequence of the peptide against which the 
antiserum R85/1 was raised. The HSV-1 genome is 
represented as previously described for Fig. 15.
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21.4 IDENTIFICATION OF THE PRODUCT OF GENE UL31
Identification of the product of gene UL31 u/as 
achieved using antiserum R85/1. This antiserum was 
prepared by Dr. John Palfreyman in rabbits using as 
immunogen the peptide coupled to BSA by procedures 
identical to those described in Methods section 17.1.2.
It was used, rather than the antiserum prepared in this 
study, because experiments to identify and characterise 
the product of UL31 were initiated when R85/1 was the 
only antiserum available. Figure 30, shows the position 
of the open reading frame of gene UL31 on the prototype 
arrangment of the HSV-1 genome (McGeoCh et al.t 1988) 
together with the position and sequence of the peptide 
against which antiserum R85/1 was raised. The reactivity 
on western blots of this antiserum with proteins from 
HSV—1 infected cells is shown in Figure 31. The immune 
serum specifically detected a strong polypeptide band of 
apparent Mr 30,000 in 5-12.5% gels which was not detected 
by a sample of normal rabbit serum (NRS) (Fig. 31) and 
was also absent from a mock-infected cell extract (Fig. 
29; Panel B, lane 1). This band was therefore considered 
to be the protein product of gene UL31.
Antiseum R85/1 was also used to attempt to detect 
the presence of the UL31 gene product in HSV-1 virions. 
The result of a western blotting experiment are shown in 
Figure 28. Antiserum R85/1 failed to detect the presence 
of the UL31 polypeptide in HSV-1 virions (Fig. 28, Lane 
3.)
The regulation of expression of Vmw30 was then 
investigated. Cells were harvested at various times after 
infection and polypeptides were separated by SDS-PAGE, 
transferred to a nitrocellulose and probed with antiserum 
R85/1 (Fig. 29, Panel B). The protein was first just 
detectable at low levels at 5 hours and 6 hours after 
infection. However it then began to be produced in
larger amounts reaching a peak around 12.hours. The 
late appearance of this polypeptide indicated that it was
FIGURE 31
Western blotting with the R85/1 serum showing specific 
recognition of a 30K polypeptide in HSV-1 infected 
cells. The first lane shows 35S-labelled HSV-1 infected 
cell proteins transferred to nitrocellulose. The second 
and third lanes (12 31) show polypeptides on the 
nitrocellulose that were detected by normal rabbit serum 
(NRS) or immune (I) R85/1 serum respectively.
-UL31
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regulated as a late gene.
To determine u/hether gene UL31 is regulated as 
a true-late gene according to the operational definition 
suggested by Johnson et al.y (1986), described earlier 
(see Section 22.1), the expression of the 30K protein was 
examined in the presence of 300ug/ml phosphonoacetic acid 
(PAA), as described previously for UL47. The PAA- 
resistant mutant PAAr-l (Hay and Subak-Sharpe, 1976), 
which induces wild-type levels of viral DNA synthesis in 
the presence of 300ug/ml PAA was also included in the 
experiment. Antisera 14423 and 18812 (previously 
described) were again used as previously described as 
controls.
The results of this experiment are shown in Figure 
32, in which infected cells were harvested as previously 
described. Polypeptide 30K was first detected in minor 
amounts at 6 hours after absorption both in the wild-type 
virus-infected cells in the absence of PAA and in PAA- 
resistant virus in the presence of PAA: In cells infected 
with wild-type virus in the presence of PAA no synthesis 
of 30K could be detected by antiserum R85/1 at any time 
after infection (Fig. 32, Panel A). This finding is again 
exactly what would be expected for a true-late protein 
and essentially parallels that obtained with 21K (Fig.
32, Panel B), previously found to be a true-late (Johnson 
et al.y 1986). In contrast 65Kd b p was clearly detectable 
by 6 hours post-infection and was only slightly inhibited 
by PAA in the wild-type virus-infected cells (Fig. 32, 
Panel C).
The sensitivity of detection of 30K by antiserum 
R85/1 was examined by Western-blotting two-fold serial 
dilutions of HSV-1 infected cells. The antiserum was able 
to detect 1.0% (i.e. 1 to 128 dilution) of the level of 
polypeptide induced in cells infected with wild-type 
virus in the absence of PAA (Fig. 32, Panel D). These 
experiments show that in the absence of viral DNA 
synthesis the expression of gene UL31 was reduced to less 
than 1.0% of normal. The conclusion reached is that the
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UL31 gene, encoding the 30K polypeptide requires 
replication of viral DNA for its expression.
FIGURE 32
The 30K product of gene UL31 is regulated as a true- 
late protein. Proteins were extracted from BHK cells 
infected u/ith HSV-1 strain 17 in the absence (17+ -PAA) 
or presence (17+ +PAA) of 300ug/ml phosphonoacetic acid 
(PAA). A third set of cells were infected with a PAA- 
resistant mutant in the presence of 300ug/ml PAA (PAAr-l 
+PAA). Cells were harvested at 0, 6, 12, and 24 hours 
after infection, as indicated above the lanes and 
separated by SDS-PAGE. Three identical gels were run, 
polypeptides were transfered to nitrocellulose membranes 
and probed with serum R85/1 [1/10 diln.] to detect the 
product of gene UL31 (panel A), serum 14327 [1/50 diln.] 
to detect the product of gene US11 (panel B), and serum 
18826 [1/100 diln.] to detect the product of gene UL42 
(panel C). Panel D shows an immunoblot with serum R85/1 
of doubling dilutions extracted from BHK cells infected 
with HSV-1 strain 17 in the absence of PAA and harvested 
18 hours after infection. The autoradiographs have beery 
trimmed to show only the relevant region.
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DISCUSSION.
22. GENERATION OF ANTISERA TO SYNTHETIC PEPTIDES
The experiments carried out to produce antipeptide 
antisera were designed to compare quantitatively the 
immunogenicity of branched peptides (Tam, 1988; Posnett et 
a l . y 1988) with that of peptides conjugated to carrier 
proteins or linked to the resin on which they were 
synthesised. This topic is important because antipeptide 
sera have already proved extremely useful reagents, for 
many types of experiments (described earlier, Section 
9.1). Their main use to date has been in identifying the 
putative polypeptide products, inferred by analysis of 
nucleic acid sequences. However, antipeptide sera produced 
using peptides conjugated to carrier proteins are often of 
low titre, so that any method of presenting peptides which 
generates sera of higher titres would be extremely 
advantag£c*i> in fact, even if branched peptides were to 
generate sera with only equal titres to those elicited by 
protein-conjugated peptides they would still be a more 
attractive form of immunogen because the method avoids all 
the steps and difficulties involved in coupling peptides 
to carrier proteins.
The method of Merryfield chemistry (1963) originally 
used for the synthesis of the branched lysine core (Tam, 
1988; Posnett e t  a l . y  1988) was successfully modified for 
synthesis using Fmoc chemistry so avoiding the use of the 
potentially hazardous chemical hydrogen fluoride. The 
branched core was conveniently synthesised in batches of 
l.Og (of a 0.1 mM equivalent Pepsin KA resin) then stored 
at -20°C, in 0.125g aliquots for subsequent synthesis of 
the branched peptides. Yields from 0.125g of resin-liked 
branched lysine core were typically 50-100mg of branched 
peptides: about 100 times that required for a series of 
immunisations. Batches of branched lysine core produced 
have all been successful as judged by mass spectrometric 
analysis and subsequent synthesis of branched peptides.
The branched peptides produced by this method were
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homogeneous as judged by SDS-polyacryamide gel 
electrophoresis demonstrating coupling of the carboxy- 
terminal amino acid of the unique peptide sequence to all 
eight amino groups of the branched lysine core.
22.1 PRODUCTION OF ANTISERA IN RABBITS
A comparison was made of the immunogenicity of six 
different peptide sequences (from five different HSV—1 
genes) when presented to two different species of rabbits 
in each of three different forms. The data obtained 
convincingly demonstrate that rabbits immunised with 
branched peptides yield sera with higher antipeptide and 
antiprotein titres than rabbits immunised with either 
protein-conjugated or resin-linked peptides.
The most usual criterion by which antipeptide sera 
are judged is their ability to recognise the protein of 
which the peptide forms an integral part. Table 4. shows 
that the titres of sera from rabbits immunised with 
branched peptides were more than four-fold higher than 
those of rabbits immunised with protein conjugated 
peptides. Initially, a four-fold difference may not seem 
very significant, however, in terms of the usefulness of 
the antisera for experimentation it is, because, sera with 
anti-protein titres of 10 or less give higher backgrounds 
on Western blots and are consumed very rapidly by even a 
modest series of experiments.
As judged by ability to recognise proteins, 7 out of 
13 (54%) rabbits immunised with branched peptides produced 
useful sera, while the comparable figure for rabbits 
immunised with protein conjugated peptides was only 3 out 
of 12 (25%). An alternative way to view these results is 
that four of the five HSV-1 gene products could be 
investigated using branched-peptide-induced antisera 
compared with two out of five for the protein-conjugated 
sera. This result also means that many fewer animals 
(about half) would have to be immunised in order to have a 
good probability of producing a useful antiserum. Any
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increase in efficiency which leads to the use of a lower 
number of experimental animals is of course highly 
desirable.
Resin-linked peptides initially seemed an attractive 
approach to generate anti—protein sera being potentially 
the easiest method, as it is necessary to remove the side- 
chain protecting groups. The matrix can be ground up to a 
fine powder for immunisations. Disappointingly, none of 
the animals immunised with peptides presented in this form 
produced sera reactive in Western blots with protein. The 
reason why this approach should have proved so unsuccesful 
is not clear. However there are various possibilities: 
perhaps the particles produced were simply too large to be 
processed in a normal way by the immune system; it is also 
possible that the presence of the synthetic resin in some 
way hampered the ability of the immune system to respond 
to the attached peptides, which may be inaccessible to 
cells of the immune system by their position within the 
matrix. Unfortunately it must be concluded that this 
approach is not useful.
Two species of rabbits were used in this study: New 
Zealand White for peptides 161, 172 and 173 (Table 1); and 
Sandy Half-Lop for peptides 177, 175 and 202 (Table 1).
The data presented in Figures 8 and 9 (panels a, c and f 
show data from New Zealand White rabbits) demonstrate that 
the observed relative immunogenicity of the three 
different forms of peptide presentation was similar for 
both rabbit strains. The effective.^1) of branched peptides 
in eliciting high titre sera was therefore independent of 
the rabbit strain used.
One peptide, 177, elicited no anti-protein sera, 
regardless of the method of presentation. There are 
several possible reasons for this: it is possible that the 
region on the protein from which the 177 sequence 
originated is inaccessible to antibody even after the 
denaturation that is involved with Western blotting. 
Alternatively, there may be something inherent in the 
amino acid sequence that results in low immunogenicity.
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This seems to be confirmed by the antipeptide titres 
obtained for this sera (Figure 8. Panel b), u/ith the 
average titre elicited by this peptide being lower than 
that elicited by the other five peptides. Interestingly 
this peptide is extremely basic (net charge +5) although 
this is not neccesarily responsible for the results 
obtained.
These experiments also demonstrated, that rabbits 
immunised with branched peptides responded to give sera of 
high titre after one single immunisation, whereas it 
required at least two or more immunisations with monomeric 
peptides to achieve a satisfactory response. The reason 
for this observation has not been investigated, although 
it may be due to the multivalent nature of the branched 
peptide molecules.
This result is particularly interesting, with the 
potential development of synthetic vaccines based around 
peptide immunogens. Especially with respect to production 
of future veterninary vaccines, where economic 
considerations dictate that a single dose of vaccine, 
should be sufficient to confer long lasting protective 
immunity. Whether branched peptides are capable of 
generating such a response requires further investigation.
The successful adaptation of Fmoc chemistry to the 
synthesis of branched peptides facilitated the use of this 
chemistry to explore the effects of adding synthetic T- 
cell epitopes to branched peptides as originally suggested 
by Tam (1988) [see later]. The observation that the 
branched peptides produced high antipeptide titres, after 
even a single injection of antigen, provides strong 
support for the suggestion (Tam, 1988) that these 
structures may provide potent immunogens for the 
development of peptide-based vaccines.
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22.2 PRODUCTION OF ANTISERA IN MICE
Although polyclonal antipeptide sera raised in 
rabbits are very useful (for reasons described earlier), 
they are however restricted in their potential, as there 
is always a limited volume of a particular serum available 
for experimentation. Therefore the logical progression of 
the use of branched peptides would be to use them as 
immunogens to produce monoclonal antibodies in mice. Such 
antibodies would have the advantage of providing a 
potentially limitless supply of reagent, which especially 
in the case of ascites fluid would be of much greater 
titre than any poiyclonal sera generated in rabbits.
Initial attempts to immunise Balb/c mice with 
branched peptides in an identical manner to that used for 
rabbits, unfortunately proved unsuccessful with no 
antipeptide response detectable (results not presented). 
One possible reason for this lack of success could be that 
the inbred, Balb/c mice are genetically identical. This 
might place a genetic restriction on the ability of the 
immune system to respond to a short peptide sequence, 
through lack of availability of a large repertoire of 
potential TH-cell receptor (ThCR) sequences. A severe 
restriction is therefore placed on the number of potential 
epitopes that can be recognised by their Th CR s . This 
restriction may be playing an inhibitory role on the 
antigenic potential of branched peptides, because, as 
discussed earlier, it is believed that an immunogenic
peptide must contain antibody recognition sites (B-cell 
epitopes) and sites capable of eliciting T-cell help for 
antibody production (TH-cell epitopes) (Mitichson, 1971).
Recent experiments had shown that conjugation of B- 
cell epitopes with either a "natural" or "forgein" TH-cell 
epitope sequence could confer immunogenicity on 
previously poorly immunogenic peptides (Good et al., 1987; 
Leclerc et al.t 1987; Section 9.3). Of particular interest 
in this respect, were the experiments of Francis et al. , 
(1988), who demonstrated the successful use of SWM-1, a T-
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cell epitope from Sperm Whale myoglobin, shown to be 
active in Balb/c mice (Berkower et al., 1985). This 
sequence was used successfully to considerably enhance 
immunogenicty on monomeric peptides from FMDV.
The experiments described here demonstrate that by 
the use of the same sequence in combination with branched 
peptides, a very strong immunogenic potential could be 
conferred on these molecules. In these experiments the SWM— 
1 ThCE was attached to the amino-terminus of the branched 
peptides. This was in contrast to the work of Francis et 
al., (1988), whose work with a FMDV peptide used the ThCE 
at the carboxy-temdnus of the B-cell epitope. In this case 
at least, addition of the ThCE to the amino-terminus seems 
to have been as successful. However to demonstrate fully 
if this lack of constraint on orientation holds true, it 
would be neseccary to attach the ThCE to both the carboxy 
and amino termini of the same B-cell epitope. It would not 
be surprising, due to the high degree of degradation 
undergone by antigens taken-up by antigen presenting cells 
like macrophages, to find that the ThCE could be added to 
either end.
Of the 30 mice immunised with branched peptides 
without ThCEs only 10 produced an antipeptide reponse. With 
only one exception these sera were all of very low titre. 
Whereas in combination with SWM-1, the branched peptides 
almost uniformally produced antipeptide sera of high 
titre. Interestingly, the only peptide sequence that gave 
low titre sera and failed to give five out of five 
positive mice in the presence of the ThCE, was 177. This 
sequence had previously been shown to display poor 
immunogenicity in the experiments carried out in rabbits 
(Figure 8, panel b). Reference to Table 5 indicates that 
immunisation with peptide 177E failed to generate any 
antibodies to the ThCE, in contrast to all other sequences 
tested. It therefore seems likely that the ThCE failed to 
attach successfully to the 177 branched peptide. It is not 
known, however, whether the poor response to this 
immunogen is due to the lack of the ThCE or some inherent
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low immunogenicity of this peptide, as already observed in 
rabbits. It is most likely a combination of both.
This method of producing the ThCE-branched peptide 
conjugates, whereby the ThCE portion of the immunogen was 
added as a “cassette" in a one step addition process, 
obviously provides advantages over a continuous step-by- 
step addition of each amino acid residue. By adding the 
complete ThCE to any available branched peptide, it 
considerably reduces the synthesis time required to 
produce the peptide, as addition of subsequent amino acids 
to peptides longer than 20 amino acids require twice as 
much time as adding amino acids to short peptides since 
double—coupling and long recirculation times are routinely
r  O '*
used. In practice one large "batch“ of protected ThCE/to 
be produced aliquot^ of which can then be added to each 
branched peptide as and when required. Also since the 
amount of branched peptide needed for immunisations is 
usually only a small fraction of what is synthesised most 
can be left uncoupled and available for other uses e.g.
ELISA assays, instead of having to initiate a further 
synthesis.
The ability to confer strong immunogenicity on 
branched peptides, in inbred animals, obviously makes them 
attractive canditates for the subsequent generation of 
monoclonal antibodies and could provide the means to 
generate monoclonal antibodies, directed against the 
product of any gene for which nucleic acid sequence data 
is available. The subsequent recognition of proteins by 
these sera cannot of course be guaranteed.
A method which employs branched peptides to produce 
monoclonal antibodies has a number of potential advantages 
over conventional techniques: Firstly, the majority of 
monoclonal antibodies produced to date have used either 
purified or partially purified proteins as immunogens. 
Although frequently successful, this approach often 
involves considerable time to produce the immunogen. 
Secondly, if a non-homogeneous, partially purified protein 
extract is used, then initial screening of any clones
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produced has to be carried out by immune precipitation or 
a similar method which is also very time consuming. The 
use of branched peptides in combination with ThCHs could 
help surrmount these problems by providing a homogeneous 
well defined immunogen.
Branched peptides also facilitate very rapid 
screening of the supernatant of hybridoma clones generated 
during a fusion by BLISA assays. Such early screening for 
peptide reactive clones can remove the need to propagate 
negative cell lines at an early stage. This avoids the 
time consuming process of freezing all cel1-lines for 
storage until it has been determined by immune 
precipitation whether they are of interest. Of course, 
many clones will be selected having anti—peptide 
antibodies which do not then react with the protein of 
which the peptide forms a part. Such clones can only be 
eliminated by subsequently screening them against protein 
in some other immunoassay.
It may be possible to reduce the proportion of 
peptide-reactive, protein non-reactive antibodies by 
initial immunisation with branched peptide in combination 
with ThCE, followed by "booster" immunisation with a 
partially purified extract containing the protein of 
interest. In this way there is the possibility that only 
those memory cells capable of secreting antipeptide 
antibody which is reactive with the native protein would 
be stimulated to proliferate and secrete immunoglobulin. 
This would further increase the likelrhood of generating a 
useful cell-line.
An added advantage of monoclonal antibodies raised 
against synthetic peptides, is that the epitope which they 
recognise within the target protein is already known, 
which may prove useful in subsequent experimentation for 
example immunoaffinity purification.
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23. SENSITIVITY OF BRANCHED AND MONOMERIC PEPTIDES IN 
ELISA ASSAYS
The results presented here demonstrated that the 
amount of branched peptide needed to detect rabbit 
antibodies specific for peptide was 100 to 10,000-fold 
lower than the amount of the corresponding linear, 
monomeric peptide, a result that was observed for all six 
peptides tested (Table 7).
The basis for the finding that the amounts of 
branched peptide needed to detect antibodies in rabbit 
sera is lower than for monomeric peptides has not been 
investigated. However it is most likely that the 
difference reflects the multi valent nature of the branched 
peptides compared with the monovalent nature of the linear 
peptides. Multivalent binding between antibody and 
branched peptide (avidity) would result in a considerable 
increase in stability, compared to the simple monovalent 
binding of linear peptide Thus there may be a
103-fold increase in the binding energy of IgG when both 
valencies (binding sites) are occupied (Roitt et al., 
1989). Similarily if IgM were the antibody under test and 
a multivalent antigen was used, binding energy could 
increase by up to 107-fold. Multivalency might therefore 
account for the finding that the amount of branched 
peptide needed to detect antipeptide sera produced in 
rabbits is as much as 10,000 (10*-fold) less than the 
amount of monomeric peptide needed.
An alternative explanation for apparent increased 
sensitivity of branched peptides might be that branched 
peptides bind more readily to the microtitre wells than do 
linear peptides so that the amount absorbed to each well 
is greater. Although further experiments are neseccary to 
exclude this possibility it seems unlikely, as other 
experiments have shown that the ratio of branched peptide 
to monomeric peptide needed to detect antibodies in rabbit 
and human sera is different (Marsden, Owsianka, Graham, 
McLean and Subak-Sharpe, manuscript in preparation).
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Synthesis of branched peptides is no more difficult 
or expensive (u/eight for weight) than that of monomeric 
peptides, suggesting that significant savings are 
potentially available by using branched peptides for the 
development of peptide-based serodiagnostic kits. If such 
kits were designed to detect IgM antibodies (perhaps for 
diagnosis early in infection) then for reasons discussed 
above this saving could potentially be greater than those 
already observed, with perhaps as much a 107-fold 
reduction in the amount of peptide required. Although this 
remains to be experimentally tested. This makes the use of 
branched peptides in serodiagnosis worthy of further 
investigation.
24. IDENTIFICATION OF THE HSV-1 GENE PRODUCTS
Following the publication of the complete DNA 
sequence of HSV-1 strain 17 (McGeodti et al., 1988) it is 
clear that much work remains to be done in the 
characterisation of HSV—1 genes. The products of many of 
the genes remain to be identified and their ability to 
encode proteins confirmed. Antisera generated in the 
previously described studies on peptide immunogenicity, 
was used to attempt to identify the putative protein 
products of five HSV-1 genes, predicted by the DNA 
sequence of McGeo^h et a l (1988); namely, UL31, UL41, 
UL45, UL46 and UL47. (Antiserum R85/1, which was used to 
identify the protein product of the UL31 gene product was 
generated by Dr. John Palfreyman, and was used because it 
was available before the sera described in this thesis 
were made).
These genes were of initial interest because no 
protein products had been assigned to them.
Identification and characterisation of the products of 
genes with antipeptide sera is important not only as an 
insight into their possible role in the virus life cycle 
but also as a useful confirmation of the accuracy of the 
DNA sequence.
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Within the DNA sequence of strain 17 there are 11 
proposed overlaps of coding sequences within UL, these 
occur in two major groups of genes: UL5 to UL14 and UL30 
to UL33 (McGeoCh et al. , 1988). The majority of these 
overlaps are at present proposed soley on the 
interpretation of the DNA sequence. Because of uncertainty 
at mapping translational start sites most of these remain 
tent tive (McGeoeh et al. , 1988). The predicted DNA 
sequence for gene UL31 proposes an overlap in "tail—to- 
tail" fashion of 19 codons with the predicted sequence of 
gene UL30, the HSV-1 encoded DNA polymerase (Quinn and 
McGeo h, 1985).
The oligopeptide (YJLYATFDEFPPP which was used to 
generate antiserum R85/1 represents amino acids 291-301 of 
the predicted sequence of the UL31 gene product, which 
lies completely within the region of preposed overlap with 
gene UL30 (Quinn and McGeoeh, 1985; McGecCh et al., 1988). 
The data presented here showing that antiserum R85/1 
specifically identifies the product of gene UL31 as a 
product in HSV-1 infected cells of apparent Mr 30,000 
confirms the accuracy of the UL31 DNA sequence obtained 
for strain 17 (McGeoeh et al.t 1988). The DNA sequence for 
gene UL30, the HSV-1 DNA polymerase has now been published 
by three independent groups (Quinn and McGeoCh, 1985;
Gibbs et al., 1985; Knopf, 1986; McGeoGh et al., 1988), in 
3 different virus strains. All of these authors identify 
the same carboxy-terminus as that of McGeoCh et al.,
(1988). This information together with the result 
presented here which identifies the UL31 gene product 
using an antiserum raised against a peptide sequence 
predicted to be whoJkj encoded from within this overlap, 
provides strong evidence to support the proposed overlap 
of the carboxy-termini of genes UL30 and UL31.
Attempts at the identification of the UL41 gene 
product, the virion component involved in shut-off of host
cell macromolecular synthesis (Read and Frenkel, 1983;
6.X '
Kwong/ 1988; Simbert and Smiley, 1990) were unfortunately 
unsuccessful. This lack of success was almost certainly
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due to the failure to produce a high titre antiserum in 
either rabbits or mice with peptide 177 (representing 
amino acid numbers 13-23 of the predicted product of 
UL41). The sequence of this peptide seems to have a 
particular lack of antigenicity (discussed earlier).
The predicted Mr of the product of gene UL45 from 
its DNA sequence is 18,178 (McGeoCh et al., 1988). This is 
considerably lower than the apparent Mr of 38,000 observed 
on polyacrylamide gels, western blotted and probed with 
antiserum 23311. The reason for this large increase in 
apparent Mr is not known, however sequence data indicates 
that UL45 is potentially membrane associated, containing 
an extremely hydrophobic amino terminus. Although there is 
a lack of any apparent N-glycosylation sites within the 
UL45 sequence (McGecch et al., 1988). Further experiments 
will have be carried out to determine the nature of any 
modifications made to the UL45 primary translation 
product.
Significant differences exist in the published DNA 
sequences obtained for gene UL47 from HSV-1 strain F 
(McKnight et al., 1987) and HSV-1 strain 17 (McGecch et 
al.y 1988). In particular there is an extra G residue at 
base 101163 of strain 17 which is not present in the 
published sequence for strain F. As a consequence the 
predicted amino acid sequences differ from the aligned 
proline residues at position 650 of strain F and 651 of 
strain 17: The former continues for a further 14 residues 
whilst the latter continues for a further 42 residues. The 
sequence (Y )GAAALRAHVSGRRA in the branched peptide against 
which antiserum 94497 was raised corresponds to amino 
acids 671-684 of the UL47 gene product predicted for 
strain 17 (McGecch et al., 1988), plus an additional N- 
terminal tyrosine, but is entirely absent from the UL47 
product predicted for strain F (McKnight et al., 1987).
The data obtained here with antiserum 9 4 4 9 7  
specifically identifies the products of gene UL47 of H S V -1  
strain 17 as abundant virion proteins of apparent Mr s
8 2 ,0 0 0  and 8 1 ,0 0 0  confirms the correctness of the UL47 DNA
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sequence obtained for strain 17. However it should be 
stated that this does not exclude the possibility that 
there are strain-specific sequence differences between 
strain 17 and strain F.
24.1 KINETICS OF SYNTHESIS OF UL31. UL45. UL46 AND UL47
The results presented have established that 
regulation of expression of the UL47 and UL31 genes is in 
a true-late manner. These findings support and extend 
those described in two earlier studies which reported two 
true-late transcripts, most likely originating from what 
we now call UL47 and UL31. The first was a 4.7Kb true-late 
mRNA transcribed in a leftward direction from the region 
of the genome predicted to encode gene UL47 (Hall et al.y 
1982) and the second was a 1.4 Kb true-late mRNA 
transcribed in a leftward direction around map unit 0.44 
corresponding to the position of gene UL31 (Holland et 
a l . y  1984). The quantitative data reported here (Figures 
22 and 32) shows that in the absence of viral DNA 
synthesis the UL47 protein product levels are less than 
0.5% of those in a normal infection, while the amounts of 
UL31 product present are reduced to less than 1.0%.
Regulation of HSV-1 gene expression has been most 
frequently examined at the mRNA level. Evidence exists for 
9 true-late mRNAs (Holland et a l . y  1980; Frink et a l . y  
1981; Hall et a l . y  1982; Holland et a l . y  1984; Silver and 
Roizman, 1985; Johnson et a l . y  1986). Comparison of the 
positions and sizes of these transcripts with the DNA 
sequence obtained by McGeoeh et a l.  (1988) suggests that 
these true-late mRNAs may originate from genes UL22, UL31, 
UL32, UL38, UL44, UL45, UL47, UL49 and US11, but 
quantitative data for mRNA regulation has been obtained
only for gene UL49 (Silver and Roizman, 1985) and US11 , .
.He**- Ul31 c-J UCMi h<\v< H> be
(Johnson e t  a l . y  1986)./Quantitative data for either mRNA
or protein will have to be obtained for the others to
identify these genes unambiguously as true-late.
At present the designation of HSV—1 gene UL38 as a
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true-late gene seems doubtful: First, assembly of capsids 
is not dependent on virus DNA replication (Reviewed by 
Dargan, 1986) but is dependent on expression of HSV-1 UL38 
(Pertuiset et al., 1989), the product of which is an 
abundant capsid protein (Hixon et al. , 1990). Second , 
qualitative data has been obtained by Yei et al. (1990) 
suggesting that the HSV-1 gene is not regulated as a true- 
late gene while the HSV-2 gene is.
The results presented in this thesis (Figure 21, 
Panel B) place some considerable doubt on the designation 
of gene UL45 as "true-late" as experiments with antiserum 
23311 have shown that the 38K product is present in 
infected cells early in infection (1 hour p.a.) at a time 
before initiation of viral DNA synthesis.
At the protein level only two genes, US11 and UL36 
have been shown to/regulated in a true-late manner 
(Johnson et al., 1986; McNabb and Courtney, 1990, 
Abstracts: 15th International Herpesvirus workshop), US11 
encodes a 21K non-structural protein (Rixon and McGeogh, 
1984) which localises to the nucleoli of infected cells 
(MacLean et al., 1987) and binds directly or indirectly to 
DNA, most likely to the a sequence (Dalziel and Marsden, 
1984; MacLean et al.t 1987). UL36 encodes the large 273K 
tegument protein (Batterson et al., 1983).
Analysis of the kenetics of synthesis of gene UL46 
have shown the 100K product is present in infected cells 
early in infection at 2-3 hour^ p.a., reaching peak 
amounts at 18-24 hours p.a. (Fig. 29, Panel A). This 
supports and extends the findings of Hall et al.% (1982) 
who mapped a 2.5Kb beta-gamma mRNA transcribed in a 
leftward direction in this region of the genome. This 
transcript was translated in vitro into a 85K polypeptide.
24.2 FURTHER CHARACTERISATION OF PROTEINS
Both antisera R85/1 and 94490 failed to detect the 
30K and 100K products respectively of genes UL31 and UL46 
in purified HSV-1 virions, while in parallel experiments
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the UL45 and UL47 gene products were readily identified as 
virion pratjLmS - The finding that the product of gene UL31 
is likely to be a non-structural protein might initially 
seem surprising: from its true-late expression it might 
have been expected to play a role in the virion structure. 
However the product of gene US11, has also previously been 
shown to be regulated as a "true-late" protein (Johnson et 
al., 1986), and also plays a non—structural role in the 
virus life cycle with its 21K protein localising to the 
nucleoli of infected cells (MacLean et al., 1987).
Identification of the product of gene UL46 as non- 
structural is also an interesting result as the results of 
McKnight et al., (1987), indicated a role of UL46 with 
UL47 in modulation of the activity of Vmw65. Results 
presented here identifiying UL47 as an abundant tegument 
protein, supported the possibility that it may act with 
the UL48 gene product.
Antiserum 23311, against UL45, detected a 
polypeptide band of similar Mr in both infected cells and 
in purified HSV-1 virions. It seems to be present in very 
low amounts in virions, as it is not visible as a 33S- 
methionine labelled band (Figure 25), and is only 
detectable with the 123I-probe in Western blotting 
experiments. Experiments to determine the position of this 
polypeptide within the virion particle have not as yet 
been carried put. Although the presence of a highly 
hydrophobic N-terminus and a potential membrane spanning 
domain make it a candidate for an envelope-associated 
polypeptide.
The preliminary experiments presented here, 
indicated that antiserum 23311, had a slight (3-fold) 
inhibitory effect on absorption of HSV-1 to BHK cells. 
Although not a highly significant reduction, it was worthy 
of further investigation in view of the possible membrane 
location of UL45. Unfortunately, attempts to investigate 
this further by synthesis of the entire predicted 
outermembrane domain of UL45- and subsequent antisera 
generation, failed to produce any neutralizing antisera.
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Unexpectedly the "free" 35-mer lacked immunogenicity in 
rabbits. Further experiments using the 35 amino acid 
peptide in a branched form should hopefully produce a 
useful antiserum u/ith which to investigate this effect 
further (work in progress, Dr.H.S.Marsden).
Results presented here have shown that the 82/81K 
products of gene UL47 are abundant structural proteins and 
since Vmw82,81 are readily released from virions by NP40 
they must be components of the tegument or envelope. 
Iodination in the presence but not the absence of NP40 
indicates that Vmw82,81 is located in the tegument (McLean 
et al. , 1990). Examination of the amino acid sequence 
predicted for UL47 (McGeoeh et al. , 1988) reveals no 
features characteristic of a membrane protein, which lends 
support to this conclusion.
By examination of earlier studies (Roizman and 
Furlong, 1974; Heine et al., 1974; Honess et al., 1973) 
and comparison of the apparent relative intensity and 
virion location of the proteins described there, it could 
be speculated that Vmw82,81 corresponds to VPs 13,14. 
However this speculation remains to be experimentally 
tested.
The tegument is a poorly defined structure which 
lies between the capsid and the envelope and comprises 
approximately 65% of the virion by volume (Schrag et al., 
1989). Many tegument proteins are poorly characterised but 
some appear to function at the early stages of infection. 
Predominant among these is Vmw65 (VP16, 65Ktif) a protein 
of apparent Mr 65,000 which stimulates transcription from 
immediate-early genes (Post et al., 1981; Batterson and 
Roizman, 1983; Campbell et al., 1984). It has been 
reported (McKnight et al., 1987) that the products of 
genes UL46 and UL47 act to modulate (positively and 
negatively respectively) the activity of Vmw65. It is 
therefore of interest that the 82/81K products of gene 
UL47 should be present in virions in amounts comparable or 
greater than Vmw65.
Vmw65 is also of importance as a structural
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component of the virion, since a ts mutation in the gene 
encoding this protein confers decreased thermostability on 
virions (Moss, 1989). Whether Vmu/82,81 will also have an 
equivalent structural role is unknown, although this 
possibility seems unlikely as recent experiments have 
shown that this gene along with the product of the UL46 
gene is dispensible for virus growth in tissue culture 
cells (Barker and Roizman, 1990).
It is of interest that two proteins originate from 
UL47. In a previous analysis using 2D gel electrophoresis 
(Marsden et al. , 1983) two polypeptides were identified 
(spots 24 and 25) of apparent Mr 81,000 and one 
polypeptide (spot 402) of apparent Mr 82,000. It is not 
possible to unambiguously equate spots 24, 25 and 402 with 
either of 82K or 81K polypeptides. However, since no other 
spots having these apparent Mrs were detected on 2D gels 
and since all three spot are labelled following iodination 
of NP40 treated virions but not untreated virions (McLean 
et al., 1990), it seems likely that spot 402 corresponds 
to Vmw82 and spots 24 and 25 correspond to Vmw81. Earlier 
studies (Marsden et al., 1983) demonstrated that spot 402 
was a processed product while spots 24 and 25 were 
synthesised in vitro. It could therefore be speculated 
that spots 24 and 25 both arise from UL47 by initiation of 
translation at the first and second AUGs (codons 1 and 34 
respectively) of the mRNA. There is a precedent for this 
suggestion from studies on the translation of HSV 
thymidine kinase, in which it was shown that translation 
is initiated at the first three AUGs of the mRNA (Haarr et 
al., 1985).
The results presented in this thesis support the 
continued use of antipeptide antisera for the 
identification and characterisation of viral gene products 
and demonstrate that methods are now available which are 
both more convenient and more successful than those at 
present widely employed. In addition the availability of 
antisera reactive with the products of genes UL31, UL45, 
UL46 and UL47 should enable the further characterisation
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of these proteins, with a view to investigate their role 
in the virus life cycle.
25. FUTURE WORK
The experiments presented in this thesis give a 
number of interesting findings worthy of further 
investigation. It has been demonstrated that branched 
peptides are highly successful at eliciting a response 
against a target peptide sequence. These have been shown 
to be effective both in outbred strains of rabbits and in 
inbred Balb/c mice, when presented in combinaton with a 
ThCE. Future work would involve further development of the 
generation of a stong response in mice to subsequently 
produce monoclonal antibodies. It should be possible to 
develop a quick and efficient method for initial screening 
of clones produced from a fusion, allowing work to be 
concentrated only on clones secreting antibodies of 
interest. The probability of further increasing the number 
of clones secreting anti peptide antibodies which were 
reactive with the target protein, could also be 
investigated by giving a second immunisation which 
contained the protein (as discussed earlier, section 
22.2).
The availability of antisera reactive against four 
HSV-1 gene products will allow further characterisation of 
gene products UL31, UL45, UL46 and UL47. In particular the 
identification of the UL47 gene product as an 82/81K 
virion protein and the availability of antiserum directed 
against this protein, should facilitate its purification 
and allow in vitro experiments to test directly its 
speculated role in modulating the activity of Vmw65. It 
should be possible to ascertain whether UL47 is invloved 
in direct interaction with Vmw65. In addition, experiments 
could be carried out to determine the form of post- 
translational modification that is undergone by the UL45 
gene product. This would involve labelling experiments to 
look for modification such as glycosylation and
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myristylation. It should also be possible to determine 
whether UL31, UL45, UL46 and UL47 possess any DNA—binding 
properties.
The preliminary data presented here demonstrating a 
possible effect of an anti-UL45 antiserum 
on HSV—1 infection of BHK cells should be investigated 
further. The production of the 35 amino acid peptide from 
the amino terminus of gene UL45 in a branched form should 
produce a higher titre antiserum with which to better 
investigate this observation.
i
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